cvm_10q.htm

0001354488-11-002531.txt : 20110809 0001354488-11-002531.hdr.sgml : 20110809 20110809161453 ACCESSION NUMBER: 0001354488-11-002531 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110809 DATE AS OF CHANGE: 20110809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 111020950 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm QUARTERLY REPORT cvm_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OFTHE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OFTHE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction incorporation		(IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer	o	Accelerated filer	þ
Non-accelerated filer	o	Smaller reporting company	o
(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes o No þ

Class of Stock		No. Shares Outstanding		Date
Common		212,754,415		August 3, 2011

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

		PAGE

Item 1.	Condensed Consolidated Balance Sheets (unaudited)		3
	Condensed Consolidated Statements of Operations (unaudited)		4
	Condensed Consolidated Statements of Cash Flows (unaudited)		6
	Notes to Condensed Consolidated Financial Statements (unaudited)		8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		25

Item 3.	Quantitative and Qualitative Disclosures about Market Risks		30

Item 4.	Controls and Procedures		31

PART II

Item 1.	Legal Proceedings		32

Item 6.	Exhibits		34

Signatures			35

ITEM 1. FINANCIAL STATEMENTS

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

ASSETS	June 30,			September 30,
	2011			2010
CURRENT ASSETS

Cash and cash equivalents	$	10,576,078		$	26,568,243
Receivables		414,126			-
Prepaid expenses		2,290,315			298,719
Inventory used for R&D and manufacturing		1,578,260			1,476,234
Deferred rent - current portion		715,806			751,338

Total current assets		15,574,585			29,094,534

RESEARCH AND OFFICE EQUIPMENT AND
LEASEHOLD IMPROVEMENTS--
Less accumulated depreciation of $2,964,161 and $2,626,759		1,097,679			1,264,831

PATENT COSTS- less accumulated
amortization of $1,267,104 and $1,205,690		434,101			356,079

RESTRICTED CASH		-			21,357
DEFERRED RENT - net of current portion		6,635,686			7,068,184

TOTAL ASSETS	$	23,742,051		$	37,804,985

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	1,274,264		$	1,497,383
Accrued expenses		196,236			223,696
Due to employees		5,582			45,808
Related party loan		1,104,057			1,104,057
Convertible notes		4,929,000			-
Convertible preferred stock - 3,033 shares outstanding		3,043,000			-
Derivative instruments - current portion		469,249			424,286

Total current liabilities		11,021,388			3,295,230

Derivative instruments - net of current portion		3,405,969			6,521,765
Deferred revenue		125,000			125,000
Deferred rent		6,035			8,225
Total liabilities		14,558,392			9,950,220

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; authorized, 200,000 shares;
no shares issued and outstanding		-			-
Common stock, $.01 par value; authorized, 450,000,000
shares; issued and outstanding, 210,584,868 and
204,868,853 shares at June 30, 2011 and September
30, 2010, respectively		2,105,849			2,048,689
Additional paid-in capital		192,272,589			187,606,044
Accumulated deficit		(185,194,779	)		(161,799,968	)


Total stockholders' equity		9,183,659			27,854,765

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	23,742,051		$	37,804,985

See notes to condensed consolidated financial statements.

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	For the Nine Months Ended
	June 30,
	2011			2010
REVENUE:
Rent income	$	-		$	91,500
Grant and other income		784,036			-

Total revenue		784,036			91,500
EXPENSES:
Research and development, excluding depreciation of
$359,343 and $316,575 included below		9,231,296			7,733,544
Depreciation and amortization		434,436			377,458
General and administrative		5,407,782			4,947,764
Foreign exchange gain		(30,704	)		-

Total expenses		15,042,810			13,058,766

LOSS FROM OPERATIONS		(14,258,774	)		(12,967,266	)

OTHER EXPENSES		(12,000,000	)		-

GAIN ON DERIVATIVE INSTRUMENTS		2,879,003			30,614,451

INTEREST INCOME		134,002			287,613

INTEREST EXPENSE		(149,042	)		(120,924	)

NET (LOSS) INCOME BEFORE INCOME TAXES		(23,394,811	)		17,813,874

INCOME TAX PROVISION		-			-

NET (LOSS) INCOME		(23,394,811	)		17,813,874

MODIFICATION OF WARRANTS		(1,068,369	)		(1,432,456	)

NET (LOSS) INCOME AVAILABLE TO COMMON SHAREHOLDERS	$	(24,463,180	)	$	16,381,418

NET (LOSS) INCOME PER COMMON SHARE-BASIC	$	(0.12	)	$	0.08

NET LOSS PER COMMON SHARE-DILUTED	$	(0.12	)	$	(0.02	)

WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING-BASIC		206,860,979			201,208,121
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING-DILUTED		206,860,979			228,443,595

See notes to condensed consolidated financial statements.

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	For the Three Months Ended
	June 30,
	2011			2010
REVENUE:
Rent income	$	-		$	30,900
Grant and other income		77,403			-

Total revenue		77,403			30,900
EXPENSES:
Research and development, excluding depreciation of
$123,519 and $113,146 included below		2,924,771			1,587,520
Depreciation and amortization		148,148			134,574
General and administrative		1,862,328			1,702,865
Foreign exchange gain		(12,100	)		-

Total expenses		4,923,147			3,424,959

LOSS FROM OPERATIONS		(4,845,744	)		(3,394,059	)

OTHER EXPENSES		-			-

GAIN ON DERIVATIVE INSTRUMENTS		1,763,311			2,754,512

INTEREST INCOME		34,416			79,825

INTEREST EXPENSE		(66,238	)		(41,402	)

NET LOSS BEFORE INCOME TAXES		(3,114,255	)		(601,124	)

INCOME TAX PROVISION		-			-

NET LOSS		(3,114,255	)		(601,124	)

MODIFICATION OF WARRANTS		-			-

NET LOSS AVAILABLE TO COMMON SHAREHOLDERS	$	(3,114,255	)	$	(601,124	)

NET LOSS PER COMMON SHARE-BASIC	$	(0.01	)	$	0.00

NET LOSS PER COMMON SHARE-DILUTED	$	(0.02	)	$	(0.01	)

WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING-BASIC		208,402,408			204,592,051
WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING-DILUTED		241,110,822			231,827,525

See notes to condensed consolidated financial statements.

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(unaudited)

	Nine Months Ended June 30,
	2011			2010
CASH FLOWS FROM OPERATING ACTIVITIES:
NET (LOSS) INCOME	$	(23,394,811	)	$	17,813,874
Adjustments to reconcile net (loss) income to
net cash used in operating activities:
Depreciation and amortization		434,436			377,458
Issuance of convertible notes and preferred stock in legal settlement		9,000,000			-
Issuance of common stock, warrants and stock options for services		137,947			1,159,450
Common stock contributed to 401(k) plan		112,030			83,023
Extension of options		135,988			212,444
Employee option cost		1,104,933			939,350
Gain on derivative instruments		(2,879,003	)		(30,614,451	)
Decrease in deferred rent asset		468,030			754,276
Amortization of loan premium		-			(3,282	)
Loss on abandonment of patents		-			5,381
Loss on retirement of equipment		2,828			2,081
Increase in prepaid expenses		(1,991,596	)		(148,774	)
Increase in inventory for R&D and manufacturing		(102,026	)		(1,352,513	)
Decrease in deposits		-			1,574,932
Increase in receivables		(414,126	)		-
Decrease in accounts payable		(350,377	)		(83,191	)
Increase in accrued expenses		53,935			115,236
Decrease in amount due to employees		(40,226	)		(25,020	)
Increase in deferred revenue		-			125,000
(Decrease) increase in deferred rent liability		(2,190	)		61
NET CASH USED IN OPERATING ACTIVITIES		(17,724,228	)		(9,064,665	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash		21,357			47,215
Purchase of equipment		(174,993	)		(368,281	)
Patent costs		(45,883	)		(15,023	)
NET CASH USED IN INVESTING ACTIVITIES		(199,519	)		(336,089	)

CASH FLOWS FROM FINANCING ACTIVITIES:

Payment for repurchase of preferred stock		(1,017,000	)		-
Proceeds from exercise of stock options and warrants		604,588			6,308,874
Proceeds from sale of stock		2,343,994			-
NET CASH PROVIDED BY FINANCING ACTIVITIES		1,931,582			6,308,874

NET DECREASE IN CASH AND CASH EQUIVALENTS		(15,992,165	)		(3,091,880	)

CASH AND CASH EQUIVALENTS:
Beginning of period		26,568,243			33,567,516

End of period	$	10,576,078		$	30,475,636
				(continued)

See notes to condensed consolidated financial statements.

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(unaudited) (continued)

	Nine Months Ended June 30,
	2011			2010
SUPPLEMENTAL INFORMATION ON NONCASH TRANSACTIONS:

Patent costs included in accounts payable:
Increase in accounts payable	$	(93,553	)	$	-
Increase in patent costs		93,553			-

	$	-		$	-
Equipment costs included in accounts payable:
Increase in accounts payable	$	(33,705	)	$	(48,657	)
Increase in research and office equipment		33,705			48,657

	$	-		$	-

Modification of warrants:
Increase in additional paid-in capital	$	(1,068,369	)	$	(1,432,456	)
Decrease in additional paid-in capital		1,068,369			1,432,456

	$	-		$	-

Exercise of derivative liability warrants:
Decrease in derivative liabilities	$	202,830		$	5,510,490
Increase in additional paid-in capital		(202,830	)		(5,510,490	)

	$	-		$	-

Adoption of ASC 815-40:
Increase in derivative liabilities	$	-		$	(6,186,343	)
Increase in accumulated deficit		-			6,186,343

	$	-		$	-

Dismissal of liability for overpayment:
Decrease in accrued expenses	$	81,395		$	-
Increase in additional paid-in capital		(81,395	)		-

	$	-		$	-
NOTE:
Cash expenditures for interest expense	$	124,206		$	124,206

See notes to condensed consolidated financial statements.

A.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements of CEL-SCI Corporation and subsidiary (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, interim condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2010.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the financial position as of June 30, 2011 and the results of operations for the nine and three-month periods then ended. The condensed consolidated balance sheet as of September 30, 2010 is derived from the September 30, 2010 audited consolidated financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three-month periods ended June 30, 2011 and 2010 are not necessarily indicative of the results to be expected for the entire year.

Certain items in the consolidated financial statements have been reclassified to conform to the current presentation.

Significant accounting policies are as follows:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Depreciation and amortization expense for the nine-month periods ended June 30, 2011 and 2010 was $373,022 and $318,800, respectively. Depreciation and amortization expense for the three-month periods ended June 30, 2011 and 2010 was $126,438 and $114,894, respectively. During the nine months ended June 30, 2011 and 2010, equipment with a net book value of $2,828 and $2,081 was retired. During the three months ended June 30, 2011 and 2010, equipment with a net book value of $2,591 and $2,081 was retired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. During the nine-month periods ended June 30, 2011 and 2010, the Company recorded patent impairment charges of $-0- and $5,381, respectively. During the three-month periods ended June 30, 2011 and 2010, the Company recorded no patent impairment charges. For the nine-month periods ended June 30, 2011 and 2010, amortization of patent costs totaled $61,414 and $58,658, respectively. For the three-month periods ended June 30, 2011 and 2010, amortization of patent costs totaled $21,710 and $19,680, respectively. The Company estimates that amortization expense will be $82,594 for each of the next five years, totaling $412,970.

Research and Development Costs - Research and development expenditures are expensed as incurred. Total research and development costs, excluding depreciation, were $9,231,296 and $7,733,544, respectively, for the nine months ended June 30, 2011 and 2010. Total research and development costs, excluding depreciation, were $2,924,771 and $1,587,520, respectively, for the three months ended June 30, 2011 and 2010.

Income Taxes - The Company has net operating loss carryforwards of approximately $132 million. The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments or are hybrid instruments that contain embedded derivative features. The Company has also issued warrants to various parties in connection with work performed by these parties. The Company accounts for these arrangements in accordance with Codification 815-10-50, “Accounting for Derivative Instruments and Hedging Activities”. The Company also accounts for warrants in accordance with Codification 815-40-15, “Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entity’s Own Stock”. In accordance with accounting principles generally accepted in the United States (“GAAP”), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred rent (asset) – The deferred rent is discussed at Note G. Long-term interest receivable on the deposit on the manufacturing facility has been combined with the deferred rent (asset) for both periods for comparability.

Stock-Based Compensation – The Company follows Codification 718-10-30-3, “Share-Based Payment”. This Codification applies to all transactions involving issuance of equity by a company in exchange for goods and services, including to employees. Compensation expense has been recognized for awards that were granted, modified, repurchased or cancelled on or after October 1, 2005 as well as for the portion of awards previously granted that vested during the period ended June 30, 2011. For the nine months ended June 30, 2011 and 2010, the Company recorded $1,104,933 and $939,350, respectively, in general and administrative expense for the cost of employee options. For the three months ended June 30, 2011 and 2010, the Company recorded $407,469 and $321,268, respectively, in general and administrative expense for the cost of employee options. The Company's options vest over a three-year period from the date of grant. After one year, the stock is one-third vested, with an additional one-third vesting after two years and the final one-third vesting at the end of the three-year period. There were 2,379,594 and 400,000 options granted to employees during the nine-month periods ended June 30, 2011 and 2010, respectively. There were 2,360,800 and 6,000 options granted to employees during the three-month periods ended June 30, 2011 and 2010, respectively. Options are granted with an exercise price equal to the closing price of the Company's stock on the day before the grant. The Company determines the fair value of the employee stock-based compensation using the Black Scholes method of valuation.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. A summary chart and description of activity for the quarter of the Plans follows in Note C. For further discussion of the Stock Option Plans, Stock Compensation Plan and Stock Bonus Plans, see Form 10-K for the year ended September 30, 2010.

NEW ACCOUNTING PRONOUNCEMENTS

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, “Fair Value Measurement (Topic 820) – Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs,” which is effective for interim and annual periods beginning after December 15, 2011. This guidance amends certain accounting and disclosure requirements related to fair value measurements. The Company does not believe that this amendment will have a material impact on its financial statements.

C.	STOCKHOLDERS’ EQUITY Below is a chart of the stock options, stock bonuses and compensation granted by the Company. Each option represents the right to purchase one share of the Company’s common stock at June 30, 2011:

Total

Reserved for

Remaining

Reserved

Outstanding

Issued as

Options/Shares

Name of Plan

Under Plans

Options

Stock Bonus

Under Plans

Incentive Stock Option Plans

19,100,000

11,168,041

N/A

7,320,225

Non-Qualified Stock Option Plans

35,760,000

23,463,240

N/A

8,690,510

Stock Bonus Plans

13,940,000

N/A

7,587,358

6,350,883

Stock Compensation Plan

11,500,000

N/A

5,386,531

6,113,469

Stock-Based Compensation Expense
	Nine Months Ended June 30,				Three Months Ended June 30,
	2011		2010		2011		2010
Employees	$	1,210,735	$	1,151,794	$	407,469	$	321,268
Non-employees		168,133		758,636		5,001		57,900

Options and stock to employees

During the nine months ended June 30, 2011, 29,268 options were exercised from the Company’s option plans at prices ranging from $0.22 to $0.48. The total intrinsic value of options exercised during the nine months ended June 30, 2011 was $10,944. The Company received a total of $13,056 from the exercise of the options during the nine months ended June 30, 2011. During the three months ended June 30, 2011, no options were exercised from the Company’s option plans. During the nine months ended June 30, 2010, 89,958 options were exercised from the Company’s option plans. The total intrinsic value of options exercised during the nine months ended June 30, 2010 was $32,999. The Company received a total of $36,330 from the exercise of options during the nine months ended June 30, 2010. During the three months ended June 30, 2010, no options were exercised from the Company’s option plans.

During the nine months ended June 30, 2011, 2,379,594 stock options were granted at prices ranging from $0.63 to $0.85 with a fair value of $1,458,764 and 30,500 options expired and 2,000 were forfeited. During the three months ended June 30, 2011, 2,360,800 stock options were granted at prices ranging from $0.63 to $0.69 with a fair value of $1,445,172 and 27,500 options expired and 1,000 were forfeited. During the nine months ended June 30, 2010, 400,000 stock options were granted at prices ranging from $0.49 to $1.93 with a fair value of $420,371 and 48,167 options expired and 1,000 were forfeited. During the three months ended June 30, 2010, 6,000 stock options were granted at prices ranging from $0.49 to $0.63 with a fair value of $3,199 and 45,667 options expired.

During the nine months ended June 30, 2011, the Company extended 306,500 employee options. The options were due to expire between January 26, 2011 through December 3, 2011. All options were extended for an additional three years from the current expiration date. The additional cost of $105,802 was recorded as a charge to option expense. The value of the fully vested employee option extension was determined using the Black Scholes method. There were no options extended during the three months ended June 30, 2011. During the nine months ended June 30, 2010, the Company extended 518,832 employee options. The options were due to expire from February 2, 2010 through December 8, 2010. All options were extended for an additional three years from the current expiration date. The additional cost of $212,444 was recorded as a debit to option expense and a credit to additional paid-in capital. The value of the fully vested employee option extension was determined using the Black Scholes method. There were no options extended during the three months ended June 30, 2010.

Options and stock to non-employees

Options to non-employees are accounted for in accordance with Codification 505-50-05-5, “Equity Based Payments to Non-Employees”. Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires management to make assumptions regarding the fair value of the options at the date of grant and the expected life of the options. There were no options granted to non-employees during the nine and three months ended June 30, 2011. There were no options granted to non-employees during the nine months ended June 30, 2010. During the nine and three months ended June 30, 2011, 100,000 options expired that were issued to a consultant.

There were 277,169 and no shares of common stock issued to consultants during the nine and three months ended June 30, 2011 for a cost of $160,964 and $-0-, respectively, of which $135,965 was expensed for the nine months ended June 30, 2011 and $5,001 was expensed for the three months ended June 30, 2011. Additionally, a portion of the cost of common stock issued in previous quarters was expensed. The cost for the previously issued shares for the nine and three months ended June 30, 2011 was $1,982 and $-0- respectively. There were 370,758 and no shares of common stock issued to consultants during the nine and three months ended June 30, 2010 at a cost for the nine and three months ended June 30, 2010 of $409,562 and $-0-, respectively. In addition, a portion of the cost of common stock issued in previous quarters was expensed. This cost for the nine and three months ended June 30, 2010 was $349,074 and $57,900, respectively.

During the nine months ended June 30, 2011, the Company extended 80,000 options issued to a consultant. The options were scheduled to expire in October 2010. All options were extended for an additional five years from the current expiration date. The additional cost of $30,186 was recorded as a charge to stock-based compensation expense. The value of the fully vested option extension was determined using the Black Scholes method. There was no extension of options issued to consultants during the three months ended June 30, 2011. There was no extension of options issued to consultants during the nine and three months ended June 30, 2010.

Derivative liabilities and warrants

Below is a chart showing the derivative liabilities and the number of warrants outstanding at June 30, 2011:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant		Exercise Price		Expiration Date	Reference

Series K	8/4/06		2,638,163	$	0.40	2/4/12		1
Series N	8/18/08		3,890,782		0.40	8/18/14		1
Series A	6/24/09		1,303,472		0.50	12/24/14		1
C. Schleuning (Series A)	7/8/09		167,500		0.50	01/08/15		1
Series B	9/4/09		500,000		0.68	9/4/14		1
Series C	8/20/09 – 8/26/09		4,634,886		0.55	2/20/15		1
Series D	9/21/09		4,714,284		1.50	9/21/11		1
Series E	9/21/09		714,286		1.75	8/12/14		1
Series L	4/18/07		951,669		0.75	4/17/12		2
Series L (repriced)	4/18/07		1,000,000		0.56	4/17/13		2
Series M	4/18/07		1,221,668		2.00	4/17/12		2
Series M (modified)	4/18/07		6,000,000		0.60	7/31/14		2
Series O	3/6/09		6,800,000		0.25	3/6/16		3
Private Investors	5/30/03 – 6/30/09		8,609,375		0.47 – 1.25	5/30/13 – 7/18/14		4
Warrants held by Officer and Director	6/24/09 – 7/6/09		3,497,539		0.40 – 0.50	12/24/14 – 1/6/15		5

1.	Derivative Liabilities

See below for details of the balances of derivative instruments at June 30, 2011 and September 30, 2010.

	June 30, 2011		September 30, 2010
Series K warrants	$	422,106	$	1,002,502
2009 financings warrants
(Series A thru E)		2,208,062		4,037,066
2008 warrants reclassified from equity
to derivative liabilities on
October 1, 2009 (Series N)		1,245,050		1,906,483
Preferred stock issued in settlement (Note G)		3,043,000		-
Convertible notes issued in settlement (Note G)		4,929,000		-
Total derivative liabilities	$	11,847,218	$	6,946,051

The Company accounted for the Series K and A through E Warrants as derivative liabilities in accordance with Codification 815-10, “Accounting for Derivative Instruments and Hedging Activities”. For the nine and three months ended June 30, 2011, the Company recorded a gain of $1,393,282 and a gain of $877,166 on the Series A through E derivative instruments, respectively. During the nine and three months ended June 30, 2011, the Company recorded a gain of $580,396 and a gain of $369,343 on the remaining Series K warrants, respectively. During the nine and three months ended June 30, 2010, the Company recognized a gain of $13,956,036 and a gain of $1,897,335 on the remaining Series A through E derivative instruments, respectively. During the nine and three months ended June 30, 2010, the Company recorded a gain of $3,120,172 and a gain of $422,106, respectively, on the remaining Series K warrants.

During the nine months ended June 30, 2010, 1,335,221 Series K warrants, on which the Company recognized a gain on exercise of $280,223 and 8,813,088 Series A warrants, on which the Company recognized a total gain of $8,433,451 were exercised. When the warrants were exercised, the value of these warrants was converted from derivative liabilities to equity. Series K warrants transferred to equity totaled $1,223,518 and Series A warrants transferred to equity totaled $4,276,972. During the three months ended June 30, 2010, no Series A warrants were exercised. During the three months ended June 30, 2010, 319,767 Series K warrants, on which the Company recognized a loss on exercise of $148,546, were exercised.

During the nine and three months ended June 30, 2011, 757,331 and no Series C warrants were exercised. The Company recognized a gain on exercise of $232,892 and $-0-, respectively. When the warrants were exercised, the value of these warrants was converted from derivative liabilities to equity. Series C warrants transferred to equity totaled $202,830 and $-0-, respectively.

On October 1, 2009, the Company reviewed all outstanding warrants in accordance with the requirements of Codification 815-40, “Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entity’s Own Stock”. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the purchase price for certain dilutive events, which includes an adjustment to the number of shares issuable upon the exercise of the warrant in the event that the Company makes certain equity offerings in the future at a price lower than the exercise prices of the warrant instruments. Under the provisions of Codification 815-40, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded. Accordingly, effective October 1, 2009, 3,890,782 Series N warrants issued in August 2008 were determined to be subject to the requirements of this topic and were valued using the Black-Scholes formula as of October 1, 2009 at $6,186,343. Effective October 1, 2009, the Series N warrants are recognized as a liability in the Company’s condensed consolidated balance sheet at fair value with a corresponding adjustment to accumulated deficit and will be marked-to-market each reporting period. The Series N warrants were revalued on June 30, 2011 at $1,245,050, which resulted in a gain on derivatives and a decrease in derivative liabilities of $661,433 and $505,802 for the nine and three months ended June 30, 2011, respectively, due to the decrease in the Company’s stock price since September 30, 2010. During the nine and three months ended June 30, 2010, the Company recorded a gain of $4,824,569 and $583,617, respectively, on the Series N warrants.

Accounting for the Senior Convertible Notes and Redeemable Series A Convertible Preferred Stock – The Senior Secured Convertible Note falls within the scope of ASC 815. Under ASC 815-15-25-4 through 6 or ASC 825-10-10-1, the Company may make an irrevocable election to initially and subsequently measure a hybrid financial instrument in its entirety at fair value. Any change in fair value between the respective reporting dates shall be recognized as gain or loss. Based on the Company’s analysis of the Senior Secured Convertible Note, the Company identified several embedded derivative features. The Company elected, in accordance with ASC 825-10-10-1, to initially and subsequently carry the instrument at fair value without bifurcating the embedded derivatives. For the nine and three months ended June 30, 2011, the Company recorded a gain of $21,000 on the Senior Secured Convertible Notes.

The Series A Convertible Preferred Stock falls within the scope of ASC 480 because the nonconversion option was considered nonsubstantive. ASC 480-10-30-1 states, “Mandatorily redeemable financial instruments shall be measured initially at fair value.” Therefore, immediately after initially recording Series A Convertible Preferred Stock, the carrying value of the instrument in its entirety must be adjusted to fair value as of the issuance date with the difference recorded to loss. The Company also elected to adopt the fair value option ASC 825. The Series A Convertible Preferred Stock should be measured in its entirety and reported at fair value at each reporting date for so long as shares remain outstanding. Any change in fair value between the respective reporting dates shall be recognized as gain or loss. For the nine and three months ended June 30, 2011, the Company recorded a loss of $10,000 on the Series A Convertible Preferred Stock.

2.	Series L and M Warrants

On April 18, 2007, the Company completed a $15 million private financing. Shares were sold at $0.75, a premium over the closing price of the previous two weeks. The financing was accompanied by 10 million warrants with an exercise price of $0.75 and 10 million warrants with an exercise price of $2.00. The warrants are known as Series L and Series M warrants, respectively.

In September 2008, 2,250,000 of the original Series L warrants were repriced at $0.56 and extended for one year to April 17, 2013. The increase in the value of the warrants of $173,187 was recorded as a debit and a credit to additional paid-in capital in accordance with the original accounting for the Series L warrants. As of June 30, 2011, 1,000,000 of the Series L warrants at the reduced exercise price of $0.56 and 951,669 at the original exercise price of $0.75 remained outstanding.

On March 12, 2010, the Company temporarily reduced the exercise price of the Series M warrants, originally issued on April 18, 2007. The exercise price was reduced from $2.00 to $0.75. At any time prior to June 16, 2010 investors could have exercised the Series M warrants at a price of $0.75 per share. For every two Series M warrants exercised prior to June 16, 2010 the investor would have received one Series F warrant. Each Series F warrant would have allowed the holder to purchase one share of CEL-SCI’s common stock at a price of $2.50 per share at any time on or before June 15, 2014. After June 15, 2010 the exercise price of the Series M warrants reverted back to $2.00 per share. Any person exercising a Series M warrant after June 15, 2010 would not receive any Series F warrants. The Series M warrants expire on April 17, 2012. An analysis of the modification to the warrants determined that the modification increased the value of the warrants by $1,432,456. This cost was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. This cost is included in modification of warrants and increased the net loss available to shareholders on the condensed, consolidated statements of operations. There were no exercises of the Series M warrants at the reduced price and the exercise price of the Series M warrants reverted back to $2.00 on June 16, 2010.

On August 3, 2010, the Company’s Board of Directors approved an amendment to the terms of the Series M warrants held by an investor. The investor was the owner of 8,800,000 warrants priced at $2.00 per share. The investor may now purchase 6,000,000 shares of the Company’s common stock (reduced from 8,800,000) at a price of $0.60 per share. An analysis of the modification to the warrants determined that the modification increased the value of the warrants by $100,000. The adjustment was recorded as a debit and a credit to additional paid-in capital. As of June 30, 2011, all of these warrants remained outstanding. In addition, 1,221,668 Series M warrants at the original exercise price of $2.00 were outstanding as of June 30, 2011.

On February 1, 2011, 6,000,000 Series M warrants were extended for two years. The warrants expire on July 31, 2014. The increase in the fair value of the warrants was $661,457. This cost was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. This cost is included in modification of warrants and increased the net loss available to shareholders on the condensed, consolidated statements of operations.

3.	Licensing Agreement Warrants

On March 6, 2009, the Company entered into a licensing agreement with Byron Biopharma LLC (“Byron”) under which the Company granted Byron an exclusive license to market and distribute the Company’s cancer drug Multikine in the Republic of South Africa. Pursuant to the agreement Byron will be responsible for registering the product in South Africa. Once Multikine has been approved for sale, the Company will be responsible for manufacturing the product, while Byron will be responsible for sales in South Africa. Revenues will be divided equally between the Company and Byron. To maintain the license Byron, among other requirements, made a $125,000 payment to the Company on March 8, 2010. On March 30, 2009, and as further consideration for its rights under the licensing agreement, Byron purchased 3,750,000 Units from the Company at a price of $0.20 per Unit. Each Unit consisted of one share of the Company’s common stock and two warrants. Each warrant entitles the holder to purchase one share of the Company’s common stock at a price of $0.25 per share. The warrants expire on March 6, 2016. The Company filed a registration statement to register the shares issuable upon the exercise of the warrants. The Units were accounted for as an equity transaction using the Black Scholes method to value the warrants. The fair value of the warrants was calculated to be $1,015,771. As of June 30, 2011, 6,800,000 warrants remain outstanding. During the nine and three months ended June 30, 2011, 700,000 of these warrants were exercised, for which the Company received $175,000.

4.	Private Investor Warrants

Between May 30, 2003 and June 30, 2009 CEL-SCI sold shares of its common stock in private transactions. In some cases warrants were issued as part of a financing. As of June 30, 2011, 8,609,375 warrants remain outstanding. For further discussion of these warrants, see the Company’s Form 10-K for the year ended September 30, 2010.

On February 1, 2011, 1,325,000 warrants were extended for three years. The increase in the fair value of the warrants was $406,912. This cost was recorded as a debit and a credit to additional paid-in capital and is a deemed dividend. This cost is included in modification of warrants and increased the net loss available to shareholders on the condensed, consolidated statements of operations.

5.	Warrants held by Officer and Director

Between December 2008 and June 2009, Maximilian de Clara, the Company’s President and a director, loaned the Company $1,104,057. In accordance with the loan agreement, the Company issued Mr. de Clara warrants which entitle him to purchase 1,648,244 shares of the Company’s common stock at a price of $0.40 per share. The warrants are exercisable at any time prior to December 24, 2014. As consideration for a further extension of the note, Mr. de Clara received warrants which allow him to purchase 1,849,295 shares of the Company’s common stock at a price of $0.50 per share at any time prior to January 6, 2015. As of June 30, 2011, all warrants remain outstanding. See Note E for additional information.

D.	FAIR VALUE MEASUREMENTS

Effective October 1, 2008, the Company adopted the provisions of Codification 820-10, “Fair Value Measurements”, which defines fair value, establishes a framework for measuring fair value and expands disclosures about such measurements that are permitted or required under other accounting pronouncements. While Codification 820-10 may change the method of calculating fair value, it does not require any new fair value measurements. The adoption of Codification 820-10 did not have a material impact on the Company’s results of operations, financial position or cash flows.

In accordance with Codification 820-10, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

Codification 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

●

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

●	Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed consolidated balance sheet at June 30, 2011:

Quoted Prices in

Significant

Active Markets for

Other

Significant

Identical Assets or

Observable

Unobservable

Liabilities (Level 1)

Inputs (Level 2)

Inputs (Level 3)

Total

Derivative instruments $

11,847,218

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed consolidated balance sheet at September 30, 2010:

Quoted Prices in

Significant

Active Markets for

Other

Significant

Identical Assets or

Observable

Unobservable

Liabilities (Level 1)

Inputs (Level 2)

Inputs (Level 3)

Total

Derivative instruments $

6,946,051

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the periods ended June 30, 2011 and 2010:

	June 30,
	2011			2010
Beginning balance	$	6,946,051		$	35,113,970
Transfers in		9,000,000			6,186,343
Transfers out		(1,219,830	)		(5,510,490	)
Realized and unrealized gains
recorded in earnings		(2,879,003	)		(30,614,451	)
Ending Balance	$	11,847,218			5,175,372

The fair values of the Company’s derivative instruments disclosed above are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock as well as U.S. Treasury Bill rates are observable in active markets.

E.	LOANS FROM OFFICER

Between December 2008 and June 2009, Maximilian de Clara, the Company’s President and a director, loaned the Company $1,104,057. The loan from Mr. de Clara bears interest at 15% per year and was secured by a lien on substantially all of the Company’s assets. The Company does not have the right to prepay the loan without Mr. de Clara’s consent. The loan was initially payable at the end of March 2009, but was extended to the end of June 2009. At the time the loan was due, and in accordance with the loan agreement, the Company issued Mr. de Clara warrants which entitle Mr. de Clara to purchase 1,648,244 shares of the Company’s common stock at a price of $0.40 per share. The warrants are exercisable at any time prior to December 24, 2014. Pursuant to Codification section 470-50, the fair value of the warrants issuable under the first amendment was recorded as a discount on the note payable with a credit recorded to additional paid-in capital. The discount was amortized from April 30, 2009, through June 27, 2009. Although the loan was to be repaid from the proceeds of the Company’s June 2009 financing, the Company’s Directors deemed it beneficial not to repay the loan and negotiated a second extension of the loan with Mr. de Clara on terms similar to the June 2009 financing. Pursuant to the terms of the second extension the note was due on July 6, 2014, but, at Mr. de Clara’s option, the loan can be converted into shares of the Company’s common stock. The number of shares which will be issued upon any conversion will be determined by dividing the amount to be converted by $0.40. As further consideration for the second extension, Mr. de Clara received warrants which allow Mr. de Clara to purchase 1,849,295 shares of the Company’s common stock at a price of $0.50 per share at any time prior to January 6, 2015. On May 13, 2011, to recognize Mr. de Clara’s willingness to agree to subordinate his note to the convertible preferred shares and convertible debt as part of the settlement agreement, the Company extended the maturity date of the note to July 6, 2015.

In accordance with Codification 470-50, the second amendment to the loan was accounted for as an extinguishment of the first amendment debt. The extinguishment of the loan required that the new loan be recorded at fair value and a gain or loss was recognized, including the warrants issued in connection with the second amendment. This resulted in a premium of $341,454, which was amortized over the period from July 6, 2009, the date of the second amendment, to October 1, 2009, the date at which the loan holder could have demanded payment of the loan. During the nine months ended June 30, 2010, the Company amortized the remaining $3,282 in premium on the loan. During the nine months ended June 30, 2011 and 2010, the Company paid $124,206 in interest expense to Mr. de Clara. During the three months ended June 30, 2011 and 2010, the Company paid $41,402 in interest expense to Mr. de Clara.

F.	OPERATIONS, FINANCING

The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and clinical trials. The Company has funded such costs with proceeds realized from the public and private sale of its common stock, preferred stock and promissory notes. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. There can be no assurance the Company will be successful in raising additional funds. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain Federal Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to capital through the MLV sales agreement (see Note G to the accompanying financial statements), it has enough capital to support its operations for more than the next twelve months. The cash expenditure from the settlement will be dependent on the stock price during the next 8 months. If the stock price remains above $0.67, the conversion price of the settlement securities, it is likely that most of the settlement securities will be converted into CEL-SCI common stock and will not result in the planned cash payments. It would seem likely that a higher share price will therefore reduce the Company’s cash expenditures during the next 8 months by an amount between $0 (below $0.67 during the next 8 months) and $7 million.

The Company has two partners who have agreed to participate in and pay for part of the Phase III clinical trial for Multikine. Since the Company was able to raise substantial capital during 2009, the Company completed the preparations for the Phase III trial for Multikine. On December 29, 2010, the Company announced that it had commenced the Phase III clinical trial for Multikine. The net cost to the Company of the clinical trial is estimated to be $25 - $26 million.

In November 2010, the Company received a $733,437 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The Company recognizes revenue as the expenses are incurred. The amount of the grant earned during the nine and three months ended June 30, 2011 was $717,298 and $33,098, respectively. The balance of the funds will be collected in October 2011. The grant was related to three of the Company’s projects including the Phase III trial of Multikine. The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free. The tax credit/grant program covers research and development costs from 2009 and 2010 for all qualified “therapeutic discovery projects.” As of June 30, 2011, the Company has a receivable for grant funds earned but not yet received of $145,157.

G.	COMMITMENTS AND CONTINGENCIES

Lease Agreement - In August 2007, the Company leased a building near Baltimore, Maryland. The building, which consists of approximately 73,000 square feet, was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and required an annual base rent payments of $1,575,000 during the first year of the lease. The annual base rent escalates each year at 3%. The Company is also required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The lease required the Company to pay $3,150,000 towards the remodeling costs, which will be recouped by reductions in the annual base rent of $303,228 in years six through twenty of the lease, subject to the Company maintaining compliance with the lease covenants. On January 24, 2008, a second amendment to the lease for the manufacturing facility was signed. In accordance with the amendment, the Company was required to pay the following: 1) an additional $518,790 for movable equipment, which increased restricted cash, and 2) an additional $1,295,528 into the escrow account to cover additional costs, which increased deferred rent. These funds were transferred in early February 2008. In April 2008, an additional $288,474 was paid toward the completion of the manufacturing facility. The Company took possession of the manufacturing facility in October of 2008. An additional $505,225 was paid for the completion of the work on the manufacturing facility in October 2008. During the nine and three months ended June 30, 2010, an additional $32,059 was paid for final completion costs. During the nine months ended June 30, 2011, $21,177 of the remaining restricted funds was paid to the landlord for a bonus on completion.

In December 2008, the Company was not in compliance with certain lease requirements (i.e., failure to pay an installment of Base Annual Rent). However, the landlord did not declare the Company to be in default under the terms of the lease, but instead renegotiated the lease. In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced the 3,000,000 warrants initially issued to the landlord in July 2007 at $1.25 per share with an expiration date of July 12, 2013. These warrants were repriced at $0.75 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515. In addition, 787,500 additional warrants were given to the landlord of the manufacturing facility on the same date. These warrants are exercisable at $0.75 per share and will expire on January 26, 2014. The cost of these warrants was $45,207. All back rent was paid to the landlord in early July 2009. During the three months ended June 30, 2009, the Company issued the landlord an additional 2,296,875 warrants in accordance with an amendment to the agreement. These warrants were issued at a price of $0.75 and will expire between March 31, 2014 and June 30, 2014. These warrants were valued at $251,172 using the Black Scholes method. These warrants are included in the private investor warrants in the Stockholder Equity section (Note C, Reference 4). The Company is in compliance with the lease and, in February 2010, received a refund of the $1,575,000 additional deposit placed with the landlord in July 2008.

On January 28, 2009, the Company subleased a portion of the manufacturing facility. The sublease commenced on February 2, 2009 and ended in July 2010. The Company received $10,300 per month in rent for the subleased space.

The Company began amortizing the deferred rent on the building on October 7, 2008, the day that the Company took possession of the building. The amortization of the deferred rent for the nine months ended June 30, 2011 was $559,868 and for the three months ended June 30, 2011 was $180,144. The amortization of the deferred rent for the nine months ended June 30, 2010 was $606,583 and for the three months ended June 30, 2010 was $201,820.

Equity Line of Credit - On December 30, 2008, the Company entered into an Equity Line of Credit agreement as a source of funding for the Company. The Equity Line was never utilized and the agreement ended in January 2011.

MLV Agreement - On December 10, 2010, the Company entered into a sales agreement with McNicoll Lewis & Vlak, LLC (MLV) relating to shares of common stock which have been registered by means of a shelf registration statement filed in July 2009. The Company may offer and sell shares of its common stock, having an aggregate offering price of up to $30 million from time to time through MLV acting as agent and/or principal.

Sales of the Company’s common stock, if any, may be made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the NYSE Amex, the existing trading market for the Company’s common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. MLV will act as sales agent on a best efforts basis. The Company is not required to sell any shares to MLV and MLV is not required to sell any shares on the Company’s behalf or purchase any of our shares for its own account.

MLV will be entitled to a commission in an amount equal to the greater of 3% of the gross proceeds from each sale of the shares, or $0.025 for each share sold, provided, that, in no event will MLV receive a commission greater than 8.0% of the gross proceeds from the sale of the shares. During the nine months ended June 30, 2011, the Company sold 3,765,809 shares of common stock to MLV for $2,457,518, less commissions and fees of $99,789. During the three months ended June 30, 2011, the Company sold 1,864,682 shares of common stock to MLV for $985,741, less commissions and fees of $48,115.

Settlement - On May 16, 2011, CEL-SCI entered into an Exchange Agreement (referred to herein as the "Settlement Agreement") with thirteen hedge funds (the "plaintiffs") to settle all claims arising from a lawsuit initiated by the plaintiffs in October 2009 in the United States District Court for the Southern District of New York (the "Court"). As previously disclosed by CEL-SCI in its public filings, in August 2006 the plaintiffs (or their predecessors) purchased from CEL-SCI Series K notes convertible into CEL-SCI common stock and Series K warrants to purchase CEL-SCI common stock under financing agreements which provided the Series K notes and warrants with anti-dilution protection if CEL-SCI sold additional shares of common stock, or securities convertible into common stock, at a price below the then applicable conversion price of the notes or the exercise price of the warrants. In their lawsuit, the plaintiffs alleged that a March 2009 drug marketing and distribution agreement in which CEL-SCI sold units of common stock and warrants to an unrelated third party triggered these anti-dilution provisions, and that CEL-SCI failed to give effect to these provisions. The plaintiffs sought $30 million in actual damages, $90 million in punitive damages, the issuance of additional shares of common stock and warrants, and a reduction in the conversion price of the Series K notes and the exercise price of the Series K warrants. CEL-SCI denied the plaintiffs' allegations in the lawsuit and asserted that the 2009 agreement was a strategic transaction which did not trigger the anti-dilution provisions of the 2006 financing agreements.

Although the Company has vigorously defended the lawsuit and believed the plaintiffs' claims were without merit, the Company believed that a settlement of this lawsuit was in the best interests of the shareholders. The settlement was entered into to avoid the substantial costs of further litigation and the risk and uncertainty that the litigation entails. By ending this dispute, and ending the significant demands on the time and attention of the Company's management necessary to respond to the litigation, the Company is better able to focus on executing its ongoing Phase III clinical trial with its novel and non-toxic cancer drug Multikine.

Under the terms of the Settlement Agreement and its related agreements, the plaintiffs and CEL-SCI terminated the pending litigation and released each other from all claims each may have had against the other, with certain customary exceptions. CEL-SCI agreed to make a $3 million cash payment and issue $9 million of securities to the plaintiffs. These securities consist of senior secured convertible promissory notes with an aggregate principal amount of $4.95 million and 4,050 shares of redeemable Series A Convertible Preferred Stock with an aggregate stated value of $4.05 million. The $3 million cash payment was made at the closing under the Settlement Agreement. The $9 million of securities will be redeemed through nine equal monthly installment payments of approximately $1 million each, plus interest on the notes and dividends on the shares at the rate of 8% per annum, with payments beginning on June 17, 2011 (the month of October requires no payment) and ending on March 1, 2012. As these installments of the principal amount of the notes and the stated value of the preferred shares are paid down, or as the notes or the preferred shares are converted by the holders into common stock, the initial $9 million due (plus interest and dividends) will be proportionately reduced until the notes are fully paid or converted and the preferred shares are fully redeemed or converted. CEL-SCI has pledged all of its assets as collateral for the repayment of these obligations. While the notes and preferred shares are outstanding, CEL-SCI is generally prohibited from paying dividends, incurring new debt or making any payments (other than interest) on existing debt, and is subject to certain restrictions on the transfer of its assets. The $12 million was accrued for and included in the March 31, 2011 consolidated financial statements. For the nine and three months ended June 30, 2011, $24,836 of interest and dividends are accrued. This amount is included in interest expense in the financial statements.

The notes and the Series A preferred shares will be convertible, at the option of the holder, into CEL-SCI common stock at a fixed price of $0.67 per share. The conversion price represented the most recent consolidated closing sale price of the common stock on the NYSE AMEX at the time the settlement agreement was signed by the parties. The plaintiffs have agreed to restrictions on their ability to effect short sales of the common stock based on the number of warrants and common shares they hold, but excluding shares issuable upon the conversion of the notes and preferred shares. The plaintiffs have further agreed to permit an independent accounting firm to review their trading records every three months to confirm their compliance with these restrictions.

The parties' respective obligations under the Settlement Agreement, including CEL-SCI's obligation to pay cash and issue notes and preferred shares to the plaintiffs, were subject to obtaining the approval by the Court of an order exempting the issuance to the plaintiffs of the notes and preferred shares from registration under Section 3(a)(10) of the Securities Act of 1933. This was to permit the notes and preferred shares, and the shares of common stock issuable upon conversion thereof, to be freely tradable.

On June 17, 2011 the final settlement agreement was signed. During the three months ended June 30, 2011, the $3,000,000 cash payment required by the settlement was made. In addition, the first payment for the preferred shares, totaling $1,017,000 for 1,017 preferred shares, was made on June 17, 2011.

As a condition of the settlement agreement, all claims against the Company were dismissed. As a result, the $81,395 overpayment by one of the claimants was dismissed and the liability was written off during the three months ended June 30, 2011.

The foregoing summary of the terms of the settlement is qualified in its entirety by the detailed terms of the Settlement Agreement and the related agreements and documents which are filed as exhibits to the Company’s report on Form 10-Q for the three months ended March 31, 2011.

H.	EARNINGS PER SHARE

The Company’s diluted earnings per share (EPS) are as follows for June 30, 2011 and 2010. For the nine months ended June 30, 2011, the computation of dilutive net loss per share excluded options and warrants to purchase approximately 33,000,000 shares of common stock because their inclusion would have an anti-dilutive effect.

	Nine Months Ended June 30, 2011
				Weighted average
	Net Loss			Shares		EPS
Basic Earnings per Share	$	(24,463,180	)		206,860,979	$	(0.12	)
Note conversion		-			-
Convertible note and preferred
stock conversion		-			-
Warrants and options convertible
into shares of common stock		-			-
Dilutive EPS	$	(24,463,180	)		206,860,979	$	(0.12	)

	Nine Months Ended June 30, 2010
				Weighted average
	Net Income			Shares		EPS
Basic Earnings per Share		16,381,418			201,208,121	$	0.08
Note conversion		124,206			2,760,142
Warrants and options convertible
into shares of common stock		(21,900,777	)		24,475,332
Dilutive EPS		(5,395,153	)		228,443,595	$	(0.02	)

	Three Months Ended June 30, 2011
				Weighted average
	Net Loss			Shares		EPS
Basic Earnings per Share	$	(3,114,255	)		208,402,408	$	(0.01	)
Note conversion		41,402			2,760,142
Convertible note and preferred
stock conversion		24,836			11,914,925
Warrants and options convertible
into shares of common stock		(1,763,311	)		18,033,347
Dilutive EPS	$	(4,811,328	)		241,110,822	$	(0.02	)

	Three Months Ended June 30, 2010
				Weighted average
	Net Income			Shares		EPS
Basic Earnings per Share		(601,124	)		204,592,051	$	(0.00	)
Note conversion		41,402			2,760,142
Warrants and options convertible
into shares of common stock		(2,903,058	)		24,475,332
Dilutive EPS		(3,462,780	)		231,827,525	$	(0.01	)

I.	SUBSEQUENT EVENTS

On July 19, 2011 the Company announced that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for Multikine. Under the agreement, Teva’s exclusive license to market and distribute Multikine in Israel and Turkey will be extended to include Croatia and Serbia. Teva is currently funding a part of the global Phase III clinical study at three clinical sites in Israel. Teva will be responsible for the costs of registering and selling the product in Serbia and Croatia and will pay the Company milestone payments upon approval of Multikine. The parties will share revenue generated from all four countries.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company has had only limited revenues from operations since its inception in March 1983. The Company has relied upon capital generated from the public and private offerings of its common stock and convertible notes. In addition, the Company has utilized short-term loans to meet its capital requirements. Capital raised by the Company has been expended primarily to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system. Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and the construction of the Company’s laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of the Company to complete the necessary clinical trials and obtain Federal Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to capital through the MLV sales agreement (see Note G to the accompanying financial statements), it has enough capital to support its operations for more than the next twelve months. The cash expenditure from the settlement will be dependent on the stock price during the next 8 months. If the stock price remains above $0.67, the conversion price of the settlement securities, it is likely that most of the settlement securities will be converted into CEL-SCI common stock and will not result in the planned cash payments. It would seem likely that a higher share price will therefore reduce the Company’s cash expenditures during the next 8 months by an amount between $0 (below $0.67 during the next 8 months) and $7 million.

The Company has two partners who have agreed to participate in and pay for part of the Phase III clinical trial for Multikine. The Company has substantial capital for its operations and can raise another $30 million under the sales agreement with McNicoll Lewis & Vlak, LLC (MLV) (see Note G to the accompanying financial statements). On December 29, 2010, the Company announced that it had commenced the Phase III clinical trial for Multikine. The net cost to the Company of the Phase III clinical trial is estimated to be $25 - $26 million.

During the nine-month period ended June 30, 2011, the Company’s cash decreased by $15,992,165. Significant components of this decrease include approximately $4 million paid towards the settlement of the lawsuit, $2 million in prepayments for the Phase III clinical trial which the Company expects to be used during fiscal year 2011 and 2012 and research and development expenses of $9.2 million. In addition, the cost of defending the lawsuit of approximately $1.2 million is included in the decrease in cash. This expense will no longer be necessary as the lawsuit has been settled. These expenses are offset by stock sales of $2.34million. This decrease is compared to a decrease in cash of $3,091,880 during the nine months ended June 30, 2010. For the nine months ended June 30, 2011 and 2010, cash used in operating activities totaled $17,724,228 and $9,064,665, respectively. For the nine months ended June 30, 2011 and 2010, cash provided by financing activities totaled $1,931,582 and $6,308,874, respectively. Cash used by investing activities was $199,519 and $336,089, for the nine months ended June 30, 2011 and 2010, respectively. The use of cash in investing activities consisted primarily of purchases of equipment and legal costs incurred in patent applications.

In August 2007, the Company leased a building near Baltimore, Maryland. The building, which consists of approximately 73,000 square feet, was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and required an annual base rent payments of $1,575,000 during the first year of the lease. The annual base rent escalates each year at 3%. The Company is also required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The lease required the Company to pay $3,150,000 towards the remodeling costs, which will be recouped by reductions in the annual base rent of $303,228 in years six through twenty of the lease. On January 24, 2008, a second amendment to the lease for the manufacturing facility was signed. In accordance with the amendment, the Company was required to pay the following: 1) an additional $518,790 for movable equipment, which increased restricted cash, and 2) an additional $1,295,528 into the escrow account to cover additional costs, which increased deferred rent. These funds were transferred in early February 2008. In April 2008, an additional $288,474 was paid toward the completion of the manufacturing facility. The Company took possession of the manufacturing facility in October of 2008. An additional $505,225 was paid for the completion of the work on the manufacturing facility in October 2008. During the nine months ended June 30, 2010, an additional $32,059 was paid for final completion costs. During the nine months ended June 30, 2011, the Company paid $21,177 as a bonus on completion to the landlord.

In December 2008, the Company was not in compliance with certain lease requirements (i.e., failure to pay an installment of Base Annual Rent). However, the landlord did not declare the Company to be in default, but instead renegotiated the lease. In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced the 3,000,000 warrants issued to the landlord in July 2007 at $1.25 per share which were to expire on July 12, 2013. These warrants were repriced at $0.75 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515. In addition, 787,500 additional warrants were given to the landlord on the same date. The warrants are exercisable at a price of $0.75 per share and will expire on January 26, 2014. The cost of these warrants was $45,207. During the three months ended June 30, 2009, the Company issued the landlord an additional 2,296,875 warrants in accordance with an amendment to the lease. These warrants were issued at a price of $0.75 and will expire between March 31, 2014 and June 30, 2014. These warrants were valued at $251,172 using the Black Scholes method. The Company is currently in compliance with the lease.

Regulatory authorities prefer to see biologics such as Multikine manufactured in the same manufacturing facility for Phase III clinical trials and for the sale of the product since this arrangement helps ensure that the drug lots used to conduct the clinical trials will be consistent with those that may be subsequently sold commercially. Although some biotech companies outsource their manufacturing, this can be risky with biologics because biologics require intense manufacturing and process control. With biologic products a minor change in manufacturing and process control can result in a major change in the biological activity of the final product. Good and consistent manufacturing and process control is critical and is best assured if the product is manufactured and controlled in the manufacturer’s own facility by the Company’s own specially trained personnel.

On January 28, 2009, the Company subleased a portion of the manufacturing facility. The sublease commenced on February 2, 2009 and ended July 2010. The Company received $10,300 per month in rent for the subleased space.

Results of Operations and Financial Condition

During the nine months ended June 30, 2011, revenue increased by $692,536 compared to the nine months ended June 30, 2010. In November 2010, the Company received a $733,437 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to three of the Company’s projects, including the Phase III trial of Multikine. The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free. The tax credit/grant program covers research and development costs from 2009 and 2010 for all qualified “therapeutic discovery projects.” The Company recognizes revenue as the expenses are incurred. The amount of the grant earned during the nine and three months ended June 30, 2011 was $717,298 and $33,098, respectively. During the three months ended June 30, 2011, revenue increased by $46,503 compared to the three months ended June 30, 2011. The Company no longer subleases a portion of the manufacturing facility, but earns the revenue from the PPACA.

During the nine and three month periods ended June 30, 2011, research and development expenses increased by $1,497,752 and $1,337,251, respectively, compared to the nine and three-month periods ended June 30, 2010. The Company is continuing the Phase III clinical trial and research and development fluctuates based on the activity level of the clinical trial.

During the nine and three-month periods ended June 30, 2011, general and administrative expenses increased by $460,018 and $159,463, respectively, compared to the nine and three-month periods ended June 30, 2010. Fees for the ongoing lawsuit described in Item 3 of the Company’s report on Form 10-K have fluctuated over the past year. The Company spent approximately $1.2 million and approximately $539,000 defending the lawsuit during the nine and three months ended June 30, 2011. This expenditure will no longer be necessary as the lawsuit has been settled.

Interest income during the nine and three months ended June 30, 2011 decreased by $153,611 and $45,409, compared to the nine and three-month period ended June 30, 2010, respectively. The decrease was due to the decrease in the funds available for investment and lower interest rates.

The gain on derivative instruments of $2,879,003 and $1,763,311 for the nine and three months ended June 30, 2011 was the result of the change in fair value of the derivative liabilities and Series K Warrants during the period. This gain was caused by fluctuations in the share price of the Company’s common stock.

The interest expense of $149,042 and $66,238 for the nine and three months ended June 30, 2011 was primarily interest expense on the loan from the Company’s president. The interest expense of $124,206 and $41,402 for the nine and three months ended June 30, 2010 was interest on the loan from the Company’s president, offset by the final $3,282 in amortization of the loan premium in October, 2009. During the nine and three months ended June 30, 2011, interest was accrued on the convertible notes and convertible preferred shares in the amount of $24,836.

On May 16, 2011, CEL-SCI entered into an Exchange Agreement (referred to herein as the "Settlement Agreement") with thirteen hedge funds (the "plaintiffs") to settle all claims arising from a lawsuit initiated by the plaintiffs in October 2009 in the United States District Court for the Southern District of New York (the "Court"). As previously disclosed by CEL-SCI in its public filings, in August 2006 the plaintiffs (or their predecessors) purchased from CEL-SCI Series K notes convertible into CEL-SCI common stock and Series K warrants to purchase CEL-SCI common stock under financing agreements which provided the Series K notes and warrants with anti-dilution protection if CEL-SCI sold additional shares of common stock, or securities convertible into common stock, at a price below the then applicable conversion price of the notes or the exercise price of the warrants. In their lawsuit, the plaintiffs alleged that a March 2009 drug marketing and distribution agreement in which CEL-SCI sold units of common stock and warrants to an unrelated third party triggered these anti-dilution provisions, and that CEL-SCI failed to give effect to these provisions. The plaintiffs sought $30 million in actual damages, $90 million in punitive damages, the issuance of additional shares of common stock and warrants, and a reduction in the conversion price of the Series K notes and the exercise price of the Series K warrants. CEL-SCI denied the plaintiffs' allegations in the lawsuit and asserted that the 2009 agreement was a strategic transaction which did not trigger the anti-dilution provisions of the 2006 financing agreements.

Although the Company has vigorously defended the lawsuit and believed the plaintiffs' claims were without merit, the Company believes that a settlement of this lawsuit was in the best interests of the shareholders. The settlement was entered into to avoid the substantial costs of further litigation and the risk and uncertainty that the litigation entails. By ending this dispute, and ending the significant demands on the time and attention of the Company's management necessary to respond to the litigation, the Company is better able to focus on executing its ongoing Phase III clinical trial with its novel and non-toxic cancer drug Multikine.

Under the terms of the Settlement Agreement and its related agreements, the plaintiffs and CEL-SCI terminated the pending litigation and released each other from all claims each may have against the other, with certain customary exceptions. CEL-SCI agreed to make a $3 million cash payment and issue $9 million of securities to the plaintiffs. These securities consist of senior secured convertible promissory notes with an aggregate principal amount of $4.95 million and 4,050 shares of redeemable Series A Convertible Preferred Stock with an aggregate stated value of $4.05 million. The $3 million cash payment was made at the closing under the Settlement Agreement. The $9 million of securities will be redeemed through nine equal monthly installment payments of approximately $1 million each, plus interest on the notes and dividends on the shares at the rate of 8% per annum, with payments beginning on June 1, 2011 (the month of October requires no payment) and ending on March 1, 2012. As these installments of the principal amount of the notes and the stated value of the preferred shares are paid down, or as the notes or the preferred shares are converted by the holders into common stock, the initial $9 million due (plus interest and dividends) will be proportionately reduced until the notes are fully paid or converted and the preferred shares are fully redeemed or converted. CEL-SCI has pledged all of its assets as collateral for the repayment of these obligations. While the notes and preferred shares are outstanding, CEL-SCI is generally prohibited from paying dividends, incurring new debt or making any payments (other than interest) on existing debt, and is subject to certain restrictions on the transfer of its assets. The $12 million was accrued for and included in the March 31, 2011 consolidated financial statements.

The foregoing summary of the terms of the settlement is qualified in its entirety by the detailed terms of the Settlement Agreement and the related agreements and documents which are filed as exhibits to the Company's report on Form 10-Q for the three months ended March 31, 2011.

Research and Development Expenses

During the nine and three-month periods ended June, 2011 and 2010, the Company’s research and development efforts involved Multikine and L.E.A.P.S.™. The table below shows the research and development expenses associated with each project during the nine and three-month periods.

	Nine Months Ended June 30,				Three Months Ended June 30,
	2011		2010		2011		2010
MULTIKINE	$	8,846,063	$	6,823,218	$	2,813,372	$	1,434,208
L.E.A.P.S.		385,233		910,326		111,399		153,312
TOTAL	$	9,231,296	$	7,733,544	$	2,924,771	$	1,587,520

In January 2007, the Company received a “no objection” letter from the FDA indicating that it could proceed with the Phase III protocol with Multikine in head & neck cancer patients. The protocol for the Phase III clinical trial was designed to develop conclusive evidence of the safety and efficacy of Multikine in the treatment of advanced primary squamous cell carcinoma of the oral cavity. The Company had previously received a “no objection” letter from the Canadian Biologics and Genetic Therapies Directorate which enabled the Company to begin its Phase III clinical trial in Canada. The Company’s Phase III clinical trial began in December 2010 since the Company had to finish the completion and validation of its Multikine dedicated manufacturing facility.

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed consolidated financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s 2010 10-K report. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company has a loan from the president that bears interest at 15%. The Company does not believe that it has any significant exposures to market risk.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2011. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer has concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2011.

Changes in Internal Control over Financial Reporting

The Company’s management, with the participation of the Chief Executive and Chief Financial Officer, has evaluated whether any change in the Company’s internal control over financial reporting occurred during the first nine months of fiscal year 2011. There was no change in the Company’s internal control over financial reporting during the nine months ended June 30, 2011.

PART II

ITEM 1. LEGAL PROCEEDINGS

Although the Company has vigorously defended the lawsuit and believes the plaintiffs' claims are without merit, the Company believes that a settlement of this lawsuit is in the best interests of the shareholders at this time. The settlement was entered into to avoid the substantial costs of further litigation and the risk and uncertainty that the litigation entails. By ending this dispute, and ending the significant demands on the time and attention of the Company's management necessary to respond to the litigation, the Company is better able to focus on executing its ongoing Phase III clinical trial with its novel and non-toxic cancer drug Multikine.

Under the terms of the Settlement Agreement and its related agreements, the plaintiffs and CEL-SCI terminated the pending litigation and released each other from all claims each may have against the other, with certain customary exceptions. CEL-SCI agreed to make a $3 million cash payment and issue $9 million of securities to the plaintiffs. These securities consist of senior secured convertible promissory notes with an aggregate principal amount of $4.95 million and 4,050 shares of redeemable Series A Convertible Preferred Stock with an aggregate stated value of $4.05 million. The $3 million cash payment was made at the closing under the Settlement Agreement. The $9 million of securities will be redeemed through nine equal monthly installment payments of approximately $1 million each, plus interest on the notes and dividends on the shares at the rate of 8% per annum, with payments beginning on June 17, 2011 (the month of October requires no payment) and ending on March 1, 2012. As these installments of the principal amount of the notes and the stated value of the preferred shares are paid down, or as the notes or the preferred shares are converted by the holders into common stock, the initial $9 million due (plus interest and dividends) will be proportionately reduced until the notes are fully paid or converted and the preferred shares are fully redeemed or converted. CEL-SCI has pledged all of its assets as collateral for the repayment of these obligations. While the notes and preferred shares are outstanding, CEL-SCI is generally prohibited from paying dividends, incurring new debt or making any payments (other than interest) on existing debt, and is subject to certain restrictions on the transfer of its assets. The $12 million was accrued for and included in the March 31, 2011 consolidated financial statements.

ITEM 4. (REMOVED AND RESERVED)

ITEM 6. (A) EXHIBITS

Number		Exhibit

31		Rule 13a-14(a) Certifications

32		Section 1350 Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: August 9, 2011	By:	/s/ Geert Kersten
		Geert Kersten, Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

EX-31.1 2 cvm_ex311.htm CERTIFICATION cvm_ex311.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Geert Kersten, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

August 9, 2011		/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

EX-31.2 3 cvm_ex312.htm CERTIFICATION cvm_ex312.htm

EXHIBIT 31.2

CERTIFICATIONS

I, Geert Kersten, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

August 9, 2011		/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 4 cvm_ex321.htm CERTIFICATION cvm_ex321.htm

EXHIBIT 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ending June 30, 2011 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Principal Executive and Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.

August 9, 2011	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive and
		Principal Financial Officer

EX-101.INS 5 cvm-20110630.xml XBRL INSTANCE DOCUMENT 0000725363 2010-10-01 2011-06-30 0000725363 2011-06-30 0000725363 2010-09-30 0000725363 2009-10-01 2010-06-30 0000725363 2011-04-01 2011-06-30 0000725363 2010-04-01 2010-06-30 0000725363 2009-09-30 0000725363 2010-06-30 0000725363 2011-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CEL SCI CORP 0000725363 10-Q 2011-06-30 false --09-30 No No Yes Q3 2011

10576078

26568243

33567516

30475636

414126

2290315

298719

1578260

1476234

15574585

29094534

1097679

1264831

434101

356079

21357

23742051

37804985

1274264

1497383

196236

223696

1104057

469249

424286

11021388

3295230

3405969

6521765

125000

6035

8225

14558392

9950220

2105849

2048689

192272589

187606044

-185194779

-161799968

9183659

27854765

23742051

37804985

2964161

2626759

1267104

1205690

.01

200000

.01

450000000

210584868

204868853

210584868

204868853

91500

30900

784036

77403

784036

91500

77403

30900

9231296

7733544

2924771

1587520

434436

377458

148148

134574

5407782

4947764

1862328

1702865

15042810

13058766

4923147

3424959

-14258774

-12967266

-4845744

-3394059

134002

287613

34416

79825

-149042

-120924

-66238

-41402

-23394811

17813874

-3114255

-601124

-23394811

17813874

-3114255

-601124

-1068369 -1432456 0 0

-24463180

16381418

-3114255

-601124

-0.12

.08

-0.01

-0.00

-0.12

-0.02

-0.01

206860979

201208121

208402408

204592051

206860979

228443595

241110822

231827525

-30704

-12100

137947

1159450

112030 83023 135988 212444

1104933

939350

-3282

468030

754276

5381

2828

2081

-1991596

-148774

-102026

-1352513

1574932

-350377

-83191

53935

115236

125000

-2190

-414126

-17724228

-9064665

21357

47215

-174993

-368281

-45883

-15023

-199519

-336089

604588

6308874

1931582

6308874

-15992165

-3091880

-93553 0

93553

-33705 -48657 33705 48657

-1068369

-1432456

1068369 1432456 0 6186343

124206

2879003

30614451

1763311

2754512

4929000

3043000

3033

-12000000

359343

316575

123519

113146

2343994

9000000

-1017000

81395 0 -81395 0 Accelerated Filer

5582

45808

-40226

-25020

715806 751338 6635686 7068184

A.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Presentation The accompanying condensed consolidated financial statements of CEL-SCI Corporation and subsidiary (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, interim condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in the Companys annual report on Form 10-K for the year ended September 30, 2010. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the financial position as of June 30, 2011 and the results of operations for the nine and three-month periods then ended. The condensed consolidated balance sheet as of September 30, 2010 is derived from the September 30, 2010 audited consolidated financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the nine and three-month periods ended June 30, 2011 and 2010 are not necessarily indicative of the results to be expected for the entire year.   Certain items in the consolidated financial statements have been reclassified to conform to the current presentation.   Significant accounting policies are as follows: Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Depreciation and amortization expense for the nine-month periods ended June 30, 2011 and 2010 was $373,022 and $318,800, respectively. Depreciation and amortization expense for the three-month periods ended June 30, 2011 and 2010 was $126,438 and $114,894, respectively. During the nine months ended June 30, 2011 and 2010, equipment with a net book value of $2,828 and $2,081 was retired. During the three months ended June 30, 2011 and 2010, equipment with a net book value of $2,591 and $2,081 was retired.   Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. During the nine-month periods ended June 30, 2011 and 2010, the Company recorded patent impairment charges of $-0- and $5,381, respectively. During the three-month periods ended June 30, 2011 and 2010, the Company recorded no patent impairment charges. For the nine-month periods ended June 30, 2011 and 2010, amortization of patent costs totaled $61,414 and $58,658, respectively. For the three-month periods ended June 30, 2011 and 2010, amortization of patent costs totaled $21,710 and $19,680, respectively. The Company estimates that amortization expense will be $82,594 for each of the next five years, totaling $412,970.   Research and Development Costs - Research and development expenditures are expensed as incurred. Total research and development costs, excluding depreciation, were $9,231,296 and $7,733,544, respectively, for the nine months ended June 30, 2011 and 2010. Total research and development costs, excluding depreciation, were $2,924,771 and $1,587,520, respectively, for the three months ended June 30, 2011 and 2010.   Income Taxes - The Company has net operating loss carryforwards of approximately $140 million. The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.   Derivative Instruments The Company has entered into financing arrangements that consist of freestanding derivative instruments or are hybrid instruments that contain embedded derivative features. The Company has also issued warrants to various parties in connection with work performed by these parties. The Company accounts for these arrangements in accordance with Codification 815-10-50, Accounting for Derivative Instruments and Hedging Activities. The Company also accounts for warrants in accordance with Codification 815-40-15, Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entitys Own Stock. In accordance with accounting principles generally accepted in the United States (GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.   Deferred rent (asset) The deferred rent is discussed at Note G. Long-term interest receivable on the deposit on the manufacturing facility has been combined with the deferred rent (asset) for both periods for comparability.   Stock-Based Compensation The Company follows Codification 718-10-30-3, Share-Based Payment. This Codification applies to all transactions involving issuance of equity by a company in exchange for goods and services, including to employees. Compensation expense has been recognized for awards that were granted, modified, repurchased or cancelled on or after October 1, 2005 as well as for the portion of awards previously granted that vested during the period ended June 30, 2011. For the nine months ended June 30, 2011 and 2010, the Company recorded $1,104,933 and $939,350, respectively, in general and administrative expense for the cost of employee options. For the three months ended June 30, 2011 and 2010, the Company recorded $407,469 and $321,268, respectively, in general and administrative expense for the cost of employee options. The Company's options vest over a three-year period from the date of grant. After one year, the stock is one-third vested, with an additional one-third vesting after two years and the final one-third vesting at the end of the three-year period. There were 2,379,594 and 400,000 options granted to employees during the nine-month periods ended June 30, 2011 and 2010, respectively. There were 2,360,800 and 6,000 options granted to employees during the three-month periods ended June 30, 2011 and 2010, respectively. Options are granted with an exercise price equal to the closing price of the Company's stock on the day before the grant. The Company determines the fair value of the employee stock-based compensation using the Black Scholes method of valuation. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan and Stock Bonus Plans. In some cases these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. A summary chart and description of activity for the quarter of the Plans follows in Note C. For further discussion of the Stock Option Plans, Stock Compensation Plan and Stock Bonus Plans, see Form 10-K for the year ended September 30, 2010.

C.	STOCKHOLDERS EQUITY   Below is a chart of the stock options, stock bonuses and compensation granted by the Company. Each option represents the right to purchase one share of the Companys common stock at June 30, 2011: <p style="font: normal 12pt Times New Roman, Times, Serif; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; font-variant: normal; margin-top: 0; margin-bottom: 0; font-variant: normal; text-decoration: underline; text-align: center"> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Name of Plan</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="text-align: right; border-bottom: Black 1pt solid">Total Shares Reserved Under Plan</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="text-align: right; border-bottom: Black 1pt solid">Shares Reserved for Outstanding Options</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="text-align: right; border-bottom: Black 1pt solid">Shares Issued as Stock Bonus</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="text-align: right; border-bottom: Black 1pt solid">Remaining Options/Shares Under Plans</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%">Incentive Stock Option Plans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">19,100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">11,168,041</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">N/A</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">7,320,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,463,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,690,510</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,940,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,587,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,350,883</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">N/A</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,386,531</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,113,469</td><td style="text-align: left"> </td></tr> </table>   Stock-Based Compensation Expense <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; padding-bottom: 1pt">Nine Months Ended June 30</td><td style="padding-bottom: 1pt"> </td> <td colspan="7" style="text-align: center; padding-bottom: 1pt">Three Months Ended June 30</td></tr> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%">Employees</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,210,735</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,151,794</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">407,469</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">321,268</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Employees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">758,636</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,900</td><td style="text-align: left"> </td></tr> </table>     Options and stock to employees   During the nine months ended June 30, 2011, 29,268 options were exercised from the Companys option plans at prices ranging from $0.22 to $0.48. The total intrinsic value of options exercised during the nine months ended June 30, 2011 was $10,944. The Company received a total of $13,056 from the exercise of the options during the nine months ended June 30, 2011. During the three months ended June 30, 2011, no options were exercised from the Companys option plans. During the nine months ended June 30, 2010, 89,958 options were exercised from the Companys option plans. The total intrinsic value of options exercised during the nine months ended June 30, 2010 was $32,999. The Company received a total of $36,330 from the exercise of options during the nine months ended June 30, 2010. During the three months ended June 30, 2010, no options were exercised from the Companys option plans.   During the nine months ended June 30, 2011, 2,379,594 stock options were granted at prices ranging from $0.63 to $0.85 with a fair value of $1,458,764 and 30,500 options expired and 2,000 were forfeited. During the three months ended June 30, 2011, 2,360,800 stock options were granted at prices ranging from $0.63 to $0.69 with a fair value of $1,445,172 and 27,500 options expired and 1,000 were forfeited. During the nine months ended June 30, 2010, 400,000 stock options were granted at prices ranging from $0.49 to $1.93 with a fair value of $420,371 and 48,167 options expired and 1,000 were forfeited. During the three months ended June 30, 2010, 6,000 stock options were granted at prices ranging from $0.49 to $0.63 with a fair value of $3,199 and 45,667 options expired.   During the nine months ended June 30, 2011, the Company extended 306,500 employee options. The options were due to expire between January 26, 2011 through December 3, 2011. All options were extended for an additional three years from the current expiration date. The additional cost of $105,802 was recorded as a charge to option expense. The value of the fully vested employee option extension was determined using the Black Scholes method. There were no options extended during the three months ended June 30, 2011. During the nine months ended June 30, 2010, the Company extended 518,832 employee options. The options were due to expire from February 2, 2010 through December 8, 2010. All options were extended for an additional three years from the current expiration date. The additional cost of $212,444 was recorded as a debit to option expense and a credit to additional paid-in capital. The value of the fully vested employee option extension was determined using the Black Scholes method. There were no options extended during the three months ended June 30, 2010.     Options and stock to non-employees   Options to non-employees are accounted for in accordance with Codification 505-50-05-5, Equity Based Payments to Non-Employees. Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires management to make assumptions regarding the fair value of the options at the date of grant and the expected life of the options. There were no options granted to non-employees during the nine and three months ended June 30, 2011. There were no options granted to non-employees during the nine months ended June 30, 2010. During the nine and three months ended June 30, 2011, 100,000 options expired that were issued to a consultant.   There were 277,169 and no shares of common stock issued to consultants during the nine and three months ended June 30, 2011 for a cost of $160,964 and $-0-, respectively, of which $135,965 was expensed for the nine months ended June 30, 2011 and $5,001 was expensed for the three months ended June 30, 2011. Additionally, a portion of the cost of common stock issued in previous quarters was expensed. The cost for the previously issued shares for the nine and three months ended June 30, 2011 was $1,982 and $-0- respectively. There were 370,758 and no shares of common stock issued to consultants during the nine and three months ended June 30, 2010 at a cost for the nine and three months ended June 30, 2010 of $409,562 and $-0-, respectively. In addition, a portion of the cost of common stock issued in previous quarters was expensed. This cost for the nine and three months ended June 30, 2010 was $349,074 and $57,900, respectively.   During the nine months ended June 30, 2011, the Company extended 80,000 options issued to a consultant. The options were scheduled to expire in October 2010. All options were extended for an additional five years from the current expiration date. The additional cost of $30,186 was recorded as a charge to stock-based compensation expense. The value of the fully vested option extension was determined using the Black Scholes method. There was no extension of options issued to consultants during the three months ended June 30, 2011. There was no extension of options issued to consultants during the nine and three months ended June 30, 2010.   Derivative liabilities and warrants   Below is a chart showing the derivative liabilities and the number of warrants outstanding at June 30, 2011: <table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-decoration: underline; text-align: left">Warrant</td> <td style="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> Issue Date</td> <td style="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> Shares Issuable upon Exercise of Warrant</td> <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> Exercise Price</td> <td style="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-decoration: underline; text-align: left">Expiration Date</td> <td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-decoration: underline; text-align: left">Refer-ence</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> </td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> </td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> </td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> </td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> </td> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> </td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series K</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">8/4/06</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2,638,163</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">$   0.40</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2/4/12</td> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series N</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">8/18/08</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">3,890,782</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.40</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">8/18/14</td> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series A</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">6/24/09</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1,303,472</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.50</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">12/24/14</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left"> 1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">C. Schleuning (Series A)</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">7/8/09</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">167,500</td> <td style="vertical-align: top; padding-right: 12.3pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">0.50</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">01/08/15</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series B</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">9/4/09</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">500,000</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.68</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">9/4/14</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series C</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">8/20/09 8/26/09</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4,634,886</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.55</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2/20/15</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series D</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">9/21/09</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4,714,284</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    1.50</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">9/21/11</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series E</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">9/21/09</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">714,286</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    1.75</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">8/12/14</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series L</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/18/07</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">951,669</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.75</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/17/12</td> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series L (repriced)</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/18/07</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1,000,000</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.56</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/17/13</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series M</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/18/07</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">1,221,668</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    2.00</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/17/12</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2</td></tr> <tr> <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series M (modified)</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4/18/07</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">6,000,000</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    0.60</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">7/31/14</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">2</td></tr> <tr> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Series O</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">3/6/09</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">6,800,000</td> <td style="padding-right: 5.4pt; padding-left: 16.05pt; letter-spacing: -0.1pt; text-align: left; text-indent: -16.05pt">    0.25</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">3/6/16</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">3</td></tr> <tr> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">Private Investors</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">5/30/03- 6/30/09</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">8,609,375</td> <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">0.47 1.25</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">    5/30/13 - 7/18/14</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">4</td></tr> <tr> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Warrants held by Officer and Director</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">6/24/09- 7/6/09</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">3,497,539</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">0.40 0.50</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">12/24/14 1/6/15</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; letter-spacing: -0.1pt; text-align: left">5</td></tr> </table>   1.      Derivative Liabilities   See below for details of the balances of derivative instruments at June 30, 2011 and September 30, 2010.   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">June 30, 2011</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">September 30,2010</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%">Series K warrants</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">422,106</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,002,502</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>2009 financings warrants (Series A thru E)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,208,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,037,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>2008 warrants reclassified from equity to derivative liabilities on October 1, 2009 (Series N)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,245,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,906,483</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Preferred stock issued in settlement (Note G)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,043,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Convertible notes issued in settlement (Note G)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">4,929,000</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">0</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Total derivative liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">11,847,218</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">6,946,051</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   		    The Company accounted for the Series K and A through E Warrants as derivative liabilities in accordance with Codification 815-10, Accounting for Derivative Instruments and Hedging Activities. For the nine and three months ended June 30, 2011, the Company recorded a gain of $1,393,282 and a gain of $877,166 on the Series A through E derivative instruments, respectively. During the nine and three months ended June 30, 2011, the Company recorded a gain of $580,396 and a gain of $369,343 on the remaining Series K warrants, respectively. During the nine and three months ended June 30, 2010, the Company recognized a gain of $13,956,036 and a gain of $1,897,335 on the remaining Series A through E derivative instruments, respectively. During the nine and three months ended June 30, 2010, the Company recorded a gain of $3,120,172 and a gain of $422,106, respectively, on the remaining Series K warrants.   During the nine months ended June 30, 2010, 1,335,221 Series K warrants, on which the Company recognized a gain on exercise of $280,223 and 8,813,088 Series A warrants, on which the Company recognized a total gain of $8,433,451 were exercised. When the warrants were exercised, the value of these warrants was converted from derivative liabilities to equity. Series K warrants transferred to equity totaled $1,223,518 and Series A warrants transferred to equity totaled $4,276,972. During the three months ended June 30, 2010, no Series A warrants were exercised. During the three months ended June 30, 2010, 319,767 Series K warrants, on which the Company recognized a loss on exercise of $148,546, were exercised.   During the nine and three months ended June 30, 2011, 757,331 and no Series C warrants were exercised. The Company recognized a gain on exercise of $232,892 and $-0-, respectively. When the warrants were exercised, the value of these warrants was converted from derivative liabilities to equity. Series C warrants transferred to equity totaled $202,830 and $-0-, respectively.   On October 1, 2009, the Company reviewed all outstanding warrants in accordance with the requirements of Codification 815-40, Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entitys Own Stock. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instruments contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the purchase price for certain dilutive events, which includes an adjustment to the number of shares issuable upon the exercise of the warrant in the event that the Company makes certain equity offerings in the future at a price lower than the exercise prices of the warrant instruments. Under the provisions of Codification 815-40, the warrants are not considered indexed to the Companys stock because future equity offerings or sales of the Companys stock are not an input to the fair value of a fixed-for-fixed option on equity shares, and equity classification is therefore precluded. Accordingly, effective October 1, 2009, 3,890,782 Series N warrants issued in August 2008 were determined to be subject to the requirements of this topic and were valued using the Black-Scholes formula as of October 1, 2009 at $6,186,343. Effective October 1, 2009, the Series N warrants are recognized as a liability in the Companys condensed consolidated balance sheet at fair value with a corresponding adjustment to accumulated deficit and will be marked-to-market each reporting period. The Series N warrants were revalued on June 30, 2011 at $1,245,050, which resulted in a gain on derivatives and a decrease in derivative liabilities of $661,433 and $505,802 for the nine and three months ended June 30, 2011, respectively, due to the decrease in the Companys stock price since September 30, 2010. During the nine and three months ended June 30, 2010, the Company recorded a gain of $4,824,569 and $583,617, respectively, on the Series N warrants.   Accounting for the Senior Convertible Notes and Redeemable Series A Convertible Preferred Stock The Senior Secured Convertible Note falls within the scope of ASC 815. Under ASC 815-15-25-4 through 6 or ASC 825-10-10-1, the Company may make an irrevocable election to initially and subsequently measure a hybrid financial instrument in its entirety at fair value. Any change in fair value between the respective reporting dates shall be recognized as gain or loss. Based on the Companys analysis of the Senior Secured Convertible Note, the Company identified several embedded derivative features. The Company elected, in accordance with ASC 825-10-10-1, to initially and subsequently carry the instrument at fair value without bifurcating the embedded derivatives. For the nine and three months ended June 30, 2011, the Company recorded a gain of $21,000 on the Senior Secured Convertible Notes.   The Series A Convertible Preferred Stock falls within the scope of ASC 480 because the nonconversion option was considered nonsubstantive. ASC 480-10-30-1 states, Mandatorily redeemable financial instruments shall be measured initially at fair value. Therefore, immediately after initially recording Series A Convertible Preferred Stock, the carrying value of the instrument in its entirety must be adjusted to fair value as of the issuance date with the difference recorded to loss. The Company also elected to adopt the fair value option ASC 825. The Series A Convertible Preferred Stock should be measured in its entirety and reported at fair value at each reporting date for so long as shares remain outstanding. Any change in fair value between the respective reporting dates shall be recognized as gain or loss. For the nine and three months ended June 30, 2011, the Company recorded a loss of $10,000 on the Series A Convertible Preferred Stock.   2.	Series L and M Warrants   On April 18, 2007, the Company completed a $15 million private financing. Shares were sold at $0.75, a premium over the closing price of the previous two weeks. The financing was accompanied by 10 million warrants with an exercise price of $0.75 and 10 million warrants with an exercise price of $2.00. The warrants are known as Series L and Series M warrants, respectively.   In September 2008, 2,250,000 of the original Series L warrants were repriced at $0.56 and extended for one year to April 17, 2013. The increase in the value of the warrants of $173,187 was recorded as a debit and a credit to additional paid-in capital in accordance with the original accounting for the Series L warrants. As of June 30, 2011, 1,000,000 of the Series L warrants at the reduced exercise price of $0.56 and 951,669 at the original exercise price of $0.75 remained outstanding.   On March 12, 2010, the Company temporarily reduced the exercise price of the Series M warrants, originally issued on April 18, 2007. The exercise price was reduced from $2.00 to $0.75. At any time prior to June 16, 2010 investors could have exercised the Series M warrants at a price of $0.75 per share. For every two Series M warrants exercised prior to June 16, 2010 the investor would have received one Series F warrant. Each Series F warrant would have allowed the holder to purchase one share of CEL-SCIs common stock at a price of $2.50 per share at any time on or before June 15, 2014. After June 15, 2010 the exercise price of the Series M warrants reverted back to $2.00 per share. Any person exercising a Series M warrant after June 15, 2010 would not receive any Series F warrants. The Series M warrants expire on April 17, 2012. An analysis of the modification to the warrants determined that the modification increased the value of the warrants by $1,432,456. This cost was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. This cost is included in modification of warrants and increased the net loss available to shareholders on the condensed, consolidated statements of operations. There were no exercises of the Series M warrants at the reduced price and the exercise price of the Series M warrants reverted back to $2.00 on June 16, 2010.   On August 3, 2010, the Companys Board of Directors approved an amendment to the terms of the Series M warrants held by an investor. The investor was the owner of 8,800,000 warrants priced at $2.00 per share. The investor may now purchase 6,000,000 shares of the Companys common stock (reduced from 8,800,000) at a price of $0.60 per share. An analysis of the modification to the warrants determined that the modification increased the value of the warrants by $100,000. The adjustment was recorded as a debit and a credit to additional paid-in capital. As of June 30, 2011, all of these warrants remained outstanding. In addition, 1,221,668 Series M warrants at the original exercise price of $2.00 were outstanding as of June 30, 2011.   On February 1, 2011, 6,000,000 Series M warrants were extended for two years. The warrants expire on July 31, 2014. The increase in the fair value of the warrants was $661,457. This cost was recorded as a debit and a credit to additional paid-in capital and was a deemed dividend. This cost is included in modification of warrants and increased the net loss available to shareholders on the condensed, consolidated statements of operations.   3.      Licensing Agreement Warrants   On March 6, 2009, the Company entered into a licensing agreement with Byron Biopharma LLC (Byron) under which the Company granted Byron an exclusive license to market and distribute the Companys cancer drug Multikine in the Republic of South Africa. Pursuant to the agreement Byron will be responsible for registering the product in South Africa. Once Multikine has been approved for sale, the Company will be responsible for manufacturing the product, while Byron will be responsible for sales in South Africa. Revenues will be divided equally between the Company and Byron. To maintain the license Byron, among other requirements, made a $125,000 payment to the Company on March 8, 2010. On March 30, 2009, and as further consideration for its rights under the licensing agreement, Byron purchased 3,750,000 Units from the Company at a price of $0.20 per Unit. Each Unit consisted of one share of the Companys common stock and two warrants. Each warrant entitles the holder to purchase one share of the Companys common stock at a price of $0.25 per share. The warrants expire on March 6, 2016. The Company filed a registration statement to register the shares issuable upon the exercise of the warrants. The Units were accounted for as an equity transaction using the Black Scholes method to value the warrants. The fair value of the warrants was calculated to be $1,015,771. As of June 30, 2011, 6,800,000 warrants remain outstanding. During the nine and three months ended June 30, 2011, 700,000 of these warrants were exercised, for which the Company received $175,000.   4.      Private Investor Warrants   Between May 30, 2003 and June 30, 2009 CEL-SCI sold shares of its common stock in private transactions. In some cases warrants were issued as part of a financing. As of June 30, 2011, 8,609,375 warrants remain outstanding. For further discussion of these warrants, see the Companys Form 10-K for the year ended September 30, 2010.   On February 1, 2011, 1,325,000 warrants were extended for three years. The increase in the fair value of the warrants was $406,912. This cost was recorded as a debit and a credit to additional paid-in capital and is a deemed dividend. This cost is included in modification of warrants and increased the net loss available to shareholders on the condensed, consolidated statements of operations.     5.      Warrants held by Officer and Director  Between December 2008 and June 2009, Maximilian de Clara, the Companys President and a director, loaned the Company $1,104,057. In accordance with the loan agreement, the Company issued Mr. de Clara warrants which entitle him to purchase 1,648,244 shares of the Companys common stock at a price of $0.40 per share. The warrants are exercisable at any time prior to December 24, 2014. As consideration for a further extension of the note, Mr. de Clara received warrants which allow him to purchase 1,849,295 shares of the Companys common stock at a price of $0.50 per share at any time prior to January 6, 2015. As of June 30, 2011, all warrants remain outstanding. See Note E for additional information.

D.	FAIR VALUE MEASUREMENTS   Effective October 1, 2008, the Company adopted the provisions of Codification 820-10, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about such measurements that are permitted or required under other accounting pronouncements. While Codification 820-10 may change the method of calculating fair value, it does not require any new fair value measurements. The adoption of Codification 820-10 did not have a material impact on the Companys results of operations, financial position or cash flows.   In accordance with Codification 820-10, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.   Codification 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:   ·       Level 1 Observable inputs such as quoted prices in active markets for identical assets or liabilities ·       Level 2 Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets ·       Level 3 Unobservable inputs that reflect managements assumptions   For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Companys assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed consolidated balance sheet at June 30, 2011: <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 40%; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Significant Other Observable Inputs (Level 2)</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Significant Unobservable Inputs (Level 3)</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Total</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Derivative instruments</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">11,847,218</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">11,847,218</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed consolidated balance sheet at September 30, 2010: <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 40%; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Significant Other Observable Inputs (Level 2)</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Significant Unobservable Inputs (Level 3)</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td><td style="width: 10%; text-align: right; border-bottom: Black 1pt solid">Total</td><td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Derivative instruments</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">0</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">6,946,051</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">6,946,051</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the periods ended June 30, 2011 and 2010:   <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center"> </td><td> </td> <td colspan="7" style="text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">2010</td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%">Beginning balance</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,946,051</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">35,113,970</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Transfers in</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,186,343</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Transfers out</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,219,830</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,510,490</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Realized and unrealized gains recorded in earnings</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(2,879,003</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(30,614,451</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">11,847,218</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">5,175,372</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   The fair values of the Companys derivative instruments disclosed above are primarily derived from valuation models where significant inputs such as historical price and volatility of the Companys stock as well as U.S. Treasury Bill rates are observable in active markets.

F.	OPERATIONS, FINANCING The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities and clinical trials. The Company has funded such costs with proceeds realized from the public and private sale of its common stock, preferred stock and promissory notes. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. There can be no assurance the Company will be successful in raising additional funds. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain Federal Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to capital through the MLV sales agreement (see Note G to the accompanying financial statements), it has enough capital to support its operations for more than the next twelve months. The cash expenditure from the settlement will be dependent on the stock price during the next 8 months. If the stock price remains above $0.67, the conversion price of the settlement securities, it is likely that most of the settlement securities will be converted into CEL-SCI common stock and will not result in the planned cash payments. It would seem likely that a higher share price will therefore reduce the Companys cash expenditures during the next 8 months by an amount between $0 (below $0.67 during the next 8 months) and $7 million. The Company has two partners who have agreed to participate in and pay for part of the Phase III clinical trial for Multikine. Since the Company was able to raise substantial capital during 2009, the Company completed the preparations for the Phase III trial for Multikine. On December 29, 2010, the Company announced that it had commenced the Phase III clinical trial for Multikine. The net cost to the Company of the clinical trial is estimated to be $25 - $26 million.   In November 2010, the Company received a $733,437 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The Company recognizes revenue as the expenses are incurred. The amount of the grant earned during the nine and three months ended June 30, 2011 was $717,298 and $33,098, respectively. The balance of the funds will be collected in October 2011. The grant was related to three of the Companys projects including the Phase III trial of Multikine. The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free. The tax credit/grant program covers research and development costs from 2009 and 2010 for all qualified therapeutic discovery projects. As of June 30, 2011, the Company has a receivable for grant funds earned but not yet received of $145,157.

G.	COMMITMENTS AND CONTINGENCIES   Lease Agreement - In August 2007, the Company leased a building near Baltimore, Maryland. The building, which consists of approximately 73,000 square feet, was remodeled in accordance with the Companys specifications so that it can be used by the Company to manufacture Multikine for the Companys Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and required an annual base rent payments of $1,575,000 during the first year of the lease. The annual base rent escalates each year at 3%. The Company is also required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The lease required the Company to pay $3,150,000 towards the remodeling costs, which will be recouped by reductions in the annual base rent of $303,228 in years six through twenty of the lease, subject to the Company maintaining compliance with the lease covenants. On January 24, 2008, a second amendment to the lease for the manufacturing facility was signed. In accordance with the amendment, the Company was required to pay the following: 1) an additional $518,790 for movable equipment, which increased restricted cash, and 2) an additional $1,295,528 into the escrow account to cover additional costs, which increased deferred rent. These funds were transferred in early February 2008. In April 2008, an additional $288,474 was paid toward the completion of the manufacturing facility. The Company took possession of the manufacturing facility in October of 2008. An additional $505,225 was paid for the completion of the work on the manufacturing facility in October 2008. During the nine and three months ended June 30, 2010, an additional $32,059 was paid for final completion costs. During the nine months ended June 30, 2011, $21,177 of the remaining restricted funds was paid to the landlord for a bonus on completion.   In December 2008, the Company was not in compliance with certain lease requirements (i.e., failure to pay an installment of Base Annual Rent). However, the landlord did not declare the Company to be in default under the terms of the lease, but instead renegotiated the lease. In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced the 3,000,000 warrants initially issued to the landlord in July 2007 at $1.25 per share with an expiration date of July 12, 2013. These warrants were repriced at $0.75 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515. In addition, 787,500 additional warrants were given to the landlord of the manufacturing facility on the same date. These warrants are exercisable at $0.75 per share and will expire on January 26, 2014. The cost of these warrants was $45,207. All back rent was paid to the landlord in early July 2009. During the three months ended June 30, 2009, the Company issued the landlord an additional 2,296,875 warrants in accordance with an amendment to the agreement. These warrants were issued at a price of $0.75 and will expire between March 31, 2014 and June 30, 2014. These warrants were valued at $251,172 using the Black Scholes method. These warrants are included in the private investor warrants in the Stockholder Equity section (Note C, Reference 4). The Company is in compliance with the lease and, in February 2010, received a refund of the $1,575,000 additional deposit placed with the landlord in July 2008.   On January 28, 2009, the Company subleased a portion of the manufacturing facility. The sublease commenced on February 2, 2009 and ended in July 2010. The Company received $10,300 per month in rent for the subleased space.   The Company began amortizing the deferred rent on the building on October 7, 2008, the day that the Company took possession of the building. The amortization of the deferred rent for the nine months ended June 30, 2011 was $559,868 and for the three months ended June 30, 2011 was $180,144. The amortization of the deferred rent for the nine months ended June 30, 2010 was $606,583 and for the three months ended June 30, 2010 was $201,820.   Equity Line of Credit - On December 30, 2008, the Company entered into an Equity Line of Credit agreement as a source of funding for the Company. The Equity Line was never utilized and the agreement ended in January 2011.   MLV Agreement - On December 10, 2010, the Company entered into a sales agreement with McNicoll Lewis & Vlak, LLC (MLV) relating to shares of common stock which have been registered by means of a shelf registration statement filed in July 2009. The Company may offer and sell shares of its common stock, having an aggregate offering price of up to $30 million from time to time through MLV acting as agent and/or principal.   Sales of the Companys common stock, if any, may be made in sales deemed to be at-the-market equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the NYSE Amex, the existing trading market for the Companys common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. MLV will act as sales agent on a best efforts basis. The Company is not required to sell any shares to MLV and MLV is not required to sell any shares on the Companys behalf or purchase any of our shares for its own account.   MLV will be entitled to a commission in an amount equal to the greater of 3% of the gross proceeds from each sale of the shares, or $0.025 for each share sold, provided, that, in no event will MLV receive a commission greater than 8.0% of the gross proceeds from the sale of the shares. During the nine months ended June 30, 2011, the Company sold 3,765,809 shares of common stock to MLV for $2,457,518, less commissions and fees of $99,789. During the three months ended June 30, 2011, the Company sold 1,864,682 shares of common stock to MLV for $985,741, less commissions and fees of $48,115.   Settlement - On May 16, 2011, CEL-SCI entered into an Exchange Agreement (referred to herein as the "Settlement Agreement") with thirteen hedge funds (the "plaintiffs") to settle all claims arising from a lawsuit initiated by the plaintiffs in October 2009 in the United States District Court for the Southern District of New York (the "Court"). As previously disclosed by CEL-SCI in its public filings, in August 2006 the plaintiffs (or their predecessors) purchased from CEL-SCI Series K notes convertible into CEL-SCI common stock and Series K warrants to purchase CEL-SCI common stock under financing agreements which provided the Series K notes and warrants with anti-dilution protection if CEL-SCI sold additional shares of common stock, or securities convertible into common stock, at a price below the then applicable conversion price of the notes or the exercise price of the warrants. In their lawsuit, the plaintiffs alleged that a March 2009 drug marketing and distribution agreement in which CEL-SCI sold units of common stock and warrants to an unrelated third party triggered these anti-dilution provisions, and that CEL-SCI failed to give effect to these provisions. The plaintiffs sought $30 million in actual damages, $90 million in punitive damages, the issuance of additional shares of common stock and warrants, and a reduction in the conversion price of the Series K notes and the exercise price of the Series K warrants. CEL-SCI denied the plaintiffs' allegations in the lawsuit and asserted that the 2009 agreement was a strategic transaction which did not trigger the anti-dilution provisions of the 2006 financing agreements.   Although the Company has vigorously defended the lawsuit and believed the plaintiffs' claims were without merit, the Company believed that a settlement of this lawsuit was in the best interests of the shareholders. The settlement was entered into to avoid the substantial costs of further litigation and the risk and uncertainty that the litigation entails. By ending this dispute, and ending the significant demands on the time and attention of the Company's management necessary to respond to the litigation, the Company is better able to focus on executing its ongoing Phase III clinical trial with its novel and non-toxic cancer drug Multikine.   Under the terms of the Settlement Agreement and its related agreements, the plaintiffs and CEL-SCI terminated the pending litigation and released each other from all claims each may have had against the other, with certain customary exceptions. CEL-SCI agreed to make a $3 million cash payment and issue $9 million of securities to the plaintiffs. These securities consist of senior secured convertible promissory notes with an aggregate principal amount of $4.95 million and 4,050 shares of redeemable Series A Convertible Preferred Stock with an aggregate stated value of $4.05 million. The $3 million cash payment was made at the closing under the Settlement Agreement. The $9 million of securities will be redeemed through nine equal monthly installment payments of approximately $1 million each, plus interest on the notes and dividends on the shares at the rate of 8% per annum, with payments beginning on June 17, 2011 (the month of October requires no payment) and ending on March 1, 2012. As these installments of the principal amount of the notes and the stated value of the preferred shares are paid down, or as the notes or the preferred shares are converted by the holders into common stock, the initial $9 million due (plus interest and dividends) will be proportionately reduced until the notes are fully paid or converted and the preferred shares are fully redeemed or converted. CEL-SCI has pledged all of its assets as collateral for the repayment of these obligations. While the notes and preferred shares are outstanding, CEL-SCI is generally prohibited from paying dividends, incurring new debt or making any payments (other than interest) on existing debt, and is subject to certain restrictions on the transfer of its assets. The $12 million was accrued for and included in the March 31, 2011 consolidated financial statements. For the nine and three months ended June 30, 2011, $24,836 of interest and dividends are accrued. This amount is included in interest expense in the financial statements.   The notes and the Series A preferred shares will be convertible, at the option of the holder, into CEL-SCI common stock at a fixed price of $0.67 per share. The conversion price represented the most recent consolidated closing sale price of the common stock on the NYSE AMEX at the time the settlement agreement was signed by the parties. The plaintiffs have agreed to restrictions on their ability to effect short sales of the common stock based on the number of warrants and common shares they hold, but excluding shares issuable upon the conversion of the notes and preferred shares. The plaintiffs have further agreed to permit an independent accounting firm to review their trading records every three months to confirm their compliance with these restrictions.   The parties' respective obligations under the Settlement Agreement, including CEL-SCI's obligation to pay cash and issue notes and preferred shares to the plaintiffs, were subject to obtaining the approval by the Court of an order exempting the issuance to the plaintiffs of the notes and preferred shares from registration under Section 3(a)(10) of the Securities Act of 1933. This was to permit the notes and preferred shares, and the shares of common stock issuable upon conversion thereof, to be freely tradable.   On June 17, 2011 the final settlement agreement was signed. During the three months ended June 30, 2011, the $3,000,000 cash payment required by the settlement was made. In addition, the first payment for the preferred shares, totaling $1,017,000 for 1,017 preferred shares, was made on June 17, 2011.   As a condition of the settlement agreement, all claims against the Company were dismissed. As a result, the $81,395 overpayment by one of the claimants was dismissed and the liability was written off during the three months ended June 30, 2011.   The foregoing summary of the terms of the settlement is qualified in its entirety by the detailed terms of the Settlement Agreement and the related agreements and documents which are filed as exhibits to the Companys report on Form 10-Q for the three months ended March 31, 2011.

H.	EARNINGS PER SHARE   The Companys diluted earnings per share (EPS) are as follows for June 30, 2011 and 2010. For the nine months ended June 30, 2011, the computation of dilutive net loss per share excluded options and warrants to purchase approximately 33,000,000 shares of common stock because their inclusion would have an anti-dilutive effect.   <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; padding-bottom: 1pt">Nine Months Ended June 30, 2011</td></tr> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Weighted average shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">EPS</td></tr> <tr style="vertical-align: bottom"> <td style="width: 46%">Basic Earnings per Share</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(24,463,180</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">206,860,979</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(0.12</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td>Note Conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Convertible note and preferred stock conversion</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">0</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"></td><td style="text-align: right; border-bottom: Black 1pt solid">0</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid"> </td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Warrants and options convertible into shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">0</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="text-align: right; border-bottom: Black 1pt solid">0</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid"> </td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Dilutive EPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">(24,463,180</td><td style="text-align: left; padding-bottom: 2.5pt">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="text-align: right; border-bottom: Black 2.5pt double">206,860,979</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">(0.12</td><td style="text-align: left; padding-bottom: 2.5pt">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; padding-bottom: 1pt">Nine Months Ended June 30, 2010</td></tr> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Weighted average shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">EPS</td></tr> <tr style="vertical-align: bottom"> <td style="width: 46%">Basic Earnings per Share</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16,381,418</td><td style="width: 1%; text-align: left"></td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">201,208,121</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.08</td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom"> <td>Note Conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">124,206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,760,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Warrants and options convertible into shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(21,900,777)</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="text-align: right; border-bottom: Black 1pt solid">24,475,332</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid"> </td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Dilutive EPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">(5,395,153</td><td style="text-align: left; padding-bottom: 2.5pt">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="text-align: right; border-bottom: Black 2.5pt double">228,443,595</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">(0.02</td><td style="text-align: left; padding-bottom: 2.5pt">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; padding-bottom: 1pt">Three Months Ended June 30, 2011</td></tr> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Weighted average shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">EPS</td></tr> <tr style="vertical-align: bottom"> <td style="width: 46%">Basic Earnings per Share</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,114,255</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">208,402,408</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(0.01</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td>Note Conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,760,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Convertible note and preferred stock conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,836</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,914,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> Warrants and options convertible into shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,763,311)</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">18,033,347</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Dilutive EPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,811,328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">241,110,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="11" style="text-align: center; padding-bottom: 1pt">Three Months Ended June 30, 2010</td></tr> <tr style="vertical-align: bottom"> <td colspan="1" style="text-align: center; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">Weighted average shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; padding-bottom: 1pt">EPS</td></tr> <tr style="vertical-align: bottom"> <td style="width: 46%">Basic Earnings per Share</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(601,124</td><td style="width: 1%; text-align: left">)</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">204,592,051</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(0.00</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td>Note Conversion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,760,142</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">Warrants and options convertible into shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,903,058</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,475,332</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Dilutive EPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,462,780</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">231,827,525</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

I.	SUBSEQUENT EVENTS   On July 19, 2011 the Company announced that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for Multikine. Under the agreement, Tevas exclusive license to market and distribute Multikine in Israel and Turkey will be extended to include Croatia and Serbia. Teva is currently funding a part of the global Phase III clinical study at three clinical sites in Israel. Teva will be responsible for the costs of registering and selling the product in Serbia and Croatia and will pay the Company milestone payments upon approval of Multikine. The parties will share revenue generated from all four countries.

212754415 128872039 0 0

202830

5510490

-202830

-5510490

0 0 0 0 0 0 0 0 0 -6186343 0 0

E.	LOANS FROM OFFICER   Between December 2008 and June 2009, Maximilian de Clara, the Companys President and a director, loaned the Company $1,104,057. The loan from Mr. de Clara bears interest at 15% per year and was secured by a lien on substantially all of the Companys assets. The Company does not have the right to prepay the loan without Mr. de Claras consent. The loan was initially payable at the end of March 2009, but was extended to the end of June 2009. At the time the loan was due, and in accordance with the loan agreement, the Company issued Mr. de Clara warrants which entitle Mr. de Clara to purchase 1,648,244 shares of the Companys common stock at a price of $0.40 per share. The warrants are exercisable at any time prior to December 24, 2014. Pursuant to Codification section 470-50, the fair value of the warrants issuable under the first amendment was recorded as a discount on the note payable with a credit recorded to additional paid-in capital. The discount was amortized from April 30, 2009, through June 27, 2009. Although the loan was to be repaid from the proceeds of the Companys June 2009 financing, the Companys Directors deemed it beneficial not to repay the loan and negotiated a second extension of the loan with Mr. de Clara on terms similar to the June 2009 financing. Pursuant to the terms of the second extension the note was due on July 6, 2014, but, at Mr. de Claras option, the loan can be converted into shares of the Companys common stock. The number of shares which will be issued upon any conversion will be determined by dividing the amount to be converted by $0.40. As further consideration for the second extension, Mr. de Clara received warrants which allow Mr. de Clara to purchase 1,849,295 shares of the Companys common stock at a price of $0.50 per share at any time prior to January 6, 2015. On May 13, 2011, to recognize Mr. de Claras willingness to agree to subordinate his note to the convertible preferred shares and convertible debt as part of the settlement agreement, the Company extended the maturity date of the note to July 6, 2015.   In accordance with Codification 470-50, the second amendment to the loan was accounted for as an extinguishment of the first amendment debt. The extinguishment of the loan required that the new loan be recorded at fair value and a gain or loss was recognized, including the warrants issued in connection with the second amendment. This resulted in a premium of $341,454, which was amortized over the period from July 6, 2009, the date of the second amendment, to October 1, 2009, the date at which the loan holder could have demanded payment of the loan. During the nine months ended June 30, 2010, the Company amortized the remaining $3,282 in premium on the loan. During the nine months ended June 30, 2011 and 2010, the Company paid $124,206 in interest expense to Mr. de Clara. During the three months ended June 30, 2011 and 2010, the Company paid $41,402 in interest expense to Mr. de Clara. 1

EX-101.SCH 6 cvm-20110630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - Condensed Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0007 - Disclosure - Summary of Significant Policies link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - Loans from Officers link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - Operations, Financing link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cvm-20110630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cvm-20110630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cvm-20110630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus ASSETS CURRENT ASSETS Cash and cash equivalents Receivables Prepaid expenses Inventory used for R&D and manufacturing Deferred rent - current portion Total current assets RESEARCH AND OFFICE EQUIPMENT AND LEASEHOLD IMPROVEMENTS-- Less accumulated depreciation of $2,964,161 and $2,626,759 PATENT COSTS- less accumulated amortization of $1,267,104 and $1,205,690 RESTRICTED CASH DEFERRED RENT - net of current portion TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Due to employees Related party loan Convertible notes Convertible preferred stock - 3,033 shares outstanding Derivative instruments - current portion Total current liabilities Derivative instruments - net of current portion Deferred revenue Deferred rent Total liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred stock, $.01 par value; authorized, 200,000 shares; no shares issued and outstanding Common stock, $.01 par value; authorized, 450,000,000 shares; issued and outstanding, 210,584,868 and 204,868,853 shares at June 30, 2011 and September 30, 2010, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Assets Accumulated Depreciation for Research and Office Equipment and Leasehold Improvements Accumulated Amortization for Patents Liabilities Convertible preferred stock shares outstanding Stockholders Equity Preferred Stock Shares Par Value Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Outstanding Common Stock Shares Par Value Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Outstanding REVENUE: Rent income Grant and other income Total revenue EXPENSES: Research and development, excluding depreciation of $359,343, $316,575, $123,519 and $113,146 included below Depreciation and amortization General and administrative Foreign exchange gain Total expenses LOSS FROM OPERATIONS OTHER EXPENSES GAIN ON DERIVATIVE INSTRUMENTS INTEREST INCOME INTEREST EXPENSE NET (LOSS) INCOME BEFORE INCOME TAXES INCOME TAX PROVISION NET (LOSS) INCOME MODIFICATION OF WARRANTS NET (LOSS) INCOME AVAILABLE TO COMMON SHAREHOLDERS NET (LOSS) INCOME PER COMMON SHARE-BASIC NET LOSS PER COMMON SHARE-DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED Expenses Depreciation CASH FLOWS FROM OPERATING ACTIVITIES: NET (LOSS) INCOME Adjustments to reconcile net (loss) income to net cash used in operating activities: Issuance of convertible notes and preferred stock in legal settlement Issuance of common stock, warrants and stock options for services Common stock contributed to 401(k) plan Extension of options Employee option cost Gain on derivative instruments Decrease in deferred rent asset Amortization of loan premium Loss on abandonment of patents Loss on retirement of equipment Increase in prepaid expenses Increase in inventory for R&D and manufacturing Decrease in deposits Increase in receivables Decrease in accounts payable Increase in accrued expenses Decrease in amount due to employees Increase in deferred revenue (Decrease) increase in deferred rent liability NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Decrease in restricted cash Purchase of equipment Patent costs NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Payment for repurchase of preferred stock Proceeds from exercise of stock options and warrants Proceeds from sale of stock NET CASH PROVIDED BY FINANCING ACTIVITIES NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD SUPPLEMENTAL INFORMATION ON NONCASH TRANSACTIONS: Patent costs included in accounts payable: Increase in accounts payable Increase in patent costs Total Equipment costs included in accounts payable: Increase in accounts payable for Equipment costs Increase in research and office equipment Total Exercise of derivative liability warrants: Decrease in derivative liabilities Increase in additional paid-in capital Total Modification of warrants: Increase in additional paid-in capital Decrease in additional paid-in capital Total Adoption of ASC 815-40: Increase in derivative liabilities Increase in accumulated deficit Total Dismissal of liability for overpayment: Decrease in accrued expenses Increase in additional paid-in capital Total Note: Cash expenditures for interest expense Summary of Significant Policies New Accounting Pronouncements Stockholders' Equity Fair Value Measurements Loans from Officers Operations, Financing Commitments and Contingencies Earnings Per Share Subsequent Events Assets, Current Assets Liabilities, Current Liabilities [Default Label] Stockholders' Equity Attributable to Parent Liabilities and Equity Revenues Operating Expenses Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities EquipmentCostsIncludedInAccountsPayable TotalForExerciseOfDerivativeLiability Adjustments to Additional Paid in Capital, Warrant Issued TotalForModificationOfWarrants AdoptionOfAsc81540 IncreaseInAdditionalPaidInCapital DismissalOfLiabilityForOverpayment EX-101.PRE 10 cvm-20110630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (Parenthetical) (USD $)	Jun. 30, 2011	Sep. 30, 2010
Assets
Accumulated Depreciation for Research and Office Equipment and Leasehold Improvements	$ 2,964,161	$ 2,626,759
Accumulated Amortization for Patents	$ 1,267,104	$ 1,205,690
Liabilities
Convertible preferred stock shares outstanding	3,033	0
Stockholders Equity
Preferred Stock Shares Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	200,000	200,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Shares Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	450,000,000	450,000,000
Common Stock Shares Issued	210,584,868	204,868,853
Common Stock Shares Outstanding	210,584,868	204,868,853

XML 12 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
REVENUE:
Rent income	$ 0	$ 30,900	$ 0	$ 91,500
Grant and other income	77,403	0	784,036	0
Total revenue	77,403	30,900	784,036	91,500
EXPENSES:
Research and development, excluding depreciation of $359,343, $316,575, $123,519 and $113,146 included below	2,924,771	1,587,520	9,231,296	7,733,544
Depreciation and amortization	148,148	134,574	434,436	377,458
General and administrative	1,862,328	1,702,865	5,407,782	4,947,764
Foreign exchange gain	(12,100)	0	(30,704)	0
Total expenses	4,923,147	3,424,959	15,042,810	13,058,766
LOSS FROM OPERATIONS	(4,845,744)	(3,394,059)	(14,258,774)	(12,967,266)
OTHER EXPENSES	0	0	(12,000,000)	0
GAIN ON DERIVATIVE INSTRUMENTS	1,763,311	2,754,512	2,879,003	30,614,451
INTEREST INCOME	34,416	79,825	134,002	287,613
INTEREST EXPENSE	(66,238)	(41,402)	(149,042)	(120,924)
NET (LOSS) INCOME BEFORE INCOME TAXES	(3,114,255)	(601,124)	(23,394,811)	17,813,874
INCOME TAX PROVISION	0	0	0	0
NET (LOSS) INCOME	(3,114,255)	(601,124)	(23,394,811)	17,813,874
MODIFICATION OF WARRANTS	0	0	(1,068,369)	(1,432,456)
NET (LOSS) INCOME AVAILABLE TO COMMON SHAREHOLDERS	$ (3,114,255)	$ (601,124)	$ (24,463,180)	$ 16,381,418
NET (LOSS) INCOME PER COMMON SHARE-BASIC	$ (0.01)	$ 0.00	$ (0.12)	$ 0.08
NET LOSS PER COMMON SHARE-DILUTED	$ (0.02)	$ (0.01)	$ (0.12)	$ (0.02)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-BASIC	208,402,408	204,592,051	206,860,979	201,208,121
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING-DILUTED	241,110,822	231,827,525	206,860,979	228,443,595

XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information (USD $)	9 Months Ended
Document and Entity Information (USD $)	Jun. 30, 2011	Aug. 08, 2011
Entity Registrant Name	CEL SCI CORP
Entity Central Index Key	0000725363
Document Type	10-Q
Document Period End Date	Jun. 30, 2011
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float		$ 128,872,039
Entity Common Stock, Shares Outstanding		212,754,415
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2011

XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R12.htm IDEA: XBRL DOCUMENT

Operations, Financing

9 Months Ended

Jun. 30, 2011

Operations, Financing

F. OPERATIONS, FINANCING

XML 16 R8.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements

9 Months Ended

Jun. 30, 2011

New Accounting Pronouncements

B. NEW ACCOUNTING PRONOUNCEMENTS

XML 17 R14.htm IDEA: XBRL DOCUMENT

Earnings Per Share

9 Months Ended

Jun. 30, 2011

Earnings Per Share

H. EARNINGS PER SHARE

	Nine Months Ended June 30, 2011
	Net Loss			Weighted average shares		EPS
Basic Earnings per Share	$	(24,463,180	)		206,860,979	$	(0.12	)
Note Conversion		0			0
Convertible note and preferred stock conversion		0			0
Warrants and options convertible into shares of common stock		0			0
Dilutive EPS	$	(24,463,180	)		206,860,979	$	(0.12	)

	Nine Months Ended June 30, 2010
	Net Loss			Weighted average shares		EPS
Basic Earnings per Share	$	16,381,418			201,208,121	$	0.08
Note Conversion		124,206			2,760,142
Warrants and options convertible into shares of common stock		(21,900,777)			24,475,332
Dilutive EPS	$	(5,395,153	)		228,443,595	$	(0.02	)

	Three Months Ended June 30, 2011
	Net Loss			Weighted average shares		EPS
Basic Earnings per Share	$	(3,114,255	)		208,402,408	$	(0.01	)
Note Conversion		41,402			2,760,142
Convertible note and preferred stock conversion		24,836			11,914,925
Warrants and options convertible into shares of common stock		(1,763,311)			18,033,347
Dilutive EPS	$	(4,811,328	)		241,110,822	$	(0.02	)

	Three Months Ended June 30, 2010
	Net Loss			Weighted average shares		EPS
Basic Earnings per Share	$	(601,124	)		204,592,051	$	(0.00	)
Note Conversion		41,402			2,760,142
Warrants and options convertible into shares of common stock		(2,903,058	)		24,475,332
Dilutive EPS	$	(3,462,780	)		231,827,525	$	(0.01	)

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 18 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Jun. 30, 2011

Subsequent Events

I. SUBSEQUENT EVENTS

XML 19 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Jun. 30, 2011

Commitments and Contingencies

G. COMMITMENTS AND CONTINGENCIES

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 20 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flow (Unaudited) (USD $)	9 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
NET (LOSS) INCOME	$ (23,394,811)	$ 17,813,874
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	434,436	377,458
Issuance of convertible notes and preferred stock in legal settlement	9,000,000	0
Issuance of common stock, warrants and stock options for services	137,947	1,159,450
Common stock contributed to 401(k) plan	112,030	83,023
Extension of options	135,988	212,444
Employee option cost	1,104,933	939,350
Gain on derivative instruments	(2,879,003)	(30,614,451)
Decrease in deferred rent asset	468,030	754,276
Amortization of loan premium	0	(3,282)
Loss on abandonment of patents	0	5,381
Loss on retirement of equipment	2,828	2,081
Increase in prepaid expenses	(1,991,596)	(148,774)
Increase in inventory for R&D and manufacturing	(102,026)	(1,352,513)
Decrease in deposits	0	1,574,932
Increase in receivables	(414,126)	0
Decrease in accounts payable	(350,377)	(83,191)
Increase in accrued expenses	53,935	115,236
Decrease in amount due to employees	(40,226)	(25,020)
Increase in deferred revenue	0	125,000
(Decrease) increase in deferred rent liability	(2,190)	61
NET CASH USED IN OPERATING ACTIVITIES	(17,724,228)	(9,064,665)
CASH FLOWS FROM INVESTING ACTIVITIES:
Decrease in restricted cash	21,357	47,215
Purchase of equipment	(174,993)	(368,281)
Patent costs	(45,883)	(15,023)
NET CASH USED IN INVESTING ACTIVITIES	(199,519)	(336,089)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for repurchase of preferred stock	(1,017,000)	0
Proceeds from exercise of stock options and warrants	604,588	6,308,874
Proceeds from sale of stock	2,343,994	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,931,582	6,308,874
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(15,992,165)	(3,091,880)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	26,568,243	33,567,516
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	10,576,078	30,475,636
Patent costs included in accounts payable:
Increase in accounts payable	(93,553)	0
Increase in patent costs	93,553	0
Total	0	0
Equipment costs included in accounts payable:
Increase in accounts payable for Equipment costs	(33,705)	(48,657)
Increase in research and office equipment	33,705	48,657
Total	0	0
Exercise of derivative liability warrants:
Decrease in derivative liabilities	202,830	5,510,490
Increase in additional paid-in capital	(202,830)	(5,510,490)
Total	0	0
Modification of warrants:
Increase in additional paid-in capital	(1,068,369)	(1,432,456)
Decrease in additional paid-in capital	1,068,369	1,432,456
Total	0	0
Adoption of ASC 815-40:
Increase in derivative liabilities	0	(6,186,343)
Increase in accumulated deficit	0	6,186,343
Total	0	0
Dismissal of liability for overpayment:
Decrease in accrued expenses	81,395	0
Increase in additional paid-in capital	(81,395)	0
Total	0	0
Note:
Cash expenditures for interest expense	$ 124,206	$ 124,206

XML 21 R9.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Jun. 30, 2011

Stockholders' Equity

C. STOCKHOLDERS’ EQUITY

Below is a chart of the stock options, stock bonuses and compensation granted by the Company. Each option represents the right to purchase one share of the Company’s common stock at June 30, 2011:

Name of Plan	Total Shares Reserved Under Plan	Shares Reserved for Outstanding Options	Shares Issued as Stock Bonus	Remaining Options/Shares Under Plans
Incentive Stock Option Plans	19,100,000	11,168,041	N/A	7,320,225
Non-Qualified Stock Option Plans	35,760,000	23,463,240	N/A	8,690,510
Stock Bonus Plans	13,940,000	N/A	7,587,358	6,350,883
Stock Compensation Plans	11,500,000	N/A	5,386,531	6,113,469

Stock-Based Compensation Expense

	Nine Months Ended June 30				Three Months Ended June 30
	2011		2010		2011		2010
Employees	$	1,210,735	$	1,151,794	$	407,469	$	321,268
Non-Employees		168,133		758,636		5,001		57,900

Options and stock to employees

Options and stock to non-employees

Derivative liabilities and warrants

Below is a chart showing the derivative liabilities and the number of warrants outstanding at June 30, 2011:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant	Exercise Price	Expiration Date	Refer-ence

Series K	8/4/06	2,638,163	$ 0.40	2/4/12	1
Series N	8/18/08	3,890,782	0.40	8/18/14	1
Series A	6/24/09	1,303,472	0.50	12/24/14	1
C. Schleuning (Series A)	7/8/09	167,500	0.50	01/08/15	1
Series B	9/4/09	500,000	0.68	9/4/14	1
Series C	8/20/09 – 8/26/09	4,634,886	0.55	2/20/15	1
Series D	9/21/09	4,714,284	1.50	9/21/11	1
Series E	9/21/09	714,286	1.75	8/12/14	1
Series L	4/18/07	951,669	0.75	4/17/12	2
Series L (repriced)	4/18/07	1,000,000	0.56	4/17/13	2
Series M	4/18/07	1,221,668	2.00	4/17/12	2
Series M (modified)	4/18/07	6,000,000	0.60	7/31/14	2
Series O	3/6/09	6,800,000	0.25	3/6/16	3
Private Investors	5/30/03- 6/30/09	8,609,375	0.47 – 1.25	5/30/13 - 7/18/14	4
Warrants held by Officer and Director	6/24/09- 7/6/09	3,497,539	0.40 – 0.50	12/24/14 – 1/6/15	5

1. Derivative Liabilities

See below for details of the balances of derivative instruments at June 30, 2011 and September 30, 2010.

		June 30, 2011		September 30,2010
Series K warrants	$	422,106	$	1,002,502
2009 financings warrants (Series A thru E)		2,208,062		4,037,066
2008 warrants reclassified from equity to derivative liabilities on October 1, 2009 (Series N)		1,245,050		1,906,483
Preferred stock issued in settlement (Note G)		3,043,000		0
Convertible notes issued in settlement (Note G)		4,929,000		0
Total derivative liabilities	$	11,847,218	$	6,946,051

2. Series L and M Warrants

3. Licensing Agreement Warrants

4. Private Investor Warrants

5. Warrants held by Officer and Director

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Jun. 30, 2011

Fair Value Measurements

D. FAIR VALUE MEASUREMENTS

· Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

· Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

· Level 3 – Unobservable inputs that reflect management’s assumptions

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed consolidated balance sheet at June 30, 2011:

		Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	0	$	0	$	11,847,218	$	11,847,218

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed consolidated balance sheet at September 30, 2010:

		Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	0	$	0	$	6,946,051	$	6,946,051

	June 30,
	2011			2010
Beginning balance	$	6,946,051		$	35,113,970
Transfers in		9,000,000			6,186,343
Transfers out		(1,219,830	)		(5,510,490	)
Realized and unrealized gains recorded in earnings		(2,879,003	)		(30,614,451	)
Ending Balance	$	11,847,218		$	5,175,372

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 23 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 24 R11.htm IDEA: XBRL DOCUMENT

Loans from Officers

9 Months Ended

Jun. 30, 2011

Loans from Officers

E. LOANS FROM OFFICER

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 04
-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

XML 25 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Expenses
Depreciation	$ 123,519	$ 113,146	$ 359,343	$ 316,575

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References+ Details

XML 26 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Policies

9 Months Ended

Jun. 30, 2011

Summary of Significant Policies

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Certain items in the consolidated financial statements have been reclassified to conform to the current presentation.

Significant accounting policies are as follows:

Income Taxes - The Company has net operating loss carryforwards of approximately $140 million. The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.

XML 27 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (USD $)	Jun. 30, 2011	Sep. 30, 2010
CURRENT ASSETS
Cash and cash equivalents	$ 10,576,078	$ 26,568,243
Receivables	414,126	0
Prepaid expenses	2,290,315	298,719
Inventory used for R&D and manufacturing	1,578,260	1,476,234
Deferred rent - current portion	715,806	751,338
Total current assets	15,574,585	29,094,534
RESEARCH AND OFFICE EQUIPMENT AND LEASEHOLD IMPROVEMENTS-- Less accumulated depreciation of $2,964,161 and $2,626,759	1,097,679	1,264,831
PATENT COSTS- less accumulated amortization of $1,267,104 and $1,205,690	434,101	356,079
RESTRICTED CASH	0	21,357
DEFERRED RENT - net of current portion	6,635,686	7,068,184
TOTAL ASSETS	23,742,051	37,804,985
CURRENT LIABILITIES
Accounts payable	1,274,264	1,497,383
Accrued expenses	196,236	223,696
Due to employees	5,582	45,808
Related party loan	1,104,057	1,104,057
Convertible notes	4,929,000	0
Convertible preferred stock - 3,033 shares outstanding	3,043,000	0
Derivative instruments - current portion	469,249	424,286
Total current liabilities	11,021,388	3,295,230
Derivative instruments - net of current portion	3,405,969	6,521,765
Deferred revenue	125,000	125,000
Deferred rent	6,035	8,225
Total liabilities	14,558,392	9,950,220
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; authorized, 200,000 shares; no shares issued and outstanding	0	0
Common stock, $.01 par value; authorized, 450,000,000 shares; issued and outstanding, 210,584,868 and 204,868,853 shares at June 30, 2011 and September 30, 2010, respectively	2,105,849	2,048,689
Additional paid-in capital	192,272,589	187,606,044
Accumulated deficit	(185,194,779)	(161,799,968)
Total stockholders' equity	9,183,659	27,854,765
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 23,742,051	$ 37,804,985

ZIP 28 0001354488-11-002531-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-11-002531-xbrl.zip M4$L#!!0````(`/V!"3]"*&?T\&X``%_)`P`0`!P`8W9M+3(P,3$P-C,P+GAM M;%54"0`#?95!3GV504YU>`L``00E#@``!#D!``#D76USHSBV_GZK[G_@9J>F M=JOB1+Q#^F4KXR1=WNE.,DEZ9N";"%#1B!W-V9G>GJ MI$'2\^CHZ.@<24AO__Z\")4GG*0DCMX=J2?H2,&1'PL#(:P;NWSX])2,[HWPJ4&*5GSREY M=S3/LN79Z>F7+U].ON@G<3([U1!23__YZ>.]/\<+;T2B-/,B'Q^5N4(2_5&7 M3W5=]Y2]+9/NI*3@)89^2E\_>NFF9$JP)?T.$W@;9.L,?&+S-']924IJDUIY M4E(F#?!6NA3[)[/XZ11>0'I5'2%UI*ME\@1/&RE;I_"V3$C2V-!4NZU^>8HR MPRH=S3QONI3T[\>%&DM$8Z.BH5G^K3 M6QE_73]G`3TS93@1&$D<45ZI9:- M)S\?O4?PGZV9NJ6_/=W.O($[K<4KT)8@^3C890%=*,DNO`R_WU2G+&GS;B<; MCH(R4U'O#7Q0R5(^KQ`H'Q8B;9;S>7HS?;6RS0U45B.D\HU4(4'3N:]:2$4% M#B.DO,<"P*;'HE>I57R/+:LCUF/1(7ML81E!X8T_D64LJO,=6<;U"+21\^O7 MY[(ZWY$^Y\85.MKK-JYE!0X]`KU"!:R.0`J-`?QN&W`" M\@3ML2M;FO>:QD9>%B?<:W$9;'.L*Y4#O8=G),T2T*YK;X&50GGN:`37%H"-+S\J]^.),KZYNWU[VE3<+MP8 MND3BA9,HP,\_XY?.>'RW:RR-A[N(?6B8*'N`<+,S"CSZ)2^?SUY7["WK>9?Y M,-BY?-YA:2R-ASN'MP%-<15ZL\XP4R],<8Y0*8`O>;Q*$OJ8I+X7_HZ]1+0N MHW*P:RMM5P%^PV'XY!N^,(!Y,T78'=[0I['?,*T%#:+NRO<;B*P--Y MN2(A3M*><%NEU*AW+H<[O(R3C$2S^\S+5MW1?J>=?U]I=>J8"SY7HRMXUAWR M%[VJBCLE-2'D2<^SL9#R>8FCM'>?U#07Z:JYH5`M M5ART4R=S'5MUNV).HB>H?IR\@"QZFQ[3=C2+DS1?J"A@ERJJAFUINM$-\#Q- M<98.5&O5-&W#=+BFK!0KC-FM(9%KF'PU6S%ODQ@BJ.SE-@1_%6P!M0-+.BH- M:5GDVI9=4:9FD*&$.K6\9AF.KO8C=$6@8/R1/(%G!8Y/-"-@`W*9#I"1H1LJ MXABUHPSGU$5,,(8AOMG$.-UA"'J(G^&@?EBYCB-_6'?B;$5W,+DT._5`53=M M&51S4?<>1G3;T)"I;AN"[BB==,9VD.'NFKBF4?K6>Z%CZ%##JD'=+&-WE*X6 MWY]$M_'$M75'[T$B6>'@(_$>24@R@@>/,BX,:U7GJ1Y@$)-.F@\\W#Y,+E;X M(;[#(83+P:V7R!"*B@S$=\-FB&%D.FG*`#(0A3YY=#^-/(4Q+%*V8AH^R.JBJ:^U3C^91 MJP>M+@*R3$VU+7,`K2F&%\$=!J=_P(2)9B*$>!:58GN@=G-@>Z)&V1A^DFRX M6EA(-^L(["(,9=-%((ZF]63#*4MO'3!,T]%=K;:S"N)UJ:SKFDC3ZFU#S6Q` M+HO[+/;_�WB"JS`=NE]@06G'WI`#R.%XLX&EY=346FPP^+VP7W`>[D-2'# ML1P!X/,`-)S$D1?>>@1"L[&W))D7]OB7!PZ241B68I.)ZKQ8JY5V`;B$]ZF[V1ZIBJ:]A\7+P?30Z_+C(;J99J MNZYK.4/X,5V;QV&`DY2&IME+7WFYJJ-;)B>LW:+[@7?J2;9C&A4G83\Z9TLA M-IQ^2#&;]0G919A6%6B90N$<[*?P>8OH+%'*^H.MU_V'/&V?;>LO6 MM0S0^TJ@*870UZQHMZ4OS;+YWG2HBK9,]7&0?-']'6C+AG"XTRQC`_1AR'?S MPY%IN4@F^:J'<^LE-PE=X\8!&_IO<<)V^726=KDIB.,]N;XZ>G^"U":OJ@E3 M'M-:T7XUICG.^2J;QPGY#PZZR;*!G49WX30ZJ-M0PXGMBNZK$6/[2(9):P^? M'&$8E\X"DL;E9I71K8CT2[A#"H>#D2PA; M-O':K]7:@WP3?2_D:S\!>PU2K_VFJGW_GBM-ZL5CRN0#W:G>>?]J&T';,1"_ M$+T#TH>%L'(BR02$%D)+:6%"R@[I_,V2* MO<2G&XTN($D8L_F>NMVA/5O8U715J)*IIF.;&NI)CY^2W)J)E*%YAFX8>F6?2"/<,&;"2J?;=)_O5V`F MK&^JX<"?K\%,6-5TP[2-7LP^X`A\GY"F"A8D8E_;T8T@$JV<:2#;=K@E_CV8 MPRD**YU!ER7Y39`'IRBN?8ZEZ9KS-2D*JZ&--(=?,A2DN';#B_=2O"AP:`S- M4>N\_1*F#P]A%5-UB/1MRY+,0UB/#.IT&+9L&L(NF*$9+K\?-4C]R`@KR8BZ@[96JR5#R0AKRLAPZ+!R",$(J\M(UUVZF5*( M"_TH*,TXOG\'UB9.`1%[R,LGP M@FVOAIQ)'(;,B,DS32.-&DM'5?D*'8SQMQ6.N!MF.ZKNV,9_@6S$.Z*N4F?( M_&^0C;")L$"&VK=4&RBBL$<_05@U)5)L!=JNT`Y*?S)#EANDDQFRMB6?S(`E MB(YDKG$F.4[:'54J&*($)%CN0?@2K.,P_,$6J!9^_.NGLT]Q0*;$9U;H9OJ; META;EH3DEJ/3+]J:<7HQZ>&W&KIFF)9T)GT,A6P*/E5`]F?67[>HQ`[);)B&'939("UKT?T&9K]A,IO3 M[V*>(.RO5XA$G-].='9H]K5KC]E#+L9#+?\DI1$1V+?9H:F,M5`TYJJ9^ M)[78H]6-M7`,I!F\-?^VM6CO`8JBJBAQ-^YYJTJ^70!"EV:8FKTVNX@0*B/)SI\&O/!>Y82">K(KGRQVAU>+O,ADY/?C+1XO`>#&_HNF`^8 M\1Q`FG[-0R^<@U&#AH'G45#.BD"A]SAY(C[TCF0<>F0A9[>1;KO\YAHA`K+9 MBT]QJ*9KF&@@?3H5Q<7>=&DD(8_4&CW$!E)_IE_02Y$U>&]Z,?6U#V\@-V%) M.CK2='%JE\\9CE(V?7>S9(M(#(+B"P"ZQN\I%B8YB?R$?M5U@?.?DX@_^FQS1+F4'FA8#M*KBWC= MP&6R%O_^PS0TVY+`NARG;R)HE&6$[:[&MUP1T'M-U77![VKM9_NN M$!!FV6>]M;I)>CC)\LZ`[>,<^Z]-:TAK%2.'.)1>#P'J$+=7M^<.XG>!F8VX MR>8X.8C][`(IB:9XI&+:X,IILLEN'3LN9\;#1+IMMS'=0I5!4UP]'5UU5=DL MMXXLE_(U&?69]_#<@I5$M4\X73E-7@[7MG.0#]/I6P]([D-07));AS9+9"E9 M/4>:ZG8BVJO-)2NHU=KA>S&5'#B-MJ^S:D4<2F_@CM7NQ.B]5UXZ!R>4WJP9 M_/3R.:6G'JZ_:3KW,_(D3R=5V]8,3:MN7>I(0"IU\6')199A6:8,YG4MQ-\G M(R5$JEY8LP]2`D7Q;YUM36T=0-LIPO!/(Z7T(3[W(6Q*<+>36ONKKN&ZG-/< M'5XJ\1[34Q9$R^I!B!]BWF1DF([3)N=]TQ!]6/8(HDPVK]Z;98/UR+\!/(#A M=5V3OPJP.[Q4XCVT5[>0(X4X9/$Q#MA7,MS\=GKYC!.?I#VWQ&T[,HBJ+W_< MYAY0&2S%W2T=.94/&(1I-C3#%8F\R)>NOJJKJR8_R=X=7BKQX8+N3[S^HKG\ M0N/MH5..R3!=5U-YCT>$@F3Z/0P'H"DD)8\LD+3LV M,O MP;]6^>D5U`FNO^*GV+-3],X1#T&?$0XN!ZT_;AYW0ZW.?5URO@O M,/@%1,_>Q-9JF&8K:L"WT7-Q$]/M"U=5U]!Q43W26NV M"0W6NA#>MV+C.'K"248=Y>LXP[41C\A5R:[F;MU-45O^`!I([$;,C@3N<(#Q M@EU#OLE0=5R"'W-B@HVS:&JV%B:W&L]=*3K MM7HF?`_0$+J[,M]_45%_KFRCS74

9CUY4OB"WN3*D0V)M2L,7='4VOK#L-P19M=E75 M5:/A:/FV99?UMT9)OD.WYF;6OOXZZ(#K-JR[U,-*(3K$GHA3_`CCWXQ)^1YG M6RD[`.UDXLP.3L,LK`%EZ1$"=C+\.S..D\9+R'UL`A=4APH+`2WIXV M%+DS9J[P0YS/S"D7SW-(/)OM?/FZK MH`_K>?ZFTOMSZ**2MJGJNM.7PS7.8,22(@S+TDW+J9%&#<9`.IWD@BQ'=0PA M.NM0+9EY4?$A+0SG:1R2@/V#'K.3T@_G<`JY\T>KE$0X32]PZB=D65XWE"\$ M0Y1W"YE]@M,'J,-/H8`O]?[','NS5-+L)<3OCA9>,B/1F8*6V1N%9A]Y(9G! M@Q!/LZ,?9]D;FOQTR7[[BZH7?_%%3`'W3%&U9:8\D`6,[M?XBW(7+[SH.']P MK-SCA$S?*&LP!9V8)*(_6T!IN5L8:!\&RWQ^\J.W6+[YB\N*6=%']Y\_?3J_ M^YV1O[E2[BBEF&,,J./*%M\+ MRP#_F.;;Z,`)3,L[4U,%Q#&^_#BZ'T^4<9PLX_Q0=,6+`B5=/:8D(!ZX:G_- MYAC>,X2_*?3*\%7DK<#K@V(A*:,`0UOF04\DT31.%IMBIG&<17&&E8"D?ABG M*Y"^$M$D8?@"J>G,,!0#.2F(%T4K8%C+=4F_7$WRM+3"24##;>4+R>9K(>06 M#9)"P61)OQ^9Y;=;`1:\Q\ML@_4Y8A5@-\@R29PO0+"^I\R])ZP\8API\8)D M-`W$3C2XSY0L9EF3%2V:5B_!,[H.3/>#EOI%$]QC?Y7D.R5IJLMG"+VB&1/B M@J3T9(T3Y;=QZLP`)8@`X\) M%?+\:Q6Q,W\8#]HRC(1(L51<5%_2'=THY%+8),-ZDY;J`HH!PZ0"581(=P&= M9_0SZ%U"Y`T9+TE$]1'T M?:/]QWG_YPW9QL@(*%!NC(`5-4;0[VF1"2A)KEG>9N>0\E?L^7-*XLNR$QF.L%-=>%]@Q7%STOL,Q$6%(`N@;*H M\3J\C6+_JR3:[?;%$T*U"DH=,8?[];B6HRQ>,G-6_/,QSK)X<2`#-\Z=(,:: MT*MC2K7=/^YMU!\L3^B!CS"E:@^Z`7GI&%[Z'GXQ0<1;GJ^D'ZSI_W0:\FUJ MQYG#'>^U-(G,LZ,V*0SC+^G9GU$,?Z+.OXXVRWWA>;O"N)!/_2F;'>GTX4%T(#--@*B`,HC$`G3!.\X*#?23#Z48!R'CHGP1 M4N`3$,P2G*]\P%]XU">(\EB0>7)!S`9@3`\QS!T"KNR\45CYE"[.%WD"R(II M\,JL*WA2E?5VYCGRMX$7N2K>@H"/D$='T+-_T&W]&&D:>_.#KCK'#H+$8-FI M+P"2#U]$J73T5]:ZR7P6QD75K&-#=W(NJFH<.ZZQPV7%7.*UA\1PVBM[S*DL MBPC!Q0;A/\;Q'XS$$]TA1AOG!^W8T0IX[1@Y*J.58.H%!15H5L>!V`K#+342 M`$U7;<+^IH;W]0RDW\;:WGK9.N[;6,^1DC_/^P<$*FS2A/9X/U^>_/_VOK6Y M;>18]/NIRG]`N>2*7071`,'G;I(JV9:S2OR*I\Q$DAA*.08#!0[+RZV\_ M9@8#@)1(B9(H&EN;C2T!@^Z>?G=/3_A?3EXI:5+*TKI941K:3.DD[;BS(B-` M6.&D4F>=^U7UMF#07KE#5JBO.Y8,C5')@BJG9!$[CV)Z$2=12OVP>;\(OXZ*$O6C3*#*@/:1"DT0&80^PJKP#4 MT*P;6!.[DC74+H%DLA(3S@=<@&RR93\X=`Y9X_5M;^3>H.HWC8%70!0G!$(# M,$L"U<'TW=TH4&%0P$U^8TJ'*?,$Y!U>/ABX=L_M:=-WT!_9`_A?#?$/FUG2 MC:'HNO90^@!L:L?V8-2P^F<&!15GR53P4OM_%481,NC!"$U9C_P!E>`BDH(& M9F>.5([-\"CO\*#G=NWQ\!&2H:VIVV)@\1[L192P?T/'=U>'#X'Q:,,F:B_8 MSPP?^`PY!-ER^2K$UC;!(E2#?^G^DRJ^`C5I'8SMKN?:W?&`MW>_5 MG$N[FGM;P[N3$!($MT!IW0PA\'ZW9P^'T@-T[?YH:/>[SBH(FPXH`;$"S%:F M=EBF^%)"S@KC]<\5"3*5\`7(!@8/NCN>/0.RX\`75WX:<`4!?:P?I*^C:^"E MGF/-03=3R<]N6DCZ MKC9P/?>7X%O\8%9Y4J6;:MX;?DZZ;#E?&9)!1"7(\?1SOB:!SGF!OU:Z15G% M+UJ2[BR]'W:[B'#B1TA3B@SPI"-K@,@!/;A7I6`29!,_D[\N]X<>AM\U]PF# MZO7H,1<^UEL9$@X01.RSBPIOIF253:\5ZQ77E*OU?Q!EY&Y)'YN,+_Z%4Q6P M.1EF..98>D^O*S14BEFN3!!,>(<@$L'T2FIEU$4M*S\"WIU2&72=W:9BERQ+ M(W`:FXH/;U%)7V*@75D9&9`W(LNTF:Q9`&UHAS'5765X]@,!$')Y93H#,YN4 MNB&'/RBFTL5>@@#GO]GVL;/.WX=P)$DQQ_,=!0Z]?DK_<%6EQ*1CU17&%.*J M]!=K$OG3[Z04K*:":]7VKJCM7ZW&?FDE7IZ4)7R,X[*&.I<$Z0-@=;TNZ"`[ M,CMPS4S-F[)HA,2Y3&X2L\G2)"5&P070Y_H"#0"L47ZD4J56-Q-4!?QUAJ)JCTG'4:`/M1E@#GTXB-*W5'-M#ZZ-@K/50C3;,>!5\L[KJV1 MV\?FP;[#OJ+JWQC^>E0U:^4F6N;Q:]1;OXG@'!\K)X"I54:_UH!%PE0@UN2I MP%DVJ#1@[3F';M^V2CC?"TQ!AWC1I_7'A:`<#"B9$DCK%7SG6&W@!R$;!D`S MG8!Q_B$-0VQQS[K1P,)=A%>Q11W!)DXG3:+>K[_I58G/WX^.OI;?>FT;+,>5 MRQKUE[!NU57`L$&$3!?6U4`/T]9(B&K]!W%0,;%8Q,#,B9$5)KS/03QX1;#C MHFZ\?L&BFC`LW-6AHF-#Z&`=1KA.BRJC!9(I MI.&KI'Q6J(-5Q$3?)4"X?'4M-NK2[X(S-F!(?9F:---WI0V=)X&(0$N>@VAP M^U\6!K*A@1@OBA2:*28UI9LTB>1)+':^,%50`L6XUOBBZ2O6MTXE#W/I#`3& MTMRW(3T'8)@H(5&XEN`'?&*'^"K`6,W`Z*5O) M,8L_Y=@'#:5L*)I/0%(#2W:AESEQF3K.CA M6U\UOZ&N!C-0Z_1>Y0C*-HNJ0S!T1^B\>/"OZ1+0G`7^DB5/658]DK"V#K>Q M9:H_%W5R7EZ1B1;R,HE(?X?R'#&I3CZT#/Z9;\G&2+)YJIT8^?,\04ZECFUY MU:,M8S)*WR?@62ZBY%J@6U"4/PVF_!)=6G!PY+<9&AQIC-YR6:60IF5)QK!:6&BF%@F*=:L8!Z[M.CU[ M['F<+!Q[8]OK-U*%L$W2-9.-I^A`8EV1O()ZU1ZSE*H6K?;+2GC.<*TBL5[= M>SGH/6=H]P9CV6[0=>WNH%;^L*77LRGPUE+`#?'ZS<6A_E%F`:2-VSI-H/PZ1.J MM8?(J:(U\ZM$YF9DBDEW\2Y]I^+@E,4B`P]"'@2&I*9K>\,QE65P]9[CV([C M:'IHOC9D53*V)L3&%;%&-!@GPD]/+@5$G9"[U,,K(*BKBSU2VVB-TK( MD=H8X'"O$Y!?IKZ(TR`$D/'/5/ON)8,Q*R@_P<-=H&WF)FPCJ=7B08F97Y6^VK/WOW87^.\#O/YO$1<;+4I2?870Z M]64Q`%B??L6=*N"0*+FQ4IT13634)-T1K\>?UW_C%OH'`35;8?B#TI%2EH2\^W=L MQ69%2C&Z=/_+0Q-+J;X1-6WP?T3U`)#6&_<]`-1@[4T.NQH#EA[RU&YSF/^5 M\72:Q/#'*:7LCOTTNCX*6.F?86SU+(_^/H16>-L\\/OY^`\6*.-T[[]HSOCHK#JJA#0]7G#HC@#^!/X`9 M7<:BY>$VK@Y268%JR)2/TYTD\LB4$#A#GZGRL.AX+T/B* MPMP-18;/M[`2GV+Y&3O.N#Z*#7C+3X<]EBFXDW9>>N>]M-\\;@QM;'LR[M__O;EX_OC;Z=E_84P./[7[R=G_VL]J19O-?=R:RS`CV0W M,N-FA51WZ,I8CX-)6_YU@NZ@[`.IQ&@JT)2.K]0E'>N8.B39Z4R%/%*7E;42 M]+95=HOS,S&6K_RT'GV:I]*GK,X9)-!-E;CX3J>XY)GD=;8)7SC$,K!?OO@S M_O16=EW^&C%Q@`DS8IQ?L%-=I'@,H,K@4VH9>$2U6#M_U^LM'BN>YP8OS.DN M,)$6G^/T(OI[!O94_5U^_BH,\@O\OO.22;P^+/I[J5J,IA1._4C1@7>O?!J- M(;T1J#H!3#/FY3?!&_+<*^YX0LTY&])W-@=XR MF]G2='.:RAN"_,S,Y;2$W("0WP0>?C78$TD;2GL#TK0-WFZ-2F# M]M7IV)4HR36\EQMOIC);+U>YL;=OH;9\M35H.VD1=VR[7/JY=9'[P[&S1'!M M=S"RG9[[$Q/A\YNCGQC[H>UU';O;[6^?!MO02+1!*^L]*U30?:W'G0T%O>CU M[>'@9LVRZ0>?%J&N9_<&GMWM[0M"-TG\\$D9`_&CMUWM[4SVQ+91D%PQ^CF M>O:XMT\RNC\L/:3SGEY_M"?X#*@A;33R=E)$&_7\G9-4U^[?XJ<_+W[8'TG% M214#N^^M#AZ>%SX#VW71U1D_D*2^H>1M^:.G2%!787V^B?);6\PM>6,,X?ET M#2$/B?Z&J#V+TL$T06CBO[YP7RP3.J[T/%VZ48,WO!-XG['C_1.WC!^;;;H[ M">T9=;BO`>Y64H_/9>>]&\%;(U%,$_]V'\:'YLF?E8X/F*<_UL<$5I'EX9*1 M![=]\Z8TM-UU'7OH/4`.=9K^XAO,^&^6I<\ M<3Y@,+)=;UO)E*?&9HA3#[W!GF#3MQUG7Y(!_:$]WEK.:?U,P#;B4!TE;CO` M7;WP4$Z^/E8]KI#1LC];YYT/F&(^[P MWS%Z,OK(,IUI5N>&C0N+EO1ERS[O!1^PS/D4<6;A*"N:0:4.GA\XG6X7.0C^ MT!OQZ1.:EHNG9@#8+)R6YX05'"4(P?HS\GGNOF./>[W*(1<"@T>?8(><_#K. M;'8]V^D/2C3UB6G9CJ[`61^(E9/U"8BE6Q`G]R7_!C<)R+%AH[$][M][V^^Q MF03%+:#RAGI=>SP>-X8?-C?3&]B>YRS?S!4;25"L!F"3:Q*<^VTD0<)$;=7J M'JA5/:*B-\8 M/B%^+,)47LK0I;$4].U9DLX$3K+;Z`H0VYAS00@Q#'=$:C!N(F5)A'I]VQWR M#2[=X4J$7"HG(PPW('6;(M230^ZT1;VQ&J5QX';&W@J,>ET'.(''=_0@[AT, M5^-SQPTB&!BAP3W1D;NT'!7/=L<\ZP;V:-!$Y('UUN.ZPZT.JPX]$G3[DT`M M,R"I7#Z=J,)T04%SB)D]]`SK?_AQX:?LDW4'TG,#]DZ*\XOR8+2GO"DR#KNO*:XO4K6#J MU.0YX24=(3F^B?&OS+N9%3A'5$[6JM&+THM M88E`3,*\R1$\Z\N:@FKD7QNK+OPP.,0[GOGVI"KSZ+U8CX&LAV`>#<-M7F_K MK?YDB.Q86BI.XL,V-?4L-M/6L4W6'&<]4N7D0>M_I'_:=0_RO.46& M)W=8E6&B-,R]6A,KQXL2/$?T)5!\.&RR,NN@>G\#W;_&,T+IO@@>$:H&>,N< M!-Y)EI6#N&L*^5`I9#W'3F8A`B$-0?4Q^H4:])(9=[PC4G/_.]U44LRE'D_% MN9\&ZH/-(7Q*W\N9BW(B)$%`08*^]5O?E6'>?&>:]25&Q!AX6-W=>OY,7P5^ MRZT_]_[0FKD=!90T>[<%PVYMY*0*Y1#D.3-PC:=Y+%47< M5N85NL,AA.P<]`+W97P<&&2A,I.DW.MRI]=E^5H&FQS8ROC:`Z"P/98I'KQC ML#X9%Y[AH50'KM>')_OD#^HKR#:Y!>R`RK^5]PF,U?=TU8.)(^WB(FB^.8#8 M'&V[C'R@[M5P8C4',4-0.&\NP6']2,OH&0-'7O8'ST6?SB@M=D#JI)@_?6,[?Z@NX*A^*X,N8TKME#Q MYB;;:)E;&&9W18`K`KVQ[0S-FR>IU%]#9(_4TE[JVJVDHT950[S"[#:S$-GT M0@1%5%X%)O,1P+YJMOKFR8;R/M#U<@W&NP2#SC4`TNYH<&/VR9BA7/57U\Q' M+"72T;*3(C>0 M8[GI>#BY>#`WY\9-KV,);DR+8HMBB^(.H/C<-:US\D^&<_7-OV7GTIO?& M&>PM>EU[X&&/J;>W&!Z4&&B9M9R.G&NXCQAW@67=[CYK7[=5NO#/Y[WEX-$; M=_3&&>TM?IX]&COV<'1?(=U=#`W_:-F?%'I[K8>)B]U>JXCW71$?[2T+#]YT MP?T=[RU^KNTYGMT;MHJXT]]?1>QVD8WOK8D?%,'[U05^4CW\KJ.Q.)U>1**@ MJUA>L7JVCE[O\H;?"_'AF]%>J^4!G>-]`/S<;L?;`03W6MTZ+L1N;]S^WB+X MDVK;FM?[=F_W=_QFKYU><[3^/N*WMLL[V-\,$[+P;CN\CZF!;T#PIF:XG42] MIH7?;;C'.XG3Z$W708U;J]3TG5\M^-5@C3:N).XG,^GF% M3?W`G42WBQRZL4N[DZBTWBMU".ZM;1R_Z;K[[+[V[*';L[NC_?5NUM2M[CXG M$8B+W=6ZZKGCUVIAQ.1X;_=WW[4PZ^#];8Q;6P3?O:N1^*C5LO4H%35H.]K=O M8=\U,@WE;HMKE/?=W]B`=?+^'IEI%3)B\FEO]W?_M7"WBY[Q_I;WU]3"W M6Z+M>,:[BU^KA4D+6Z_F-,*Y=8N?+WZ#UBW6/6?[2X/A&\_=YW3Q]A3R3J)7 M4[Q?-MS'G<3)>[,OS6,#O$CM#BIT'63<00[G`(ZK1[EZT8B%[ MNGO1#K@Z&7)?9W5W[<%7FC):SN([B7%0>\\;Q#C7,`_K!_A:; M1O;`&=O>'I>2G$YON*S%VMT3;;JF\2#.=CWKT!K>:4##3N*^&HD']$U7HE&? M([W&H&,]ZOP!!P.7SNW=_KD046!-KIND7E3HJ6BZ:U3X,IN%4Y%6X,29V._# M5$S!;JW"ZWE*A!Q=41JPX=[$`I[=&P_MOK<7R-`(H"56Z0Y'I'<2/SU\8IGE M1?]_+VSO:B26V)\W-"R_\J.]O1SCUH\\R14*;NW*DIL]IU7>%*Y1NV+#^EA> MN$"?*#8AUF[>-[&7EVB<"@Y<)WB9!EU,%(C<#Z-,7?TS\2.\19/^;ERH$<99 MGA9\0V;]I@SR)D[%(I<7V5=YE(JZ+O,C'O-I$? MK=Q0LAD$MQ_0OOW"$F7WU*Z[*@U9W:C2&-WUU>6?;V9&Y24M:E&^!@M=_RR) MPF!=V,QUR="OM7!%&M=:FV%NB6@L7%%@J+\>DI#KSRI8^^Z>_N"E4<^Q_EF] MX6H9'OKJBXUW3@G_RQ4:ZN"V;]*M.XU]XI1&MVN[LO$A+SU[#2_,*Z_AU`X?[*H<["S_7 M<$&B1[8S6$W;3;_WM/CT;,<;`CZKQ>3)&&14-:9R[6ZO;SO]]2W%;C.5:X^=@=T;>3O&5%]3O.<( M;TVOWQ^\6RGY^GZ_?/GD6WAL4T':)7W]2Z):3&, M:F+@CFQ#SME?7[=GC[OCC;BR#18J"S^;X*#^\6Y'->R<);D?K3##:^]DN=P# M["4M;@5)`0)\BW>][BXVEG1=>]0;VEUW=(\=O8T*^TW"@3WN#<`-ND_F80T* MWE9->`ZYMT>J*2S%1'?M81?=0^(WKF%G_+#-O^YG5>'L@JL*[Y+YPH^O+7\Z M38HXQZ@O2:FLH+-26"N@+$%2G%]8QY;JT;#\;%5,".X:+I@&6)BPKL+\PGI' M9T.F/EZR:HW<_B&GZTP$IDF4I&`B46D1D#83E>G?&_YZQ$""&B(HC6+6B5GL M`'A_$\$Y/G8TA5^S@92KC'[M6)5]_"#QC<-8R)O'4R&L.?SZ(K,$R&"@BR<$ M#Z9L;7I%$2_%ZV/Q.=\Z]P'W9&8=N+8W]NSNJ$MK&K\8#8>V.QA@W&R0V23P M\B*.#9_)%@(1$M$US]-_7Z2AO$I]'?"M]4#OCQP`?E`'W!N,;:_G*[78=VQTV>$9F6*N0V"MQ^B>!H':BK>KM.%+,4`2T9JJ;A,)% MAL:3L]82J0.>N+H(IQ>WB4YL">-F]H,NR'RWZVD9&MDCD"QG-"KE9)-OY!2J ME#K/[GF>W>N[UI5(A?YRT+'^N!#,Q%=FYU_U*1:<2S\JA*QY9^7S\(?,FG+> M0.4L5UBE/)'9S$Z3<%8._Y=QTHIW(BE3GX`++'V`IY4]N^^.9/F\1A=S"6O) MZSV[.P3/>]BMJ)`5.I!@*+<\3I9\KT[+VUW67 MH;A"=HXB*RGR+(?-1J6L>61):,0^'#!+*CB"`29MA$L]IQX-O1>Y2.?L^($( MP"HIL)81"EFO(+0YGD]$@'+[0?AYD8K75IC!,P%(!S$IO'$,(55^K18>_)I9 M7ZYBZQ0K-V;4='81(O\OPBD!LDB3RS!`D;CP`3^$&MA%!@R_)#B7T&FY.Q1I/[ M:_GGH#!Y%R6!*%3U@_\KLIQ_#B#BYQ=%.KWP874:)49/34$'HN?]3B^22,H#8#8O(A^34K!(O2,!V/%@8+NC`68P.M;Q M:DR-G,SG*BN9SDJ&#K!T"W@/)/LO80)@OT#$X(<0(V)!RD=/0[;M@J0*D2.` M!CN06?#A^10]A(1-2%7&![JE0:@I`+J*10SQYU>W9_,,;UF/3]D61BN0QC3+1K72;W-$XA#^:71*?J4L".>R;",#S(&.O4P7FDV5/#GMVD3KS M89YS.BN_082U<"&,[6H;5J M[N6-6S,%G71=<\.7&$$(H:Q).`-7N?3;E\"<<3EDDU+.FK60+@V*+57JC>1N M->RN(W6FY>9V#7F+DNN-'!TF$-,E,:>1,G+0V4^7R245?L`S*`4Y6&/@6F9: MN19*C0?_!;109=A&-/`)6-G/DS2,D$>UEE^FS`Q5(Y5?8$IA1;.5407!<:;B M`Q#Q^5P$(8"![\S`?3?68"&I%-!NH"$+&`D[OF+FX*HJF'UH4PW/,8P`/-CM MY>C!T`Z^CKLHQD5/.J"<@LJH0'0(D`C\A19L6()U[:VEYT9]/,H2I0/)_0Y@ MAQM1'&^Z5(6U.K/I9=_,=S*#8NRABC"J=@H4'!L:5%D5U>DW7'VB#?H1&9(` MHXE,Y0BX?&AFJQ[1Z&VW^LXU":Q#.%6U?3O56]6]XTAU.V9?$GFNQB"\C\0\ MGW1S2NG>[A$)]G)?95K]""+KR')'E(<95B5\"O\?"5)S(-I]:QY&$2K:!<_U M*L\W=:Q3UFF4N\B2B!3C`?:&V92/%/.PF%O)ILOT26'?U@A!`]ZLDU(*PA*Y,HE,F):UE/TE$(%7%M^5ZE M;^.F=W%>="7QS"FJ[S$FO@$RJ?$^FI7J3ZMZ<_:(F?920D[B6JH)DZL@)W:W M+\T<,RUXB``+^(-Z]^NY/+ZU1,I$GSN\`%PVL^@=)&!IKX6?HHLC)7)(H9+7 M44XBEB$JN;**4Z>_2%9XZ-GN:$BR4EKIC')_$YFK]"U8+0@YIQG`'T`,`(6% M'P:'\(&IOPASZ!A^4M*@&M#L-7"0'T=B,*C24)9$0%@BZGT MR)8*M22KO/))O::!7*4(V`O#!(#AA^T1$^^E9$K;]?`^[+*@B%&Q5J6LEE;E06//TJ=460X4-2(Z4`84`@! M2$`,7TE(\$DVW`%C`Y(GAV6"&<:PY,*_-'HK#*B9%!6!\>M_Z8 MA;HF&]M`W/C$"L`XAF3@K"N$C2`@^$#;"#!N`2DTN?8'M7;'.L;@J/YC7H/Q M`W(G5Q*["W`C!'U?EVQQ54*#2O7''P]/WYT8J3J"`UP#B&)4";!*BVZG[Y2T MH-^J74@H.)IPI8X1[A/"/=@MBL7-'SJK>5NE-EXQ=A*@PN9PO414.0MN,&;@W!U@%:IK]_H#V0DQ3;+\#I:- MNP=JUHV*=O)U,1 MSJ(#7+3ES."9BI9UO=*N%BPI,:7+M`FP"'V;]Q$VC'R,.-'VXBIM5L5+IBM:0[CA2*@CDY@%OB2$U*R%O$S\-D"G40,R,^XM0 MX6-?##!I8+;%H!:X@1OEM%!X5>;9V*:P?BHMC)^Q)W<5NU'V<]S05U*Q+:\J%EY#];II@`ZI M31E(IHO1V6`J5#8==PD75GCYU)37:`!=ZGE;)[%>GQ./^JZJE?KL1B>?^(%4 MI-D6Z#?!;'75CB,E==4',4D+']Q75[&7%N(E'"([DHU0&[U>#+6S6AZG='_^ M48#/[[G*^S-C;[/EJ-I&5NV#!O[B!IK^\'YN2R,@5TTHC^JV6#671;6+W\EM MV2.6W,O1I]YV1Y]^!$T<4RASI'IT5U4+?E8^V$VD*DF6P;*N>]A*V=V+.LN* M]$[K;FS.I;^]3D%9O`V3!>B0N6]]_/C.>E76V>G7957\M550"U/CJ!N!Q*":P,BJQ4W`A^'36T0P<#+]C?2U2+()KC[=$G.%3':'<3II1`12- M4"K.`2RA^Q7!B09?DGJBZ".6^L`7K*.70('3"LL)WAGM>U-]V8]J;4>KO@V[ M7X+(Y&2/,VM6I/0QU4G"QA.)@`T!-/HC8V;5)[B6R(`M":J" MC@#BK*&L(/P>XTH40%1H4H\@NAQ!X.,RBX9_9,"H24,VYU<29.L$,13X8ZU- M)X=H=95JHK,EDO1VQ+O#)##[F#:H_<+(RH1LE2E99A ME/9!$&@E<]Q2M.$Y#>DM\GZ14UF=W(#>6*Q/GN%Y-'^JP:CUSUNR?]Z:B_PB MH;86=B.;W[O%QYSZT91[T66/_X%K.V[?'@Y=,Q0S#[62O]P(H)?UHMQMR,&P M4L_);CE@C*1;>J29L\@'[I"$N?49=]QG[&W79Y07A^D+PUJ'\3D@]9:MN_0: MKY4]Y2,DAIIPQJIVPZTB9=H-E6O%5(1ELXFA5#-*$V7)'%L<,>%=#?>Y7*>R M6`L_S?F0;@7$Z++),Q=57AL5N2B95^)RPT!]H> M_E.7S:D%@-5J>TO`LT-J98+*M3WIE-Z4ER+3:F2FZOT>-_L"?#*IYPSL,9;L MMIUSPG32+>DFF1M;,^6T<<[IEC)9U=]KQM>>&]E>PW&CN==VE1HZ#JV1A;J4EA!EU!O;W7'_#K7D M!E%6]BF535E^3%X&9T3Z=9_6.+2!Y=<;/=I3P>?HK&,Y-$-[`F&,Y_N)?JML MZ%_>%-GAN>\O?J'S'-):'U,F!!=]#RXR6/8B%6=`\[<1//.W/_T/SNG]BWKQ M`W@V_T;'IGPVTP_39!#XRSSZRW,A&H>N/AP=/*-0/[WTGOW\[_G3\ M^>STL0Y^G0Z$D7!'=UVL6HJH?I2)M4[Y5Q*[5A1%WD>O-\(HJ-17)C M?>(#:^3Z&N<+`8,0H;&)F/1'8\0&PZ#"[P-/MUBSUY^(J M2;]SX8`^0FW>QI$W:F4'1(*,HF$IOI8_P3/$60'J*A'+9RQC3.HBR0+^>LI)D,NK!G8IC;@V76DY-F2FZZ`#01)VI8ZR:A\&PVD11=2HEV40;LM92ACL4Y%,#M$S)^S0\0]D M+1#(J%+7T*4\66G%+%LX#1=F6Y8A*G0TM5JT.17:;0K(R(H^R"EN\`\H!PTAN(DIA=Q^!\L1L+KT#A%-($0[CLEP?WF5== MO?WLO.='P657,&A\=Z/DV6\BNA0H;0``&,S#)]?`(Z]&VLTSD4O^I#2&,<;J MBU8)2J]1```"]Y\BR=5I$SF,]78EA=,J:E"`ZG:!IH M=2]40&:5^ES7(Y6C6'J$$"&&LO*)V4EP"G'C8O4W?2*2=#25@FJ?HQ8RS(GZ MZ?)M;C*'O62)DE<:ZW%$U5A3<9K&ET:#\HPZE*R,ULZC-1XPO.!D:L@R#-%6[:/)C2W+UJ1":KXMS4F M%%E&P:/T2LNU*=?/P:\,GPM48JM&%9N!J,Q/953WI&S`9$_ M+9NP;R"2X3NWX>>.(W4F>VSI2C]K(K`0E4D'2M;\5HB1GDM7'5F&3?28)"I2 MRNR"I(3PPMT4GYN(N72_5C+$0UF)NS+H`\/S0*S^!%1\*J$Y+1V\AY2<^_[SA2)M(ZER M4LFQ=ENA:H6J%:H-_ZFD$ZH"Y;4"U0K4[@C4&5Y@][PYLGX5_5TBC$?;]J>3 MBL=-?BQCH`9[/RT(CTN$=N/;C6\WOMWX=N/W?..WX8ZH-^I>5;?3WX9?]5[H M"Z&,ZV76(^L#@;0U7E_A,A.85I`4$)'=']J#.TK!HP#GW$T^FC[\XVUMRV$M MA[4C+:E MYRE;>IHSB=;HZWD>C+4..[5--FV33=MDTY8OV_+E/O4#M$TVK5"U0K7E?]HF MFU:@GH=`M4TV4=MDTU9>VXUO-[[=^';CVXUO-WX'W)&VR::M&MX9N+8%HN6P MEL-:#GO.'#:PQ[V![?3=EM-:3FLY;0LM-M&S[JYYDHX4GI*)/22U?A2\3RB> MXKT6:O#U1`!4,=U[B0/!^99U/=(S%?J2PA6CM"V^(]&8O$00%$MF?^DZ@AY3 MMP#(DV#IA80$SIJ=*L^;0Y[O!)EI@M^(__K"?;%,RTSIFN&]3EMH"@P?E`+Z M;I"'CM[7VM$=J>+M2.E.D\R[D60/70Y#G=G2[4YTNS$HW&923&K?_N#E_>%^ MJ^VV--;K;;X$8;0%"!ZBROUH+KN"H;NL>/WHOOF#4N2.=?V611Z61;R^[;J> M/1ZNF9/:`1[9B7Z%,WG="?;<[IP_N,]EK#%>A(O_NUN^8:_C@"?'^0'W?6"[ MHX'M];S=WO<=4TY)D;=<^HA<^LJUN^[8'GE/IIYN:8]M]WN[^]VW^ZYC]\:[ MN=\/V4NQE8#]FX#O_Q>/(,9X<6.J_GKNAW%Y[[R&*(PMX:<8;]ZQV^)I&ZMW MOYOZ"3JH7W7MT1"]NCM:]@?*`ZYYS*!EL-UG,,^Q!V[/[FVO1OGP'/8,NN". MN4KW=I/$7UO//]_Q>OXSGYG1LMKS8;6^[0[[MC>LP-A],$X[G/GS,+K^I6T> MV1""IVD>T8T>^D;6)1=D!4L[L=5-\AA73!*\H"^EVZT!?F"`M:[HJW>2U.ZC MO`BS/$EII@+?FHWQRV6"=\.7-\TNA1C>`T&"):[H-NW,^KUSVK'.4FIFN;;> MAO#3U,_%>MWYF6G<&NO8T`CK_]Z7]0 M4?U%/\SWPL?GW^C:;_QN^3#.>L']_B9F?WWQ`6B'1I!Y5*^:9*A+()%?!94(16!JH0G$H!WYD_U[8FPX#2"UQ&6/`W]**O>QHU$GA74.4?*D6E+E`,2 M3(4(^$95G=HAK4MM=^!%A%/ZPH*T."#I1X+N4X0EILE\#I"1O@2T4Z`#;R0K M4'HKF8=9AA#'"6C,*F!7J$DG0EUVR+L"A$[]$,B)G@-B#EA-_468\TVPLQ!O M0BG>-O6#,BBY!KA)N&&C&,"\'X(M1Z)\0,^QT9)KR!$C9VPNP9 M)W2Y:$K#L?(E$`,=IR++9D6$'T-XJ3&R!`OIC2LG%D[:LBN+X'[@U;3G(A:I MS\QY#6!="H03B:_8,X"])XI+PE5N22\7)#3GBTCD#"T(!P"';%WC"]J39$*2 M\4$$>.&E]3XMSJTC@_]@1U]]>'_TFAES`6!<(D*R$U/MOX0NPX\#021'\QV< M/G&&2*?P31Y.AG=N%K$4RH[U>Y2#I<]%=%VES!R\I0HJ!(,A+8KSU-=MA0VI M@`5+-+)I*LZ+B$5%H5#!/BMFH&E"OFJ3"$^89,5B`3PAN3M#)8?R!Q99WWNL M@9V(*(17^:I:%-8B)DU![_K9!5+B@NX=QO\1O]!.25[.+]*D.&?E]>GCOWF; M+?\\%7REYZM,".LS"(WU=ZE\>$.F4_X^?DJR/*R6Y8`U>5:O;8"`>$S$]`'] MP2IZL%F\VSR!:IZD@B^/9@[ZD5OY%5Y&#+^)\PMF0)X@A[B)'PML`4;*E.HB M$WD>J0M)65`"@<_1SO'*K!O8(PL*&E^G/SC2WSJ9-1Y.Q1PSSDP$/KNI*(/:=?I'11UT#E%E*N)?(O(!P,6,)A/ M8($*=#YXL^%_,+0@GHM@6Q[XVMG6[=H4C[J#D%\E M=$=QC#7IJXL$?HA1&:HCZNKG^XM#]&WH_G8T[OXUJ0[\E9*=K[`6L\/)R4G- M_-##GT`.PN]A+#K6:=@PKP`(=:EK)R`K)J#:0+$:7H#DNZ[CC*OF0UF.0/,D M^"0`G:'F-(P6PK<4K"^Q]1X,*$W![(YY"F;U.R"]"5JS0-XGC>HV8)LG?[H9 M(.)W*JDQ]/>[OR@DG02 M@TV^E,S18(R48G)TZ$#U>9[=\X8$WWF*,0VZX"EM]E?@2#0O7U.P[^S>HT`= MH4,:D`"\0SU_-"6YPN]8K[Y^/7IW]+KJ0&/U%6*F_](!''8?493A"5+S&:%BV!=!-FP#<28"!KR*4([#T#`X*[L'0'=K=\8@U/V#O MC$<4]RP$)42BZ]*'4H-G)0#D+1L6-HK@%;X)_LLT3R2Q78:=H<4O&H>.&,+5 M.1UP`?]/3#F0C`I,22K3V5`'L$A--HGTN,1E&`!)L[F/>2&\CST,#C,*F28A M[N0%1$%@H>?^5!0\SI.>$H&,$R_1;K/_!BX%04!A2;%`''RK[[RTP\"UG)I/Z"OD/)-+R_'OT4TG*PQC7L9T9*4I^0 MLC&`\B4!I38D(#)_KGD"WCV<`3$9]1*:-_P:4`'^,+?H>]G*L%8&F>0:5F"@ M[R+]-"8LP7*OAK\NP^M:[U]'/3CZU3JBM&.%$9N!EB^%DJ0*ORVQ)XZ3+#\I MT0 MX;MHJB=%&%&=/`9]@,5R<*P@FK)Q0O,UV"EI,]5C-KC'(:71XBQ$)0=:@G(, M/V1.@^`9>M@!;66@YC!$%B*WI#'4U$F,I<5),""4F*4_=@L MT7XGYZRL`A&97%?>E[DT(&`Q\RF%49HU[0HO^5AI#FL^)VIP3E)(,QM@YBB4 MR%^6$'QX?\04B_3NA&R7?(LR=?C^%6S5M312N++*`5+<&<<%9XXPI$6C(V-D M5LAV?]@GXAJNRBQ,89-Q.04=?;S,6C36%!F@1E419`<> M&%(^&,#,>>6G02:/FY-4X,=D[IMEK,P03Y-BP2Q&20Z6!)7XJ^\MLHGG>':W M.\)GF,NR\$>9="/V(S!,=K$QWD0_HQZ%T7[!_QA`B#+#JM`R\NBKP)YB+@>" MR'^`Y&$.MMM#W\0!7]C'?%*"V4#@YH"4E932<@TEF:7<4J*/T_T<(6.=!!WY MD^4*1"]>57>L?*I,G-?'`(`&?DT26&:R#_KNR!Z.'9DE9$<*U^'RA=PH<*M3 MUJ?@$8*^(/<=$TXV>WZ-55T(%?IVGS8H3[0S#E*9)E>$%SFC"3N:E6*`R2#E M=P-5?4`.();,=&"!Z?U<=MRGK'J!):)KZX.8I+Q)L$$)>EWE9RM?%#6^)L?Y2^^WSQ.=!KD]+JVTQ]7 MP<2D=F0`RDEGW/3F1U>'I#;LE6N[PZ'"D_/'^+;!H9(_RLUD201<(I`K:;,F M25QPL);$!EQWRZ^@@W.$]M2V?L/T.H:)X-H`;QX^H3^UCT[B"7-.F:ZK M1,S.AW%#J:OZ<<6JL0_R*NR(CHUC3B)TJI0_$%-["QAG5:=ZJUU3-D_?X.>O M.]9OR16$R:E=Y;0`N`]!"<0T\E-1-Y\32KJ"BO.QC,"))'P$W:G,JIHPC&81 M%.&3+A3G28XEL4#K6&FT3PP31:E4D@).Y5+RGZ5*.AVZ+K5,56C=5$^'4:6" MM:.G3P52VL-/,0Y'$QYB]_%!'!.$1/Y,#M@&);Z&((;1?` M"VY4*,N76'+EU`"\YW9)(7C*)*@O,QB"JB823%S=Z0S-U6G6#:Y,ERYI>@UH MS1YK\JFN'8697$R/R4$?+#.UK<(;>(\@.!@Z=M_MLS67FM&VAJ.AW0JU`<9OQ`1DGF$3O@I/_EYJNWIBB416D)1);$JP7VB7)OG,I5I M)TRKUUO^,>K18_;N]M$H=N4P)@24VT9/IQ<)AG9SD5\D@4[4FDOAUG/VE#TH MJF3*KA#.4H*U-,F$#YQB+1261H5U#$H4V#"3&>]75-Q^9X-B!+<,*R=6KYK? M5J'C$OU<.LQ``[KJS'#ET-$P4O&I0#.OA,.('XV-#@2X8!!0+X`:(M#?(`B6 MJ:+1`U=76O-_7Z2^L/G7FFFT3`MDV"8MTT#8&;&F[ZY>,VI^B4?VR4A

SRD?UB+#6FJ&&EMK,S& MRGFIKFF$151JS)(B95<./0Z=0ZDFVYG+S?4H#L6@D!.^ZK!UQ8VT2B.B@S;7 M;?ERUY%2?/GIX[]OJ%.9_.@ZRWJ.JOS8Z!8EA_73]'.(S1/61W$%;C,3U!O] M:OT[\K_;UL>/[ZQ7`,=KW=6NTL\4UU$>H=+"R"E6:@2;8/21BO,P8S`FUSC< M->;B%]X?',WDKV4,KAM2K5D85;P?#-OJ3O[491&_\\%`0("NW#Q[`ZNC+0E ML8Z#-]CB!BMC\UO4"MR.(W6*@F$FT9:=EQ+-N_W+'G47).9N3LLH=)`DD@!R&$$7E$:1XR.+J]G"#X_+^GQ];1 M7/RP97\8B"KYGZE/*S$J-Q6&JU0SO@S$,3[HJZ7F_G>L4&`_#_JIL/0#J2E`47Z8KN6#CRTH?MFCSL@N^1WF1BDL_C(SR),DST(M/*%`Q M5SY;]HEQMQ,>@C'>KRQL*Y&GYDL"GG,B&)3-PSQGY1?Y5QUJVZ"9+%?'3/@@1/,809C)#O&R-$?ZC\)3UH'P(])-H!KQ_]=X0\802W9Q M(B[\:,9[D9;U7MEJ"OZ+6H*:S[#D?A6K5DJ+(Y7BJ>1\PB?"@G MY+"0.KA5QY_`5CR5MP1S"K)"E47O9=D@"A&E/BS&9I2Z)M1I($I-$-]@CR$G MMIV.T^T3&_&CE#O.DBBP52ME8%M\=@8%/[&P@U6>'$$VEUF1*N`*/#JI,NHX M*T!DOUN?2VE`N5DEL9(Q`@0LSQX.^O;(&:_RG*2F0320``==N]4.%%^I=FT9JS([?)FN\-8E3-^ MA]?@G=.<&L?>A]Q(`,)7I*7O=)H4Z#?$Y>]!=G"__A=;+:J(T)LE#AUL:D;7 M)$R*3'82EI,2`%2U)0`/G8/D`[HS,8`AQC,BH$.B29J] MUEZ`//FKOG%*#>4$PS_Y^*XZ_!;R91TW'7WCEZU_EA4AL[ULZ6OL!)?'>'5T M*VNU%(TJTR&=9?D1AHZJ9KKRQ96Y/#P,PJC(^6B@/FX!3K^"@32F40I:KBYM MY3(91P(;U*BZR$9QCX_-L38'QI9'P^D^CA4G%QDCR5&R(*NZ"(W'%+I4/^:] ME2QNUWR<9#\T=K&7889'Z17>5Q"0X&`S1BL>[`P MCBYWV<27">-]3CT85,DP:,DK60(>X8$^4>#/P9N'CQZ,*[]>(+;P(99/]1#2 M&^NZZF3+K3Q5(0\WROEE>Z/2.:LX9(EXJJRAXI=E+Q@BV='T"T0LSY08M/DS MLXQ?Z;54"I2`S;+R)*PN17#IJ\Q,<684\T+B''25$=;)!)/J?9$\(%LZE^]_ MV8`*ZFV9JFB=DQU'ZBB":%JEW$S/%4_K7(;G24JFCZ=J*$5O4!M3^888C=T[#6"&N\[[-?Y)M'OE4CC_KDE:]YG\+YD)PAV?>O(PIN<9#J MQ3P'3^?P#?<)E>!E$@:JFJM.MY9=CEP^2"GU@-W?+(!:ML&?^2ZGF<@FM=RH M`QHO".Q8QED@;Z_5=5V$&*CV18$S*8Q[O`B8VCRE0,`&!CJ70.D5DOHC20]9X<;'3!\$Z/4\+[Q))I05"` M5IL6>L1"$I\G^.>5YQ7TP(\XP=O$$/0X05[_`5IHBDHZ9TYSSRA3V.TDPTO2-X5%E#7!A,2ZYTC!22DFUUCQ8LS-T8 ME.+@="%'&F4$0K_"Y#(54O"DN$^SDUE@Z1V[VG0*_`XT1-D1/^38(\-6\YG\ M\GS/=TR1''C:/S&G2C`%L-<,7!C]!"9)2R]6"F5)"]5$5O5T\:P3OQF'R@V6 M8)A^<'WB3]DAIRLUNIAB'$,^Z'7&?0T@0MVSG;YC.$X8L8!&PF](1^8(%(?^ M,`'R54>AIUS`:GR;RE*!O)Z0O^OH[[+V7D5*5.64[Y:J%H,R9`N=NR<0EO&A M7'?5!I2'7%2U0:;2*3'%V3E*_V"3K-%C;)Z*:AY`.W#UYY`#;=C@(M/62VGU MTF\,0HRK#(4O22^Q365/[>@E=2?AD9NY9%L-1WE%I!01RE.Y0]GJ09$OMS7! M0BJ\EFEL5--JI=>F:4I4UR,W/78I1&:WWB"&U@-UYC)+054GN826Q MQW$KV(P:)%J@V)DFD'Z"$>)Y-(*EW02W]52*,'U0\>*CVOJG`E#P&.W"/4TN0@GE-$AI0T?1X[3I+7E;#H^&WH%+NDD M1XQ!YW*,F#2ZH4 MSA24.L7M:D:A0&LZ3;'5EPZNX%=J_;HD202#["%V2;7C%&\2AF4#I3K6![/? M:IUY$'CXIF>/O`'!O)1MF1#83D8=ZZ2IGN0W"],Y$^TR%%"QERK5HZ=ZZID1A3[WQY-3Q0\Q M7^3J>9W5-DYJ&S)VJU2R>U7I#V0ZG1YM/QB((,TS<(=\?\=@T'%DK^7KDVMZX;^$H#L6+$SD^)2Y]6_R"/N&KU]/: M%SR@23G%Y"K%9DH$?&8.\KE-T%K>W'&DSO1,&;#W5*')BCDELR6;5-+V!K]" MS%].-Y3]+5AH2@5PC%2:@J9[_YV1$,I6WD7`AFO);M#Q6 M[7Y0;DA[5TMZ:2$>Q`@)CWXFX.N[SN&_JH??^&R#R8'UJ?_\X3!+\> M?[-.?SOZ=EQVUCVL>#<$N7+IT%,HJ"U2^VRYZ%%K"-7=F`.-\12OCK^>OB[3 MB]C)SA/34#2KAT_54-):BO,V-P_#^2+7!U2Y3>629SA'U(:L@"$P.,V!J9)% MKGMJE[;%5:HXEE=ZDRL"EXF8^@5/:PM3#BTI;N$Q\ISZ4<5*W4^C^Z,V-*7- M37TL'MB0#7-NK!-1)&\?^^L+YP7]'<_,J[]+0*["(+]`2)R7Y06-M,I=KG.< M)OB-^*\O7/T!4S"GU`KR0)=5WO?VO>T`H51B#9H5:G#Y=7PE%9^"C`J#SZ`* M-&2?6"4<-U7"&NA%S8OH6NYZG)L=-J?J_Q=2\=UK__]>OK@.JEJ1GN#E_<'^ZV?A5/KV/3L*+I8;]\E)/TM M`'+GBV254_'R(0+L-2^,53#4@:#+8^\/Q:MNS^X-/-L=.9O!\R`T6?,J^+WG MC4VM]`,S2=<9V*.!8X^'XQU@DCL29W^Y94N_)H!9=U M!6:[P&U?Q9X.PAW@KXV+P3M+O]UGM)]>EZU?4]X-+5:W M^6^HB;G\T5U:LN&OD_1-U95H6Z.?SL./?K+6:&<-]+;E[K;<]:PZ4]O6Z+8U MNFV-WASLMC7Z&30TN@/;&[EVSQUM!LY-)/DY]W/GVIE=N^N,;+?K;F]G'YLX M^\LMNR']3L=Y&+EO6Y#OGA'9@1S;%NQ*MP?J9W"WM,;C4:#=]>T:'7LXP-NQ M[YC.:O?]F>Y[VY#<]C-M52IVN^K^2(T!K[JN/78<>S@I[0M89?[[.,?4=OO>MF2F;7': MR1:=)VIQZH[L7L^S^^/^CO%7V^*T=ZK,Z3C[U^(4;3`.-MI>?].OUF9LW/:J MW`N(:&\ZH<[TF.=V2N3.L->SZD1I6Z':5JBV%:IMA=K+9HA7GNVZ/;O;7S,> M:H=$[F[CT,-U54'0['3A?UOLFWELXNPOM^R((H%H=Q>:[MHAD6W/QFH0>BYJ MLLT_WS;J/.--;QNT?LY]_YD:M.X-ZCI3(=>>!MDR\G856,\>>6U;\<^UZ:YK MCR$R'W?O6*EL-_Z9;OS/9+8>*QA@H[C?>HP_CF#K==R,YL`N&V,A4N MQ`.>[;GN'7MZW!LO<'TTTK6LMO.LYHYLQP-6ZPU;3FLY[2$Y;0M;^G24:WN- MGTILS(ZW)ZQ-;`C;MAP!"*LARO*Z:Y:UEN[H$]9!6P[;EFY^<%;K]ES;=1U[ MU%TS"?UHO/;<^XY;M;:L$KMK7+:5ON.VE_CG\/.?5>-P.T/Q>?!2VSC\?`C7 M-@ZWC<-MX_".]_L-'`AINKW-@&G;AG>O,_;AVH9[=G_VQ MXT$P<,=BZP,U*-R]!:QEL-UBL$WG.NY4!TS+:<^(T]I>J[;7JFU*V'C.1&\` M$=6Z5]?N1F="RV'/L=?*<^U1=VCWUSTYU?9:[3+3[;9:6W_JQ6YHM-6]5G]Y M4V2'Y[Z_^$557K^*E.JN9P#BVPB"\;_]Z7^0*?ZB'CPM)IGX3R'B_/@2_I/I M!S'*1\2^B=E?7WQ(DSDVRAS"OXZ;)SAM[]`9''K.B[\A"&N/DVS,GY1DZ=Y& MEE\MO725X/]79'DXN[X_S4\Z+%1C6H:Z@4Y_?WMZ_*_?CS^?$>#'_X8_L3NS MHEEH#4P1F*,T]"/;^DU$EP+]-0##C[/#M1"5/PSC0.!Z3J;6A9]9X@<\%=`/A16%4Q%G(%.6?YX*,0?J6U=A?F&=B4O?^@I"-O>GHB#W MVSJ)`]BM-`0`/^9!A\"8):GUJ8CR\'L8BX[U.ZR/KG!$@6YD`>#:S\',)I`8RI MR!8)T!MSC$@Y_,XTR7+*+J;B'!"'?490`.!,1!'^&1]:I$E03'-9SR:!D7XH\RWUF!]-4'&5?9FP>1O#O"ZN( M0_X%O_;""L0TG/M1]M<7)Y\_O/A;U^T.^[V>V__+F_6^UH3M*_@&X?1#!%N\ M'BB_G[XWX0`CYG9'HV'7\<8F%,:ZZJ/O_OWIE^/_%.$"V>,=\N,)"U!P$A]- M:6NSK_XU=S6O9T!O`LOYRYL-OK@=()VQ`:3S8$`J'H0'4P&*X[W@_S^)WX-@ M7_J8/?@8^I,P"DG"MD#-KM,=>4[)_FM^>GL0;TS:?M]U>N/[@WP4H/=`*NTL M.0(G%@LY?O35#V&#WOF+,/>C+Z`*TVV0^;!.Y[6_ODVP-Z;U88/8&\.-8G`4 M<)GLR^PHFX[1O#IBC\*0G" M&40RK!!UD\3V>6WYA^X%TGVYZV:0E.W\)B*,?;Y"?'1]!D]D_I2:1T#$IU&2 M%49*ZI$R38^?FMI.%N.XF9?Z^.7H\RD!_.';ET_6EP\?3MX=?[/NF9EZ:D3W M,@?U5N170G`B"IQV,9^`MPI".*)4!)U"1)&TK4_^CW`.*L>/+4S'1'[JVTN2 M5906^@H1<8CY/UK$MX(P%=,\26T+8M58)JQ45N/`M<&OM9W^D/-0F+;`QS@M M\2GMZ.]9$^&GF)+)!7P@Q[R-VW])AW>NX3>9R#/.HBA0@P2H&2>8?;L4]#+E^#%/M4B% M2M<0\)AZ2XJ\`K])(M`I&1"(U^R$V9 MP!>N*!-89LR,1_7V=:PC7B.'_3>`A%>#0MA$N3"V?'`!T\"/IX)3A^I!AJ), M`YK;!_Y0`1^N[-.5TNY7%R'`*C!;`0YLY1FD60&88$[.M0>]D=WM]8P.O1NV MQFS>0R;P@?HAP`QO'3@=B"J0(V@E)J\&!]-?@IT/\JCQ74"!B`)+8!HOL4HI MZ%%*MM>QOA9I5L`*^.MWAGGA/*$@RV'UALYAWV'BS/PPM2[]J!`*%0T#THL^ M7N@$ZRQ,D9N!M@&G;6%;0&"PV@32DY$`9>2<(R/C&S0]U601VB[?`D`5$B>0H9V2V_2)/B_$+R MU=!6O!4AKY]?$"05YH+O4ZX4O\Q+RA3H5(C@AFTN.1>($P-#AO'Y2FWS7FH7 MX&5D4.#D7&:28P$[!?)$,@NPU&04N3X6YPF('*9!?50<"?R,I`D/0"@`M417 M61@W0Z1S4#BH&?U421\"3Q!4$:CR$4DCO2T_TOBXWF@IIO@]JA4,F"])_&UD MXE5*AB-BN[HO4_C?1*@F6217=2#A"BJ;0L><$Q!D&*E4.W%@PL2KPPF,DYL!XF34K4I5@09.3DESJ MC'R=IDR*RB8"[PAPJ(.ZT@(MG%S=I+)&O;'='?"5_5S%_Q#$@=HS3% MTJO0?EB=*(A!B&MG1<1:G/P@,0^+.:D5#T^4]<%*2+5<,>\)2*N&`'1/F$C[ M7`H6&WQ1$;\Z$*1VOH#Q14/@-MX"ZO#'-5DODB@@;5U$`7G1:8DM>>KPC1![3H`R=G?418))&UL550)``-] ME4%.?95!3G5X"P`!!"4.```$.0$``.U=W9/:.!)_OZK]'WSLP^U6+0%FDNPF ME=P6F8\4M3,#-TQR^Y82M@#5&HE(-C/<7W\M@XUM9%OF2^+JYF&&@6ZYNW^2 MNEMJB0^_O\Q\9X&Y((Q^;'1>M1L.IB[S")U\;'P9-KO#JUZOX8@`40_YC.*/ M#S3`'+D!66"GV83//OB$_O5>_AHA@1UX!A7O M7P3YV)@&P?Q]J_7\_/SJ^?(5XY/61;O=:?UY?S=TIWB&FH3*9[FX$7/)5E1\ MG7?OWK6B3V/2+,R9KRK6;GHGG9>?4BO$9LV: M268S$D1V!T\.TX#LM1#*50]%# M@LXW"XWN741>)@NX"C?T(\COX/\,!WX),$S87MR.E&F_X`[>EDVT(9AVFD[, MD7X)`;RS8G26C]<2T2_`'D3IP6ODR:<=!O.NA%GU!7@MI\C:9D35@8`>527:G+78=Q\%>08K;;\5,0=S-=:#M36E.TA(P69$--`ITCYA_#[%YD MZ;5565TETFC`TQO.,R:3:0!R&T5O'8B(1^QBD'WDXP<\4@X]K"X,8:6C MK740#3B>(^+=O,SEE*4&)4^C!\.E(1C4&EEG^!Z5/IGQY0,N&`M9"CVCOS9D M=)4V!S3Y=O3W]?[;-1YCD,=[A">O)1LPG@XOLO8LH]>S[AM#UJW6U+KNO5*I M++PP/.TQR&R"Y0!BLBA"!>_(`GL] M&B`Z(>!*5RH6HE/%8T/DH,!'3U7K$'K$(N#$A:Q&'9\^,.J617EU^&T(-A3( MU3>!'HHFW+HJEE5ZI!,Z=.C^_7%=KZYDLL&U5_CT$F6M&_MW!(V(3P*"R]<0 M5'06I*(#M)29F582FJ90%P>8D^W3Y60FW7PNMB4*VL= M/-"UB@6G1?OH6D341?>GJ2D8CBRU/@ROX2X+J`5+&84W\ M7K6+5:"K=0`55RUF85'1F=W6SX==A7O[VX1F'6!)H2@KE]O2/B1+%1FM0F*; MRJRKTX*A2#7K,*B5MNV9A1W+Y6DAK`;.) MO0Z..]A#@6G3$C^\"N*DU!6>.$UHB?O:EGT[)K(Z;]?3I+A36M>M-GK(6'1U M=#\$R3>)YVILK.A@A&!Q\P+S(-B94,27/;!4M*T*G&!$/S)-@#D6A2?ICOA` ML]W\!+94=3)%5[3-(_6#*>:@&48P%+1_`6D=D@\=20*BUDXWAUN5S_N\:KOSV:7,+4 M'W^A4^Q-Y,Y77$?5HY``A9E[F;9<^\[MF2VG/G4'V=?NULT*#SBHRDMR)&9# M-:6\68B.WB%LPS#193UQ?<(4CXNV_`N)S89H>K@6ZFC?')U1J+M`Q)=%_4\L M5>RSWA/^A`1Q-8:>3B,6#4Y]G5,PJ[O!D8],WS,ONH92*M0!0>S8K]TR/L1\05PL^OS*1V16E!G7:\+L`MA>`.]DK&-' M9JGX1:9RG(Q"<$5/['6[\X>\CDL-6C67V56MO7#2-K;=WT%_61E9"R8Y2N^Q;1FCTQOQ=2Y>I;A];VVF+ZJ-_F M.ESM)=Q"=K.GY/=S4G6-9!W,Z<"I/[[&H^":B.BZJ0'',Q+.U/!JL.G!^IN- ML&H;Q3HXXSJD/@6)YTR0E0KY>RC5H&HSZT'[SD9H:QK(8H"'R(?@.',9;'(3 M;!6^Y;S:6;S5^.K8QSIXMQV*SEWNU5R:D%JY,J-KDS,`,[Y1O7!EL()%$T8K M5VRTK'$&&%[CR&U$555EWE2/4Q-1.Y=H:MCF#(#=(:?9(8_I6+F*HV6-,\`P M=U6N+HY;;)I86KDDI&V5\\`S=[UN#4BW.#51M7+YJ(YMS@!8K=O)--@T(3V[ MU2.[#U(72[[#2%6R:N)JY?)1+>N<`;:V%_-VK%QI^A\LSE5T[/3UL;D+:+3' M?VD;VC4*9]$%=.QE'>P%-EB=.-F]W$G);U7OSGX?D'Y2F.6RLBBJ!+R*M%!E M$OO*G2'5B>;2)]9UOX>$X\)O35/#6H??RC(J/8#KF^D,H-;;[=)@L[)\:D=@ M:^QPF3^IH-([^:[Z'=V-DM_H;;[,Q=B+S@6E:D/$S0OF+A&;6NRMKZRL8K/2 MX93`E_UN2SVC6!?YC"5UR'6DBZ[LM$Z>8_N'DQ\FA14P2 M]WL(@D$`M44[[;R4DL^)&)TLY[$$O6.(1D,M3C&WA>SDA8QX'#GBG0W7L03< MG%9*IH]M$2_R(FZX?G%2?,<[WC2;D>@J!9FBK\[L3C!5CO[.95[8%+>#:'2N M*/6^VI]&8 MQ8EYI'1K3R!_C2`EA7?^"U!+`P04````"`#]@0D_BK8J<.8#``!Y&@``%``< M`&-V;2TR,#$Q,#8S,%]D968N>&UL550)``-]E4%.?95!3G5X"P`!!"4.```$ M.0$``,V946_:.A3'WZ]TOX.7/=Q.NB&DK-M:E3MU72LA=;?=4*_V:ARGL9;8 MG>T4^NWO<4I,"(0$2-CZ0$-R_G__CFT./N+\XRR)T1.5B@D^=/Q>WT&4$Q$P M_C!T[L?NQ?AR-'*0TI@'.!:<#ATNG(___/D'@K_S5ZZ+OGX?<4TE)IH]4>2Z M\.P\9OS'F7F98$41C,'5V4RQH1-I_7CF>=/IM#<=](1\\([[?=_[_N5F3"*: M8)=Q,Q:A3JXR+NMT_NGIJ9<]S4-7(F<3&>=C#+P'#%-=//(QX*F62LP)^919*&0X<\ M)3"D[_??#?IFP-=-I/KY$?:(8LEC#-/A[<9X*7A`N:(!7"@1LP!K&GS"L9GC M<42IK@%MK#\,[1V6,&L1U8S@>%_TM6;=Y3'6\&H67=V&MX_P,3>+K79)8K/3 MH3/8>TVVL#U,;I=81=>QF.Z;3-FG%?IQFB18/M^&8_;`60BSP_4=C$X8K=M, M3:2M,/Y+IQ>$B!1*&W^XDX+#)7F9E1K$!LIV9E$+\B,2<0!?V%<_4ZC`=7-7 M*6B%YQHS^1^.4_J%8I7*1G.U4=,*U8W`7%U+D=R&L%L@\QJBROA6:!:UX9IQ MJ.*P0VIX-BA:JB1)PG0V[_!-#F7`[%HX]=5_%!LH6R&\PI*#L[JCEW;/B.-Z.,!-TS\6%OM@6+=<<=$_2$*>QWGE3YO)E9KC-.#,5_P;>+G'3 MF:9P7@MR:&Z"YBZ_BG]]3V"3&>R0##I:,GUSV.1J.CF;V=MFF2WLD`C1PA`=W7.< M!@QB?HL$:];Q9-]L?YF[K'%(F%:45, M=B]RPUTP0`N'CK";=)"6^D.9&M1H(4=E?5=37=U<6M33E0DNB/Y"N:PCPLV] M9@[I]\N01H@976Q)*\F3;%U=I6@2LGFA M2(4O'GM__0$@*?$%;Z0EL"-P%ZP''B1^'/+\Z_ M.WN!<.A&GA_>_?SB9GEJ+4>3R0N4I$[H.4$4XI]?A-&+?_S]/_\#D?]^^J_3 M4_3/WR9ABF/'3?T'C$Y/R6\_!7[XQP_TGULGP8@\(TQ^>$S\GU__75\MW7N\<4[]D#[+Q2]*+5H*3^_\W;MW+]FO MI6A+\O$V#LIG7+PLX>Q*)K_Z$OD*DL3_(6'PKB+725E3*1^#A!+TK]-2[)1^ M=7K^ZO3B_+O'Q'M1MBQKP3@*\`*O$:OF#^G3EC1_XF^V`07%OKN/\9H/)HCC MEU3_98COG!1[]$'OZ(/.W]('_:7X^LJYQ<$+1"5O%A-AO=[5RBJ47IH&.\>Q M'WEVV`]U4WL@^,O4B=-G5*"J;[P*JRAU@E[@JYK&84]QOQ;?ZYEO:3(HXWXM M7=&LPP[HEU?D4PTX?DQQZ&&OA$[+D@QP[%%LW"W*WI4>N;5R`SI81C&W15B1 M"7:_NXL>7GK8)T6?G],/I_3#Z=EY,1[^A7SUNQVF?OJTP'=^DL9.F$Z=S:Z= M695^?B$6>]E$216LN(3JQ*ZBOH7$2S"F"J,R0O;RS[<9D!I34 MI2%GNM^Y,)L$J`F!8@(/F9`2N3`BTHB*#\$.BP#Q*)C+P+GCU*OQNRDV<&&5 M+*C]"*+W>8B:O;Z3051HB+X>97%,,?J)ZP3_PDXL'@S$HJ88H`);DD$D!X(7 M"G!-BA3B*)='5&'0P2$W5G[%0?!+&'T.E]A)HA![DR3)<,RIKD+>K#FI@%TW M*P7"($BD@[#)I$F""DO3053S]`^JBDI=E"O_8SA2?8J"+$R=^.G2#\AB7%CM MEIQ9$@E@ULG3$`)$&CXR&5EV&HBI#,B08C!`TK M!=U8RG)E`;%'"E!(HJ\3M--`N0HJ2AJ038S-(S*/WD6QV`/2D#++'2[$.F5J M(H"8PL,E\'PP453*#D>(>78;^.YE$#FIL%HU&;-DX,"K4Z$B`(@(;50"&N2" MB$D..,=$FTT4+M/(_6-Y[Y#FF&4IV\@E8Y=X6)0J&9YO-"K0F'4D&H"(I`%3 MY%IEFHBIGJ!<&56TA_3!Y0N[W.US2;[CF3,26=.^."'=&$"V-+&IN,)\-0=GRMI);AG\+#F] M_6TF"T\2ZI1N0;M/"$0F98(L<("4*7V)PCDAAM9R] MRZ6]6D*B0K$$TV)$2]8\,01PV_QH"`*C"1]=R^][LUC8TQ6"Q)J1D]Q;H4?_ M9_^9^0].0.J16.G(B>,G8D9]387A0(J^8QWCJ^9S]N<9B(QK.FD$GF\`%6N5*7`,,.+JPF'PHAA',I(*28 MA`^$PE'\1/@LJ%U=Q"0A>."J=*C^#H8,'%"M#812!&4)]M`ZBM'BK\YF^^.8 M34H;)\S6Q(3*X@/X<-R'#>O[L[<79ZSG1Y^N?Q_C-29CE[<@,(I1;$ZW,:*P M42F5L`DVZ`&FO)!+#LX0+7BMU7>A@%BXQ"ERB\");:X%8Q2IK0!T5@D#KK.4 MZRNC/$DK!R'4S2;@"#M-L6.&PS1@$&,>1UL;N0J M9NT1-?BZ=2*6'WSPZ0"R9GZ`HG"7)<-]MD`3V-@CR\C;'KLW-S*%JCKUZ= MO'O[^N3\[3F;^LB?;U^]/?G;FWA6HLEBN`8;'6C!;-KBUHI0=S9:$G2AHDM/9T$GUWSMRHJ_.3UZ]_=O) M^=GKG)WDS[,W)V_?G<%@YP(G:>R[!#K?&3(E_)#.R5T*,,G:[A6K,EA?&PR; M.T/FC-&KQ62TLL=H9"T_'GW50-ZQV;K3TH&K,<3Z00*=MXC@B`].&WV,K>6$ M?6DO%H0ES`M_BD*O;I(Q72M5Y92N[N"C44_`34I>3:SWDZO) M:F(OV:)BN9J-?J&+"GNQ_)HM.%;_`D=5O;UFF<)`=-38=19+0Z1$#)OAIO$Z4XG**%U1;*&TT>D\.N1:O MQQ<%0R,YOI9EOI=&(16'0:$%]C#>,,-P#W`>%\XW-N:R2$/[T0TR>NC&\CR? M^M"<8.[XWB0<.5L_=<2.WT,5;]8_?]A&J7OO#U,VF-?@P!62O3?;LE24T&+1 M*;HX.;NX0$E^-"PZSM&P9TSY./8?')HJ5GOI(EM91[YH*!"_BNZ'[?]P&'PG-)+2FS3.-"K#.K)@*(23Q&P:O*F.J>I8?S$A26$=@ MS2*I/03.#J(I1_R4390T2BT*:>XK'+H$($T]+_0$*;3,>MBTJE#WM$E5P(PW M>CA;'H39]?5DQ4*V6>#%:#9=3:8?[.D(S.YXYW`@*`%`W4)^OH`@G\YA/7## M>#@^.$&EN9*&C\:*H#;.QS;%P!!'C(US4K;JQ3Q!7WUW=D[WEM`#U?H1.5EZ M'\7^O[%W@LC#3\[.S@H7YX\HC$IOIT\3OWHL\]9"C4-HKU^PXA6(QN?8H24YV3 M[]_L?/%.BOX["S&Z.*,(#:L.^T_0MY.Z[0[MI1'-/G#JA\C-%6!P:8%3QP^Q9SMQ2%Z=Q-H?QR(K M8=_UQ4>7U(IFMT1U*U+?[%1I@>&=-E1.F%OE^">3A,&]MBFK;?,.O8C06SS` M\GD(\?%='TE%_&N6HRD%,O^ISCFH?3X"-4@G4Q3N-*X.++YIHN6?C'KN891C MVC)=TTF^,MHO#SB^C7973O)-&#Z^UL0!*)%%;;;;IS`@GP-,/Q"&6973X\(L M"Z(6.5CQAN/W#]HHC7#_@Y0-QGXZ<(5D5E:U_#R[%$XPJ7:>\S"/&$>[`MF7 M5]A),!T>T62SC:,'O(&3#E&2ZJ%2ZVKC";J@3T%`DG4H*JJ9P$-0"IAWI#=T MV=M0%6=OPYQ\#8;<52M%_X3ST*='=<\M0]N]$&-KG4:&M_,J"!Y67>?1IX"! M3CQH5DQP"$*A#8:$G2%W"?GN%NK])>Q\@EN^:&!M;8)65)`-R)=1)^#DY M0CIMLDV3.8X9)[6V],3*P^V4JBHDWCP5:8(913K!%6^Q,NWR[B!2"F+J$,F9 M8[1V6W):[=)6&HZ,H@J(2=C4`$H^`4Q-TNWUX+*.72+;A7&EPM!LJP-7,2V7 M!LVR&D1-AN4Z<-FEMMU!&>P]K/0OQ33O9X\+:'>DF_@.$G74T=+3TAPH-JF+ MC:>A!H:+^E@%04V03;O6I9=*NTZJ,1#U="PZB3A$JFG:VUB7`<,<`;!V2O5/]O3&_@$&+69;'#OT.!?;J4\FH1MM,#,) MZ4[],KL-Z/?R0^$=RS!)J%[5J[*M4P%@J-@'=3OY6I@BGVG"H&H!]Y)T\(?8 M"84IW#ER`XQA;9B<06PO!(8Z(F1->K`?\R,JZ3V.(3)%09!A>"&C`[#3Y`U4 M_'AJ4*DJ=N-><6>FRMJ1R`\R2XE@DIC"8(42%L$DD^[>Y/5W:2R`F41G5 M:(7>F)`[B%@XH_Q^6X6.X4N.U/`;]QJ)%<"02@=EVX2IQ*=Z>ZT3A,NDB*V; MX]!7%V_>G5R\OC@AG\[?GKSYVQORZ?S5QJ8>H3@8TJHQMO/T5.A(V5:]/`X&Q3[@ MD(SO`:V/M_%#GX[M]!RQ?(14:IFDFF85JG13J("AG![.EC6?:^6,J^G!X-QE M%&/_+LQS/;I/*[+X2(A!0=Z)#XX?7D5)\AZOB12T2Z<2C$;G=Z]:+2Q? M7QT,1[MC;O*U*('.X_?D>XSNB"(,JK:L7UTK>>`UA]9:`]8"502/OU*%=1_* M#GONG*.D5]6R*CD(5=I0N639BX$9<<386@03&3@_V6@R7:X6-RP%)!3Z/^"$9;+,)X))F&+2L"+_ ML%C<+'7EH.O$Y,L"HIT48)-4D^G*II>0$RJ-9MX$.M4 MJ8D`8@@/EY`8Q?P*A1FE>4DW4/-,N1DQ%`K[,PJ+E6TN1]:W.+$?T]B)8L\/ MG?AIDN(-NV&`:)*&"IC%JABBCOA$PQ/TL9NN,8,?ZW&P%LG'KVCSU9S:*_0- M74=]6XS:Z+U].5O8Y5\KZS=`YG!>Z6*P>8]#O!8F!Q1*FW]/A)#;'&^)`AKI M9?C:(W[)'C1?S#Y-EF1I#H-%4YPJO3@-&9.,X<*K\J0F`&OTXD%3CC?/987[ ML&%=??;VXHQU].C3]>_7D>>O?9<-F;/UKT[,BT&3"9KHK0[!+]:BT6%ICU9HV^UH/C!_3"QE54B3(OTC>\=Q+?U7D) M=$H9;'31KZ)P_%$7`7B$T@:OMIFL3];DRGI_16:\&:)W:1!^+S]:"[M(%PF# MX&7:WO+HH(S&`EF39)7"K5*2*SCXZ*B#3LVLN;VH$>KTO;6P'62H\ M7">4'I)3#<@R5A6B8'E5Q\=C%MLN:Q%J/+FZ6=EC&)3Z%?MW]S2_WP-9\-[A M:49O0IBM6Z>[9$-7QS),TJ]7]:JD[%0`&*KV0=TD\*_VY,-'PE,RU]H+ZX-= M(_$2S6Y6RY4U'4^F'R`-D8*:%^^J[C'2SJ4`X+2JBAJL%A4!G=<*W,]@ML98 M;3(,J=_1!W#)_-106Z<@0(4G5>.0!56LBPP5*<[C2?5W,"\V!Y0L^!L&#O`][+U_NDEH#N4=NRUZ@Y1.EN$^!1GV8O2L:,.1T;$4,/3L#;V5 M#<%:?D275[-?ZV%TTP_(&JTFG]C=%]*37G`\X69G%47O<'`=W1%^H$LNO/_+ M\I"/9!4M,.TG/\"U*JVBPPPSQWF4V2OECM=8]?OH#O\<,*_+$2O7O@EO]RB4 M1B@N'X9"G*)O`O*D;XNS\?1G^J5+GHLR\CCR/=J%DB)G]T0@YV"O")@[9HLL M<9H&+'7$AUB\PRF1-WN=@`)V_5(!@3`8*JL0MG;)DR1S2"/1LZQN):%[&*7T M>M#0:Z5V)RP,\!V]&FWW`!@$+*LR6[-=%"OTRKW`RRA>XOC!=\E:.!X%CK\1 MAB=W*\-H($>?ZM7".[H4`(;0?5#+25Z]:O=S419C>L[O:,NBG-@=+4E1_E$B M!"H[?C3,*O9OJI6JYB*&M`%7\8/J.0'YUL'D++;FY&[ M5Z0S.%']YH]OT98H'(5$]F.*PX1%/LQRXG+JQ1,R110QP)(:;0D09!#":GOB M"D$ZO!2C!XP9D3$Y!T_I*X\_%PD;OV)6"+AU4TM+E2$Q:,F`+?/0'Z`NK1-0#EW1AJ<& M8PAI5WM<+`=HPC^R5L8$.EDPZ)_W$^H/>[Q/42TYK07*8(:CKHC;.PVY'EW\ M>>5R,&:W=M)K$6%0M9HN9[8>X]MT["=NE(7I/,8;/]N(O#]J/:,>/=UJU-QS M*B4P5-1%VG*<5>_/)(96$#DA]4U0%1C\*Y.1S$)2HVV4^'D5FU>("MI%6]MH MXJ-N5:HE0-)3!6XS97`)99J5TQFG,@)$_S.ZQJ:CK#DHX# M7\ZXB@)@NK51RKCF%])/S(^_^*NSV?XX9E[^C1-F:\=-LQC,91N\Y1DS05@& M(:G9J*0K#RM313`CL2]O'O`/+I=/;C?!F^&[6_ICH2 MQGMIJ#2S7.8`2.;.$\6IW1`MO6'I)JB&G'(-)<"TXR.5#6].H4'6P4P%,/_B M#'M7OG/K!RRFJDNCM%0'9Z&@,DHB-O1@^RZ. M$ROTJH?"]>T1:2$#&X0:%528AI(2`--6`[9T/-W0X11Y&0L.Q<6V,5P>[_:8 M9-?!:>@-O7SA5D-W1Q#656^Z2&7C:&4'$-!E3N*:]9G7N;HP>-AY9NL$$=%,4\P6"I_KDI08-U*0#FB3@>:?6UP67SZ8:;=P:+'8&[ M6=IC1#,B<\Z_@:9NGJ'W`(<[I04!H+)&134H+2D%S*#<&[KJ<.=D^LE>=CG< M.:SSD]3-=U/LT<;HX)VKJPWM`N550N4%K>J`8:4F4.$"*G>&EAKL7!T,ZLV= MI^+LH>7^F?DQKNWODV6B*CBC2P$FZ=B]8E5BZFN#H6AGR$VRS@F:>TI6>"$: MK;II!K9IZ`W*29U@-J427`9J!K#-6:0:.WH`Q)^D;X0\VXJ!:EX^SZS$E9* M8MS*E1+/F`1-W4L_=$+W`"LE:4$`J*Q140U*2TH!,]SVAJY:*5U.IM9T!'*E M5$XQEU&\P-O"8)FM1_OL`?,R90#;WU#,5/K%#&$F=*TDSVK0+0,,JWL";]L4 MK!@6@1?ORF%Q\?6<$D!X'4+W?9,.+$`!=3Z9/&DTE4AR* MF?**B*C)UP+)32E4.3D3HK`C)@P.ZMLYSS:4H%JPS[-X#FIK\5Y:&0K]O&XJ&$Y=N623&9#Y34_<@=?#-#!=BC-I](->.?NML0S1"\SUX3IF@)K8#5*3YPBQOYO,KFUZM M;EV1&>YRMK@N[L";HNELREZCU<*:+JGI-IL^W]?(S5:7[S*-Z"83F:2#S*-6 M9^-:')Q2'8$VF;2B3KOCY`@N`\EZ&UZ=2S"67;A? MU7:IA[NI@Z!8/\RMG+-E*?#LL,LHKM>QBSG!41[<4A-62&FZM31!,+`SW"[& M'8L6:+#SR/Q;X`239J3NJ/QLKBC>6E_-/.?4E6BS3:P#C&=*H/($*+DRV]J/ MF/KA8JN?,^'V']S!3;`])U8HUW!VAVS.>MN_!?OLXI6SL1*K35O3_&BE597V M@"55`S9FZ6!M7R6Q#TNJ9(7?G6'>128!"07EG=[FU%I[[2W0'OK=H/KSR/78NK/I2\)+7+_2S/8XF=G6#N^&1P'SE;GPS<+&N?H)4ZZ`]V M\:-.M82W.>3]8MQ:4)Y05X$M-/I6"*-'K`2[;( MI0?FIL-G:2MSOS]^\/I.87#)A4[Q0`RXY(98$,9@HX;6N M!RL4J'EE+4>(Z)R^/COVSJ6.MTM+`X@'MJ/G%015]##*\YD>PWNEWO3.-EE` MKQT=8S+6^7(//D]\D(UM`6CN5G9#%AA=A``5V]6E$DTT2K4,33U:H^204XUZ MBH%D:@C1F3,OQGZR\9/$"6;KG6N)&#\S@GR;ITZ0F!M=E(VM;#I7:+?$T=8$ M,8ATAMM:])0%L*M,=]M[-/8EVA=R'/.E=8M"<8,;SW"1R`ZP7.;#Y2R3ZX(P M**-`I[A'Y:`75ZA,$VVOBH;.`$:*GE=%J0!IMM(%"\E+IQPC>PVLD&:S[K,8 M)$YIHSV*1728K8MEMMT&[%);)RA/3DY",HUNF.](<6Q66]OD-D7'*E4W)S15 M!Y\/^^%MY6^(TN>'IA\J#BK%-+4T'9*G6'SBJR%E-JZ)"[$>OU03`4,3/JY6 M2@!"H-Q"(M-<1N29->T7NJ7M!(,OL_C."?U_,Y:/HC")`M]C?[QW$C^A%WSC MA+X5[*LL\4.<)&.HP7MP9UEF;)"JF!M4\PHB)V!WVCYG37:M4,:EUE,*3MBK@U'E?TOT9Y"3#X>>GX M,4L*M:^,TN91Z)CDH1;\*O>D"F#XIH.RR3&J@Y@2NL8.50$T#"XPV]R;.W'Z MM(J=,"$+4)H86'\@[%2"20KVJ%J5D!W4P="S.^8F6:\BHI7GY2TO[H5!U%TV ML`5VL?]`K1#U>"C7,3H>ZL"OC8[)Z2`G9]%TD@#(9-*H1M)V,ICW*%@;(\*_/GU3/.F4W+ M+6MP/JY6##:3.D&%W*"-+&Y=<,VJ:,^!FK$20BTA;%L*4/-*P+56>7O1H?FK M2#)1#6T'V=0Z;8S^9XS73A:DB`6G_.]`3=UVENHY@0$UO`2KVCT@'45]I096\.76:IW?)']2(2$RKC#T[E;X`:O06I MV;BEP$#-63A_PCM>6+-0"%`#B[$)_%SA';(U`IF/&@OE1AM\%27LIK;<:9$1 M7'M'W'N\CNC=V51NY3SBQ'Y,8R>*/3]TXJ=)BC<)O:"!:))GDB?#KY(49TIN\*H MR9,7AZKEG2!6XG"=SKN=;S=\]KJ3D*,-JZN[@N;U,HL!+0M!MT_H&UH.\L-O MT7[RV9<%JW_W5_WTZ5^.-OS^E8'NV+^[HL#V[^'O%`7?OS+0'?MW5]1P_6L@ M'_+P/=H'K?!R`;G^`-UWQ"2&,+JN&U;NR2Z5]E!^_6'2MPW?K<_'WDZ6LRN) M&L#[LA`MC)X5+8H[046!*"]QP#?V(*FNAN_,#B!%+R=?;8"NZ94"!$872(") M,DOM10=HZB.<;H?1$?HX14?;A9H#=--1CHS#Z*@.0(7)3H2JG*ZJ?G5%/I&O MRZ_(/[>DX\DW_P]02P,$%`````@`_8$)/R/.`9*>%0``G&8!`!0`'`!C=FTM M,C`Q,3`V,S!?<')E+GAM;%54"0`#?95!3GV504YU>`L``00E#@``!#D!``#M M76USXS:2_GY5]Q]XW@^W6W4>VS.3;":5N2V-7U*N>"R=[4EV/TW!)"3C0A$* M2,KV_OH%2%&B*+PT*%&`9ID/8\5&0^CG`;H!--#XZ6\OTSB88Y82FGP\.GMS M>A3@)*01228?C[[<'P_NSZ^OCX(T0TF$8IK@CT<)/?K;__[G?P3\OY_^Z_@X M^+^_7R<99BC,R!P'Q\?\;S_%)/G]1_'/(TIQP+\C27]\2].JN8L:^9_)9KRM9:DY,>T:-X-#5%60&7\FD!90OS?<57L6/SJ M^.SM\;NS-R]I=%0A6R#(:(SO\#@0/[_<72^_-<3Q<1J2-R&=GHB_G5S0,)_B M)!LDT662D>SU.AE3-BW:RMM?5/;$\/CC43B?\J\\.SO]_MVI^,(_042SUQDG M/B736MO\^G4\1>A^-[,DG(F*.39"/^[2'!ILX$$=U)&V_Q\R`,:8FB/1F)' MEF0Z)5F!._?DW`R(7LNGD(L_LG;E$-S5(5WY'E>DSQ M'SG7^7(.Z-ZJXKJVS!A.>=F"\QO^BS41_))A;K&CJB+1J.UF=_S7HHI3/IL. MCH-*HOZ1S^"#4CRHRR\:734[IN%:2V,QXZ7,U(=^_?Q5U\K!8YJ)%4)538P> M<5Q4_I6+PB1/VK1T`6DQ`1^C]+&8A>?I\02AV8E0X03'65K]IE#J^/1L,1G_ MT^+77Y>>]`$]QEBN1+-,L[GU_C!@ZTU'+*PJY1_7.L/F\F%1XF16S$J.PR<2 M+_O1F!L\2U@7[:!*12CCCH:O#4]/_>"`#R9\S3^F!AYJY=QS(>]!,M1KS=XI M\BD.WTSH_"3"I`2=?VABS7_UM>PJ=WA"1`])LELT5?1X>4D3U@NE3KL$>:.+ MU(#6Z5?K`7O&^YRWFJ'XFCN%EU_PJP[PC:)`Q,\<0ZY0T07FE65\X-7J75)9 M`HCP6V<(RQ1R"2R?M!'*O4YTP1NO1[A1%`CU.^=02U5T@?F`MR82+;J*T42. M=:,($./WSC"6JN0"V_.<"7VN2!JB^!\8,6V75I<&(OZ=,\1-BKKSC+_A./XE MH<_)/48I37!TG:8Y9CH/J10!TO"]8T]I4-D=%[_2..=PL=V5&0<;!0% M8O]7Q]@K5'0X,RQ'YAV>429V9H0NN19ZE020@1],O?(I=7%&2+%Y"A-U&1_0$T!M5?&)N,5)M_0.AY@WF)O:6YPM M-%6,(*V$RQ`#E":(SGZP,V)XADAT^3(3TU@Y'\TR+D,.4`;D>OF!^74BCGI1 M]GJ+%2-@O83+V`(4;YE.VZ(M/PN&QY@W)KKC7[=HUDCLYJ[.JS46T)KR+@,' M4&#-^OK1J=?T`@PVY3*L:X+S-)3TWI:;*EA7-RFB&XJ*D8YM/9YAE MKZ,8E4?X^$QB)F;G2GNDEW"Z(PMW"&:E_1A)5R0A&;XA'SAU)- M)4$F&:>[A5"*8(K[0=(=YFJ0,,.1?$I^2Y-09PMMY*'D.9UPV0/2^?2`=YKA MV':.(!6",N#-3$&CNA_CIU1*-T^`H^[!#.%;F1K<$/1(8I(1+&[L;%X'TV]] MP:6ANV%.IPRV8/@QLFJM!NU7ZLI#:>IDVF`-OY0YKSW!63:^L-(RSG-GM#+R4IJN)07CJ9M=GRHM?9#VHNCK!REW.,)X6KC(57-'U7*B&/%% MG._R)8QS<9QP$$7%"1(4CQ")KI-S-"/9*I](<^=A5[5#:>]D?69%^ZX1]:.? M7&!&YDCDQH).5_02X`"X!-@I!R7"_4%/HYQOX27;.?Y+,/$QT$E!:/%B2 M`33W@Z.:6D8W!&?`_;1>HM>A.QY-[BS>U@^J%9I!"'QXSCFE0/W]&%>V@9(= MA$;>NY_U'4I$1++04QUSD12$\M'112N+J(=&3S^(J%V)U!W7WB@%I:"CM"(6 M%*@T]`-_JWVB;;=]WG>4GJO77O]US<--?_][S1/[? M\?JWG?>98_9(4^Q^IK$VD^4Z\#$O(.>?8UQ@GT2#J3BB_<_B]\I[*@J6=U:[ MWQ?4=PRB'XL(S867FL)UQ>2=H$T][F^[M[L)9`#&#V+K97 MQ^+74Q&+>LV%VKK*(T)##]&H\QT#/+LB3+RS]5>C(ZX31G' M*55;,Z;2WE^FBAS?%BQ5Y1UG6MV2H76M_67'."'9U2RDJSRL6_+D[12D%LNU M-KDJK8#3[`MMB?+;26TT5.>AE(6AQ+@/;AOT]904 MP$IY%WG:.WJ68QMZ8"[)AUBFX9'L92#S/2R0N:HNH.-@56'PYR\)RB/"R[B, M9UXG'`V\;*1^1T!9V(>(V4%%+0VP]X'*/E"I/MQ6W%0Q[()OEO(]6*G2RP]7 MOC#0&HY3/-M;'[WW.NQ'_O?:6E&45X,V<#@A304:05<9LVV M(0B@M1_T_(P3KE4LVAA-25*\'B]NW&M'D5'(9=3;AB:@]GY0=449)I.DO!L9 MOC[PB4O*U>*0_HQ(\S(/Z$5.FU4%+F/:-A2V0,4/.C>4!,XB'$>O M;;A1JOC-S`3+U9SH90;VZ@6=QDQ;\;>IIB=C*'O"[)8FM*&4@@QE::45J-ZR3#''-EI$15&DJ<\TFD26%?:"E;I;60&X7` M^WCN29"JYPOVE?L4.XYE/IF$70ON$\^G+'F`_](GL4O4%G)_X@GBLROJ@+.PT5;]]CU"J MZX>UN,69:5G1*.(T#;\-_E+5W(TAZ2L^GVE$QB0LP!N.?T-,$_E2E76:?]^& M$+VR'HZ'P1R16)Q%>*"UHU.+TU:?4$I"P(B!5.(T*W_K,06'Y]`]5Y6LISH& MK.%>4=1IYG@;AK6J^C%&FTV\('&>J4[5*@L[30*^#2,-=?W@Y#=,)D_BJO*< M*S;!M_GT$;/A>..8J6;D6%;A-&FX#7^MH/&:U44/!)Z>MJ[$:=+P'3!K@N>@ MCE@;$D=]M^UY:V]R2/5GKB5#;:/#[GR\]6>NG<)_R&>N]WY$SMDI;)LS<@>: M.J%^B,E\5LOMH=^VA[,.:`(@'K6^BNGSIL?_OHW'%]4%HCY/+EC5\A-6FAJL MAU["!_]S4&X?0D#O^WO?K]FG%?UFQ.B<<*OWZ?5+*E*H+2WS(,S(')"7K$T] MOL\6VF/CQZY#9S&I3FYE;8$V/%;E]"V%_\_+$R>I>.DUI$E(8KS6X`>ZD['8 MS3>YG"C"\L%V"+`?79UQ3R1"H>N$ MMTNQP9,61V>&L[7L-XV`MZ2^)\?5K7H-67+1%?1GHQ6E76:WW<_ M-.IA\H/*`[QQTLG-R7VYSEW>50%&1SZ4V^0)GHC-;/?1D4T,ZF\Q<^PQU_XQ M5MWKM!!W>M_368\RH.F'W:DO`X?C"_R879`TI'F2C1B>DGRJV%8QBSE-@+PG MTL'H^4%V=:%\F/!FSA9/9PW'S5="Y)2#A9W>#MX3\99(^D;_/8JYGUM[Z,?P M5!)4%DK^(>^DV>'H!_>;[HE;J!DBD>$ZI4G*Z<5S9ZY=CIVO3(O[O0G_-@*? MRJV).$WB[8QC"6J^$GR!"Q=4Y%;0N7"8I-.$`PYGZRH,?66]Q0JMU:KLD'?P M0*CY2O`@+)82Z0B]JH]A`<2<)J)P1K0"/8_)9CF.:@_36?"](0FE_-O:PU-C MZ"OK%SE^H,/QF(28-5^2!_MP;1U.$Z"X\^8`7+WM$\M]0TV*<8`8E/E#WH`# MH^<[V2WLOE34:6X;YZ1[:_GA!SKE[-O(.TVFLJ+4&AUIW"+QGL\TJ1';GV:'VCTZXKDB`^L]UZVJ6M!]I?.HFE;S/M`J#CQ^BO MC-4597=XEK/PB<\PAN-SRCLTRX3-6G]T6V_7X;4XS4:T!6F;9MX6.4]X9S3$ M."K2ZM9.!Z>7+YB%)%7E?0.(09GM)%:^&V:AV/A'Y?)"#"L/YI2/%YNY5,E! MR>QDW;MS,O7H^,$F7.EMW2R=\XXL0KR8 M$1HU=PKD/<2N!O`-4F=3L#:(^#'6Y2T?\"[-V"OOO<5M#!L2-T2A[+F[IV^% M0>O!.RMZ`V\0RWP=PKNC_>M;./&=S*]W1[Q092?47R8>W#>JOE9H9W$7W=@5!H\SB,Q!6D< MOM)3:%<#E*Y.0AH[8X*VU+Y#(JO9@N7!P_8'#M]W,K-NA>=FO.G@#A`V]]G+ M!T75N8:AXE`R.PE)[(A,,$K.+&1[RVB1ZL1#AFRPZ28%1A5BW,:#65<"I:R3 ME4D'3JPEBOOU8U>4K;?3TK%)Y*$\=A*B:0LZP-DIH>J8L3L.'Z]<+(W*T[N& M\Q(P22A+G2P'=\F2&1Z7-G(KVPAGJ9/0R?8L68+D,KNZ81"N\I[4SM,:WZZ` M"4-)/I35FR5JOBX>I(V'+AT4PE"J.UD%VO*B/UVN`<.70^BJ,A'@>(1 M(MP"G:,9R5!<7&V5U:M`>K$D3Z(*)J86RUBZ2)G3%,/1;P: M*`K.F.@7/5;`>.B?K M22!%=D95BI-W([AVAUBNAIQA@!B4T4[6GM:,@G'HU#W:O&!MDH'BW\FJTAI_ M&`+>#9]!1&=E4P=I^,/9=^]/3:\RJ,M#"3N4%:(9FX[WU%JL[;9=TWW?42H1 M(Y+@A?G^=J#S:1Z+A*\7F`]H8MP_D4E`4>\HFT-5:>N<2N&VJ@CG\W*MYE07/F+ZV1,V;0D2O]*+%08VA<.9>5DB9H? M>X?7288Y[IDP3;=8.=UO%()2U\FZRA9GJM9#R<2>WZ*^SZ=3Q%Z'XWLR28J= ME"0;T9@O0VJ>>_G\]%^#XV#5(\5;U*6X>&6Z5D&PK&%GKN&69CA]H(L1@N+5 M"]>&Z^0`.:+G6CL93?C'$*\_2K5T:3\T71J7#E;B04.^=VB]0^L=6N_0Y#D95';G$K'X MM=J3+C0S.*J65?GN@+9"R+UCJ2?';B0%6?J3#QM+I)K0?P<+L=Z-]&ZD=R.] M&U$^5KQF942_6MD4@^NP$/?=75@CX=Y%+%_'_8R1:*)\U7%VVO020BXH!(,U MR=Y1](ZB=Q2]HY`AO[0U*TMBV@`SB/CN$$`:NW<"-Q0E12;!ZF&=30=PUG0` MA4P@(`F64KWQ[XU_;_Q[XR]#_@X71T9'B&6O#XS;#MYO1/99\#K!J@+?'4,+ M--R[B<4C/+R9RX,?FX[B;=-1K*3^)UC)]:ZB=Q6]J^A=A72=4%F)VI.^IG6" M7L1W=P#2V+T#.*?3*2FOA8H4I[0(B^!$>O;J[%W3$=2D`Y1$P;I\[Q!ZA]`[ MA-XA2!,,J^T.>/E@6X?O+J,=)NY]R"5B"6^I2&1__\21V'0<[YN.HQ()N$Q0 M"O7>HO<6O;?HO84,^::%,3@&37'??8!14_?F_CY_3/$?N3@Q-9>'EK_;O*-1 MB00+F=[:]]:^M_:]M9??P%PW,*;31NKBOEM[HZ96UG[Q%_'/(THQ_\V_`%!+ M`P04````"`#]@0D_5_<;BN@&``"P.```$``<`&-V;2TR,#$Q,#8S,"YX*)$A''&`J_<4%L)4SWYQ`20`2@BJ+606RVT+``JZ&%9JEPX M4Z+=X./5`F\1UY`6W;&X%R,/C+Y.-Y=XA*D++KPSXN#`A2CH(.H?=*I1>A;@@+A36WB4$9#S;JP*)"! M$M'L)68VBGA0ANC8S%-DB`-)[!%[%U[[@DB@"84N82`6C"$50A9VK3RV+![`) M9G=CP1E<6E&21KZO`U2[_FW>]4"#4AZT3+2-CI\H;GV9<=%#,](_X(B^6WT[@6FXB-V`W)%L'9-)J'+IRI]W.OF?:P)4,B`LA3; MZ.9+CIF\$-P;.5!+(>'J]W;R[LW%$8.2*-$?!M=FV[J+BB#=RVHFI%S MRR:JW;N;=V\J_AM:$&RC@P?<\Z@*E^XIT[L__6`B+-UUU`&J'=[/.SQ#$YXW M+1%MH^//L6#@`#DF8C*#UY7(VX71:A?OY5VTUY8-NO:N[S27LC;C+JJ ME]P*J6I$]"\CD3/TD-';-?J]G;FT4TW742)UPWI*)'(;*%'?4:Q0(U2AM%%J M$E?)!9>1KSW6MWM.I5/K+B$ZH='U;.,7B^.JDHT0`2XY1 M%QY4NNQ$O\.O&8Z@0E%NWX9UU`Y$W'R.ZFJ$`!;8;0X5\30*_`#;)+AIH)%_ M"A[X"9`"I,Y"XA`AB'T#@X-`Z(/[,00BO%]L5QUBI?91I5+)U#3JV8%59$K5 MLDD>9T1A\?2\1ET3-7)66U8.:Z=Y5]P.CXVUW,CY!PN!PZUV9%7E[!J9]E]: MH]]-.0L/#?5KJ:#30!'[EN]U>W^-08'$K@:XEEIX/E>$R3`<(S]NOT8VE!M<`9; ML>CX?F%#T>!:;$M+<<,,73.AOXO0GH$R#UA_CGQ)\92Z5+_)YU=P8WC;5NXM M5]C5:VY.A$4E&3E%`YX2*YN"-[3II?>K^:"M0K4M5F=D43-M.SPNPNX84UA7 M`^Q3I3_02EXS5@/;NO"2'*M_Y5B)^N8I>&IS/]+J5%IO>_M[W7SZU2':EGHK MZEO#,MCBM%O:CP2>/GPFMCZ7M6A)D2_%M-6T8IY59V"+S3BCTJ-28G?D+)XU M4`%&#T3X^"D\!\N?CZTAT;8%ERGAE@4:V.=S7W]<*4MJ?`'0TDUD9OW4/[^: M`%MJX^J<:YZ=+5Z,UUP1> M`Q0````(`/V!"3]"*&?T\&X``%_)`P`0`!@```````$```"D@0````!C=FTM M,C`Q,3`V,S`N>&UL550%``-]E4%.=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`_8$)/_;`J8+!"P``.I(``!0`&````````0```*2!.F\``&-V;2TR,#$Q M,#8S,%]C86PN>&UL550%``-]E4%.=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`_8$)/XJV*G#F`P``>1H``!0`&````````0```*2!27L``&-V;2TR,#$Q M,#8S,%]D968N>&UL550%``-]E4%.=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`_8$)/]?HQF_<'P``+*P!`!0`&````````0```*2!?7\``&-V;2TR,#$Q M,#8S,%]L86(N>&UL550%``-]E4%.=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`_8$)/R/.`9*>%0``G&8!`!0`&````````0```*2!IY\``&-V;2TR,#$Q M,#8S,%]P&UL550%``-]E4%.=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`_8$)/U?W&XKH!@``L#@``!``&````````0```*2!D[4``&-V;2TR,#$Q M,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`4 )`@``Q;P````` ` end XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 9 133 1 false 0 0 false 3 true false R1.htm 0001 - Document - Document and Entity Information Sheet http://cel-sci.com/role/DocumentAndEntityInformation Document and Entity Information false false R2.htm 0002 - Statement - Condensed Consolidated Balance Sheet Sheet http://cel-sci.com/role/CondensedConsolidatedBalanceSheet Condensed Consolidated Balance Sheet false false R3.htm 0003 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Sheet http://cel-sci.com/role/CondensedConsolidatedBalanceSheetParenthetical Condensed Consolidated Balance Sheet (Parenthetical) false false R4.htm 0004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://cel-sci.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) false false R5.htm 0005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) Sheet http://cel-sci.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Parenthetical) false false R6.htm 0006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) Sheet http://cel-sci.com/role/CondensedConsolidatedStatementsOfCashFlow Condensed Consolidated Statements of Cash Flow (Unaudited) false false R7.htm 0007 - Disclosure - Summary of Significant Policies Sheet http://cel-sci.com/role/SummaryOfSignificantPolicies Summary of Significant Policies false false R8.htm 0008 - Disclosure - New Accounting Pronouncements Sheet http://cel-sci.com/role/NewAccountingPronouncements New Accounting Pronouncements false false R9.htm 0009 - Disclosure - Stockholders' Equity Sheet http://cel-sci.com/role/StockholdersEquity Stockholders' Equity false false R10.htm 0010 - Disclosure - Fair Value Measurements Sheet http://cel-sci.com/role/FairValueMeasurements Fair Value Measurements false false R11.htm 0011 - Disclosure - Loans from Officers Sheet http://cel-sci.com/role/LoansFromOfficers Loans from Officers false false R12.htm 0012 - Disclosure - Operations, Financing Sheet http://cel-sci.com/role/OperationsFinancing Operations, Financing false false R13.htm 0013 - Disclosure - Commitments and Contingencies Sheet http://cel-sci.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R14.htm 0014 - Disclosure - Earnings Per Share Sheet http://cel-sci.com/role/EarningsPerShare Earnings Per Share false false R15.htm 0015 - Disclosure - Subsequent Events Sheet http://cel-sci.com/role/SubsequentEvents Subsequent Events false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - Condensed Consolidated Balance Sheet Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Sep. 30, 2009' Process Flow-Through: 0003 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Process Flow-Through: 0004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Process Flow-Through: 0005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) Process Flow-Through: 0006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) cvm-20110630.xml cvm-20110630.xsd cvm-20110630_cal.xml cvm-20110630_def.xml cvm-20110630_lab.xml cvm-20110630_pre.xml true true EXCEL 30 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U93)A93-F,U]E8V$R7S0V-6%?.#)A9E]C8C)E M,C,V8F1C.#(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]0 M;VQI8VEE/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5A#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I!8W1I=F53:&5E M=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!296=I'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S5E M,F%E,V8S7V5C83)?-#8U85\X,F%F7V-B,F4R,S9B9&,X,@T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\U93)A93-F,U]E8V$R7S0V-6%?.#)A9E]C M8C)E,C,V8F1C.#(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!U6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U93)A93-F,U]E8V$R7S0V-6%?.#)A9E]C8C)E,C,V8F1C M.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-64R864S9C-?96-A M,E\T-C5A7S@R869?8V(R93(S-F)D8S@R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-H86YG92!G86EN/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPQ,#`I/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U93)A M93-F,U]E8V$R7S0V-6%?.#)A9E]C8C)E,C,V8F1C.#(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-64R864S9C-?96-A,E\T-C5A7S@R869?8V(R M93(S-F)D8S@R+U=O'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\U93)A93-F,U]E8V$R7S0V-6%?.#)A9E]C8C)E,C,V8F1C.#(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-64R864S9C-?96-A,E\T-C5A M7S@R869?8V(R93(S-F)D8S@R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E M6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UE;G0@9F]R(')E<'5R8VAA M&5R8VES92!O M9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!F;W(@;W9E6UE;G0Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\'0O:F%V87-C3X-"B`@ M("`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`L M(#(P,3$@86YD(#(P,3`L('1H92!#;VUP86YY(')E8V]R9&5D(&YO#0IP871E M;G0@:6UP86ER;65N="!C:&%R9V5S+B!&;W(@=&AE(&YI;F4M;6]N=&@@<&5R M:6]D2X@1F]R('1H92!T:')E92UM M;VYT:"!P97)I;V1S(&5N9&5D($IU;F4@,S`L(#(P,3$@86YD(#(P,3`L(&%M M;W)T:7IA=&EO;B!O9B!P871E;G0@8V]S=',@=&]T86QE9"`F;F)S<#LD,C$L M-S$P#0IA;F0@)FYB2!E'0@9FEV92!Y M96%R6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&QE M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE&5S/"]U/B`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`W,3@M,3`M,S`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`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'`@'0M86QI9VXZ(&QE9G0G/CPO<#X-"@T* M/'`@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'`@6QE/3-$)V9O;G0Z(&YO'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`T-'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H.B`S)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I M9VAT)SXQ,2PQ-C@L,#0Q/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I M9VAT)SXW+#,R,"PR,C4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXR,RPT-C,L,C0P/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXX+#8Y,"PU,3`\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXV+#,U,"PX.#,\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO M='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,2PU M,#`L,#`P/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU+#,X-BPU,S$\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-BPQ,3,L M-#8Y/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`T-'!T)SXF(S$V,#L\ M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`T-'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H M.B`T,"4G/D5M<&QO>65E6QE/3-$)W=I9'1H.B`S)2<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T M9#X\=&0@'0M86QI9VXZ(&QE9G0G/B9N8G-P M.R0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R M:6=H="<^,2PQ-3$L-SDT/"]T9#X\=&0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^)FYB6QE/3-$ M)W=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I9VAT)SXT,#6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)FYB6QE/3-$)W=I9'1H.B`Q,"4[('1E>'0M86QI M9VXZ(')I9VAT)SXS,C$L,C8X/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@ M("`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`@9G)O;2!T:&4@97AE'!I65A M'!I2!V97-T960@96UP;&]Y964@;W!T:6]N(&5X=&5N'!I0T*,BP@,C`Q,"!T:')O M=6=H($1E8V5M8F5R(#@L(#(P,3`N($%L;"!O<'1I;VYS('=E65A'!E;G-E(&%N9"!A(&-R961I="!T;R!A9&1I=&EO;F%L('!A:60M M:6X@8V%P:71A;"X@5&AE('9A;'5E(&]F#0IT:&4@9G5L;'D@=F5S=&5D(&5M M<&QO>65E(&]P=&EO;B!E>'1E;G-I;VX@=V%S(&1E=&5R;6EN960@=7-I;F<@ M=&AE($)L86-K(%-C:&]L97,@;65T:&]D+B!4:&5R92!W97)E(&YO(&]P=&EO M;G,@97AT96YD960@9'5R:6YG#0IT:&4@=&AR964@;6]N=&AS(&5N9&5D($IU M;F4@,S`L(#(P,3`N/"]F;VYT/CPO<#X-"@T*/'`@65E'!I6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2P@;V8@=VAI8V@@)FYB'!E;G-E9`T*9F]R('1H92!T:')E92!M;VYT:',@ M96YD960@2G5N92`S,"P@,C`Q,2X@061D:71I;VYA;&QY+"!A('!O'!E;G-E9"X@5&AI M6QE/3-$ M)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'!I65A'!I'!E;G-E+B!4:&4@=F%L=64@;V8@=&AE(&9U;&QY('9E'1E;G-I;VX@;V8@;W!T:6]N M'1E;G-I M;VX@;V8@;W!T:6]N6QE/3-$)V9O;G0Z(#$Q<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE'0M9&5C;W)A=&EO;CH@=6YD97)L:6YE.R!T M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W=I9'1H.B`Q,B4[('!A9&1I;F'0M86QI9VXZ(&QE9G0G/B`\9F]N="!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5R8VES M90T*("`@(#QU/E!R:6-E/"]U/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=W:61T:#H@,38E.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN M9RUL969T.B`U+C1P=#L@;&5T=&5R+7-P86-I;F'0M86QI9VXZ(&QE9G0G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`X)3L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[ M('!A9&1I;F'0M9&5C;W)A=&EO;CH@=6YD97)L:6YE.R!T97AT+6%L:6=N.B!L969T M)SX\9F]N="!S='EL93TS1"=F;VYT.B`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`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)FYB6QE M/3-$)W=I9'1H.B`Q,B4[('1E>'0M86QI9VXZ(')I9VAT)SXT,C(L,3`V/"]T M9#X\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)FYB6QE/3-$)W=I9'1H.B`Q,B4[('1E>'0M M86QI9VXZ(')I9VAT)SXQ+#`P,BPU,#(\+W1D/CQT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT+#`S-RPP-C8\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP/"]T9#X\=&0@6QE/3-$)W9E6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!" M;&%C:R`R+C5P="!D;W5B;&4G/C$Q+#@T-RPR,3@\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F'0M:6YD96YT.B`M,"XR-6EN.R!T97AT+6%L:6=N M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2X-"D1U2!R96-O9VYI>F5D M(&$@=&]T86P@9V%I;B!O9B`F;F)S<#LD."PT,S,L-#4Q('=E&5R8VES960L('1H92!V M86QU92!O9B!T:&5S92!W87)R86YT&5R8VES960N($1U2!R96-O9VYI>F5D(&$@;&]S M&5R8VES92!O9B`F;F)S<#LD,30X+#4T-BP@=V5R92!E>&5R8VES M960N/"]F;VYT/CPO<#X-"@T*/'`@2!R96-O9VYI>F5D(&$@9V%I M;@T*;VX@97AE2X@5VAE;B!T:&4@=V%R&5R M8VES960L('1H92!V86QU92!O9B!T:&5S92!W87)R86YT6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE&5D('1O(&%N($5N=&ET>28C,30V.W,@3W=N M(%-T;V-K)B,Q-#@[+B!4:&ES('1O<&EC#0IP2!S:&]U;&0@=7-E(&$@='=O+7-T97`@87!P&5R8VES92!A;F0@2!M86ME&5R8VES M92!P2!O9F9E&5D)B,Q-#@[(&]P=&EO;B!O;B!E<75I='D-"G-H87)E2!C;&%S2P@969F96-T:79E($]C=&]B97(@,2P@,C`P.2P@ M,RPX.3`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`Q,G!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE&5R8VES92!P2!T:6UE(&]N(&]R(&)E9F]R92!*=6YE(#$U+"`R,#$T+B!!9G1E M&5R8VES92!P2!397)I97,@1B!W87)R86YT2!N;W<@<'5R8VAA2`F;F)S<#LD,3`P+#`P,"X@5&AE(&%D:G5S=&UE;G0@=V%S(')E8V]R M9&5D#0IA6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2`Q+"`R,#$Q M+"`V+#`P,"PP,#`@4V5R:65S($T@=V%R'1E;F1E9"!F M;W(@='=O('EE87)S+B!4:&4@=V%R6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!E;G1E2!W:6QL(&)E(')E7)O;B!W:6QL M(&)E(')E2!B971W965N('1H92!# M;VUP86YY(&%N9"!">7)O;BX@5&\@;6%I;G1A:6X@=&AE(&QI8V5N28C,30V.W,@8V]M;6]N('-T;V-K(&%N9"!T=V\@=V%R2!F M:6QE9"!A(')E9VES=')A=&EO;@T*6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2`Q M+"`R,#$Q+"`Q+#,R-2PP,#`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`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$R<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I2`V+"`R,#$U+B!!7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'`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`^#0H- M"CQP('-T>6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I M;G!U="!L979E;"P@:6X@=&AE(&-O;F1E;G-E9`T*8V]N6QE M/3-$)W=I9'1H.B`Q,#`E)SX-"CQT'0M86QI9VXZ(&QE9G0[(&)O M6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T M;VTZ(#%P="<^/&9O;G0@6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@ M6QE/3-$)W=I M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;3H@0FQA M8VL@,7!T('-O;&ED)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN M9RUB;W1T;VTZ(#%P="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M=#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W9E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`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`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q M,G!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$R<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&IU6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q,#`E)SX-"CQT'0M86QI9VXZ M(&QE9G0[(&)O6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D M9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUB;W1T;VTZ(#%P M="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O M='1O;3H@0FQA8VL@,7!T('-O;&ED)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@ M6QE/3-$)W=I9'1H.B`S M)3L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT.B`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`P)2<^#0H\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W!A9&1I;F6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)W=I9'1H.B`U-B4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`X)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q M)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@6QE/3-$)W=I9'1H.B`X)2<^ M/&9O;G0@6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@'0M86QI9VXZ(&QE M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)O6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`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`@'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$R<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C,30V.W,-"F%S6%B;&4-"F%T('1H92!E M;F0@;V8@36%R8V@@,C`P.2P@8G5T('=A'1E;F1E9"!T;R!T:&4@96YD M(&]F($IU;F4@,C`P.2X@070@=&AE('1I;64@=&AE(&QO86X@=V%S(&1U92P@ M86YD(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@;&]A;@T*86=R965M96YT+"!T M:&4@0V]M<&%N>2!I6%B;&4-"G=I=&@@82!C'1E;G-I M;VX@;V8@=&AE(&QO86X@=VET:"!-2!T:6UE('!R M:6]R('1O($IA;G5AF4@37(N(&1E($-L87)A)B,Q-#8[2!E>'1E;F1E9"!T:&4@;6%T=7)I='D@9&%T92!O9B!T:&4@;F]T92!T;R!* M=6QY(#8L(#(P,34N/"]F;VYT/CPO<#X-"@T*/'`@F5D(&]V97(-"G1H92!P97)I;V0@9G)O;2!*=6QY(#8L(#(P,#DL('1H M92!D871E(&]F('1H92!S96-O;F0@86UE;F1M96YT+"!T;R!/8W1O8F5R(#$L M(#(P,#DL('1H92!D871E(&%T('=H:6-H('1H92!L;V%N(&AO;&1E2!P86ED M("9N8G-P.R0Q,C0L,C`V(&EN(&EN=&5R97-T(&5X<&5N'0M86QI9VXZ(&QE9G0G/CPO<#X-"@T*/'`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`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`R-"P@,C`P."P@82!S96-O;F0@86UE;F1M96YT#0IT M;R!T:&4@;&5A2!W87,@2!T;V]K('!O2!I'!I2`Q,BP@,C`Q M,RX@5&AE'!I2`R-BP@,C`Q-"X@ M5&AE(&-O'!I2`R,#`X+CPO9F]N M=#X\+W`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`F(S$T-SMA="UT:&4M;6%R:V5T)B,Q-#@[(&5Q=6ET>2!O M9F9E&ES=&EN9R!T2!S:&%R97,@;VX@=&AE($-O M;7!A;GDF(S$T-CMS(&)E:&%L9@T*;W(@<'5R8VAA&-H86YG92!!9W)E96UE;G0@*')E9F5R2!T:&4@<&QA:6YT:69F2!T2!T:&%T('1H92!L:71I9V%T:6]N(&5N=&%I;',N($)Y(&5N9&EN9R!T:&ES M(&1I2!I&EC(&-A;F-E6UE;G0@=V%S(&UA9&4@870@=&AE M(&-L;W-I;F<@=6YD97(@=&AE#0I3971T;&5M96YT($%G6UE;G1S(&]F(&%P<')O>&EM871E;'D-"B9N8G-P.R0Q(&UI;&QI;VX@96%C M:"P@<&QU6UE;G0I(&%N9"!E;F1I M;F<@;VX@36%R8V@@,2P@,C`Q,BX@07,@=&AE6EN9R!D:79I9&5N9',L M(&EN8W5R6UE;G1S("AO M=&AE&ES=&EN9R!D96)T+`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`S,"P@,C`Q,2X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`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`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@6QE/3-$)W=I9'1H.B`U)2<^ M/&9O;G0@6QE M/3-$)W=I9'1H.B`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`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`R+C5P="!D;W5B;&4G/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Q,#`E)SX-"CQT6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H M.B`T-B4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W9E6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)O6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!B;W)D97(M8F]T=&]M.B!";&%C:R`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`T-B4G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)W=I9'1H.B`U)2<^/&9O;G0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&QE9G0G/CQF;VYT M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT.B`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`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)V)O M6QE/3-$ M)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$ M)W!A9&1I;F6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$ M)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I M;F6QE/3-$)V)O'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H M.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)W=I9'1H.B`T-B4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M/&9O;G0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F6QE M/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)W!A9&1I;F6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0M86QI9VXZ(&QE9G0G M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U93)A93-F,U]E8V$R M7S0V-6%?.#)A9E]C8C)E,C,V8F1C.#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-64R864S9C-?96-A,E\T-C5A7S@R869?8V(R93(S-F)D8S@R M+U=O'0O M:'1M;#L@8VAA'0M M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2`Q.2P@,C`Q,2!T:&4@0V]M<&%N>28C M,38P.V%N;F]U;F-E9"!T:&%T(&ET(&AA'!A;F1E9"!T:&4@;&EC96YS M:6YG(&%G&-L=7-I=F4@;&EC96YS92!T;R!M87)K970@86YD M(&1I2!F=6YD:6YG(&$@<&%R="!O9B!T:&4@9VQO M8F%L(%!H87-E($E)22!C;&EN:6-A;"!S='5D>2!A="!T:')E92!C;&EN:6-A M;`T*2!T M:&4@0V]M<&%N>2!M:6QE'0M86QI9VXZ M(&QE9G0[(&UA7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C M:&5M87,M;6EC&UL/@T*+2TM+2TM/5].97AT4&%R=%\U93)A93-F,U]E8V$R7S0V 8-6%?.#)A9E]C8C)E,C,V8F1C.#(M+0T* ` end